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ABSTRACT 
The goal of this review was the evaluation of information on assessment methods in the field of 
alternative neurotoxicity (NT) testing. We therefore performed a systematic and comprehensive 
collection of scientific literature (in English) from the past 27 years until mid of 2017 on state of 
the art alternative testing methods including in vitro test methods, in silico methods and alter-
native non-mammalian models. This review identified a variety of test methods that have the 
ability to predict NT of chemicals based on predefined key NT endpoint categories (27). Those 
endpoint categories were derived from the Mode of Action (MoA) of known human neurotoxi-
cants. Pre-evaluated MoAs of human neurotoxicants allowed the identification of performance 
characteristics with regard to the ability of a test system to correctly predict a chemical effect 
on an endpoint category. The most predictive in vitro model that covers a large variety of end-
point categories are primary rodent cells or tissues. Human based systems derived from in-
duced pluripotent stem cells (iPSC) are promising and warrant human relevance. There is how-
ever not yet sufficient data on these models to demonstrate their suitability to reliably substi-
tute primary rodent cells for NT testing purposes. Test methods for glia toxicity are rare and 
glia endpoint categories are clearly underrepresented. Therefore, a focus for future method de-
velopment should be placed on glia, astrocytes, oligodendrocytes and microglia based models, 
preferably in a co-culture se up. The review on in silico methods, resulted into 54 QSARs publi-
cations, relevant for NT, of which 39 on blood brain barrier (BBB) permeation. The QSARs 
available in the publications were developed from data on drugs and chemicals, but there ap-
pears a limited set of experimental data for chemicals and pesticides on blood-brain barrier pas-
sage. The evaluation of NT methods using alternative whole organism approaches demon-
strated a majority of data for C. elegans (nematode species), represented with high true predic-
tion (96%). The main endpoint category was inhibition of cholinergic transmission, with specific 
endpoints for AChE activity and motor activity, the latter confirming the added value of a whole 
organism approach among alternative models. Though D. rerio, the zebrafish model appeared a 
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promising model for DNT studies with numerous advantages, it was poorly evaluated for NT 
endpoints. Next to the need for standardized protocols using C. elegans as a test organism, the 
zebrafish model needs further exploration for NT relevant endpoints. In conclusion, a NT alter-
native test battery covering identified and relevant MoA for NT is recommended. Therefore, test 
methods with relevant controls and standard operation procedures have to be set up for cover-
ing most important MoA. To link the human in vitro testing to rodent in vivo studies and vali-
date the stem cell-derived systems, it is advised to include rodent primary cultures into the 
studies. For more complex, behavioural readout, effects in alternative organisms should be 
combined with electrophysiological assessments in vitro. 
© European Food Safety Authority, 2018 
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BACKGROUND AS PROVIDED BY EFSA 
Neurotoxicity refers to any adverse effect of exposure to chemical, biological or physical agents 
on the structure or functional integrity of the developing or adult nervous system (Faqi, 2013). 
Many common substances are neurotoxic, including lead, methylmercury and pesticides 
(AltTox.org). 
Neurotoxicity studies are indicated in the list of “Toxicological and metabolism studies” under 
Part A, Section 5 of data requirements for active substances listed in Commission Regulation 
(EU) No 283/2013, in accordance with regulation (EC) No 1107/2009 concerning the placing of 
plant protection products on the market. Such studies should be performed in rodents in the 
case of regulatory applications of active substances having structures similar or related to those 
capable of inducing neurotoxicity, with specific indications of potential neurotoxicity and/or with 
a neurotoxic mode of pesticidal action. In addition, neurotoxicity studies “should provide suffi-
cient data to evaluate the potential neurotoxicity of the active substance (neurobehavioral and 
neuropathological effects) after single and repeated exposure” (acute toxicity studies point 5.2, 
short-term toxicity studies point 5.3, long term toxicity and carcinogenicity studies point 5.5 and 
reproductive toxicity studies point 5.6). 
The recognised test methods for the evaluation of the neurotoxicity potential of chemicals (in-
cluding pesticides) are the OECD Guideline 424 (Neurotoxicity studies in rodents) and 426 (De-
velopmental Neurotoxicity Studies). However, both these methods use complex in vivo tests 
which are often too laborious and expensive and might also not well reflect the human situation 
because of inter-species variation (Leist et al, 2013). On the other hand, the data requirements 
mentioned above clearly indicate that “tests on vertebrate animals shall be undertaken only 
where no other validated methods are available. Alternative methods to be considered shall in-
clude in vitro methods and in silico methods. Reduction and refinement methods for in vivo 
testing shall also be encouraged to keep the number of animals used in testing to a minimum.” 
It is now recognised that the future of chemical safety assessment must move away from ani-
mal tests towards a combination of complementary approaches that address functional mecha-
nistic endpoints tied to adverse outcomes of regulatory concern. The Adverse Outcome Pathway 
(AOP) concept can assist in the selection of the most important tests to use in integrated test-
ing strategy (ITS), which are expected to efficiently combine different information sources in a 
quantifiable fashion for regulatory risk assessment (Bal-Price et al, 2015a).  
The present Call is based on EFSA’s draft 2016 Work Programme for grants and procurements 
in science. This call is launched without prejudice to the approval of the 2016 Work Programme 
and the 2016 Budget by the EFSA Management Board on 03/12/2015. 
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1. Project Summary 
1.1. Background 
Pesticides are globally used substances for controlling undesirable pests such as insects, weeds, 
fungi and rodents. Most pesticides are indiscriminate, implying toxicity to non-targeted species, 
including humans. As most pesticides’, especially insecticides’ targets involve the nervous sys-
tem it is not surprising that a number of these compounds can cause neurotoxicity in mammals. 
This family of chemicals includes organophosphates, carbamates, pyrethroids, organochlorines, 
neonicotinoids, and other compounds. In addition to insecticides, some herbicides and fungi-
cides as well as other non-pesticide related compounds like metals, industrial chemicals, sol-
vents, natural toxins, pharmaceutical drugs and drugs of abuse also possess neurotoxic proper-
ties. The effects of pesticides on the nervous system may be involved in their acute toxicity, as 
in case of most insecticides, or are suspected to contribute to chronic neurodegenerative disor-
ders, most notably Parkinson’s disease. This was comprehensively reviewed in Costa et al., 
2008. 
Socioeconomic costs of overall neurotoxicity –including acute, chronic, central and peripheral 
nervous system effects- are difficult to estimate. However, there is sufficient indication in the 
literature that environmental exposure towards chemicals contributes to neurodegenerative dis-
eases amongst those Alzheimer’s (AD) and Parkinson’s Disease (PD) as well as parkinsonian’s 
syndromes or other degenerative motor syndromes as a form of chronic 
neurotoxicity(Landrigan et al, 2005; Tanner et al, 2014). A cross-European evaluation has re-
vealed that on average each patient suffering from neurodegenerative disease costs € 
28.000/year (Jönnson & Wim, 2009). This number is similar to the cost for PD in the United 
States (US) with $ 24.000/patient/year (Landrigan et al, 2005),. In the US, just the treatment 
cost for PD range from 12 to 25 billion US $. Considering the increasing prevalence of neurode-
generative diseases in developed countries and the so far qualitatively confirmed (Costa et al, 
2008), but quantitatively unknown contribution of chemicals towards such diseases, it seems 
necessary to prevent chemical-induced chronic neurotoxicity as well as the other forms of neu-
rotoxicity as indicated above. 
Animal experiments are currently the gold standard for NT testing (OECD TG 424, TG 418, TG 
419 and TG 426). An iterative assessment/testing strategy is recommended and the first animal 
data for NT assessment are most often provided by standard single dose (OECD TG 402, TG 
403, TG 420, TG 423 and TG 425) or repeated dose toxicity studies (OECD TG 407, TG 408). 
These studies include clinical observations and morphological examinations, which can reveal 
adverse effects on the nervous system. If evidence of a direct effect on the nervous system is 
provided by these standard, single or repeated dose toxicity studies, NT testing by the specific 
NT guidelines indicated above may be conducted. 
Such presently practiced animal tests for NT are problematic in several ways: (i) they are ethi-
cally questionable; (ii) they are very expensive, laborious and time requiring since identification 
and detection of every possible change of the nervous system cannot be ensured by one single 
method due to the multiplicity of possible effects; (iii) they require highly trained and compe-
tent parties because of the complex array of behavioural, neurological, neurochemical, histopa-
thological and morphological approaches needed to acquire neurotoxicity data. Furthermore, 
while such guideline studies are currently necessary for consumer safety, it is already known 
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that these animal tests might have limited prediction for human neurotoxicity of some com-
pounds. One example is provided by paraquat and rotenone. While the guideline using rodent 
studies for these compounds did not reveal hazards for Parkinsonism, a recent Scientific Opin-
ion by EFSA on ‘Investigating experimental toxicological properties of plant protection products, 
having a potential link to Parkinson’s disease and childhood leukaemia’ (Ntzani et al, 2013) dis-
closed epidemiological evidence for these substances as neurodegenerative hazards for hu-
mans. It is to note that regulatory studies are intended to explore for any potential hazard but 
they are not specifically designed to inform on specific and complex human health outcomes. 
On the other hand, observational studies on the effects of pesticides for the induction of neu-
rodegenerative diseases have weaknesses in providing causal exposure-effect relationships. 
Thus, experimental and mechanistic data focussing on specific neurologic pathways is needed 
to support epidemiological human data or to assess human hazard of new substances. This 
need is strongly supported by observations in pharmacological research where also due to lack 
of translation from animals to humans new drugs, e.g. for treatment of cerebral ischemia, fail to 
enter the clinics (Leist & Hartung, 2013; Perel et al, 2007; Matthews, 2008). 
New data type and methods, like in vitro or alternative organism (AO) in vivo methods and test 
strategies, might be more effective in hazard identification. However, any alternative method 
can never be a ‘stand-alone’ test for neurotoxicity testing as structure and function of the brain 
are very complex and especially intellectual output is very difficult to measure in any model 
other than humans. However, to even be able to successfully use cell culture data and other al-
ternative approaches for human risk assessment, one needs a framework where such alterna-
tive testing results based on cell free assays, cellular models and non-mammalian in vivo stud-
ies or in silico approaches can be embedded. A framework like this could for example be an Ad-
verse Outcome Pathway (AOP)-based IATA (Integrated Approach for Testing and Assessment 
(Tollefsen et al, 2014). Such an approach is currently applied for the assessment of skin sensi-
tizers (Patlewicz et al, 2014).  
The AOP is a framework helping to organize existing scientific knowledge on a chemically trig-
gered initiating event leading to an adverse outcome, e.g. human disease (OECD, 2013). It can 
be utilised to assess either biological plausibility or to instigate actual risk assessment. As EFSA 
is recognizing the value of the AOP concept for protection of human health, the EFSA panel on 
Plant Protection Products and their Residues (PPR) organized in 2014-2016 a Working Group on 
‘Experimental toxicology data of pesticides and their potential link to Parkinson's disease and 
childhood leukaemia’, where all available information on paraquat and rotenone with regards to 
the induction of Parkinsonism is collected within the AOP framework and re-evaluated for bio-
logical plausibility as well as its usage for risk assessment (Ockleford et al, 2017). One outcome 
of generating AOP-based IATAs is a testing strategy for human hazard assessment. As a testing 
result is only as good as the model used for generating such result it is of outmost importance 
to test key events (KE), which are hallmarks of the causal chain from initiating event to adverse 
outcome, identified with the AOP concept in biologically relevant models. In addition, it is fa-
vourable to employ as little experimental models as necessary because also non-rodent testing 
produces significant costs. Therefore, a thorough evaluation of cell-free and cell-based in vitro 
as well as in vivo systems using alternative organisms, supported by theoretical modelling ap-
proaches (e.g. QSAR, grouping of structural similar compounds) seems a prerequisite for build-
ing alternative, AOP-based IATAs for neurotoxicity testing. Here, one focus of the model evalua-
tions should lie on currently known KE for acute, chronic, central and peripheral neurotoxicity of 
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reference compounds. As a start, KE identified in Bal-Price et al. 2015 (Bal-Price et al, 2015b) 
will be included into the search strategy and supplemented by common modes-of-action for NT. 
 
1.2. Review Question and Objectives 
The review question is summarized as “Which alternative test methods or approaches 
are available to evaluate endpoints (KE) for neurotoxicity with or without exposure 
to predefined neurotoxic compounds?” 
With this question the main goal of the project is a literature search, analysis and appraisal on 
state of the art of alternative NT testing methods (excluding developmental neurotoxicity, DNT) 
currently available or under development in order to support the peer review of active sub-
stances under Reg. 1107/2009.  
In particular, the 1st objective is to perform an exhaustive and comprehensive literature 
search, collection and appraisal of all relevant information in English for the period 
1990-2017 on the state of the art of respectively 1) alternative in vivo neurotoxicity testing 
models (e.g. non-mammalian animal models), 2) in vitro cell-free and cell based neurotoxicity 
test methods that allow testing of a large number of chemicals (medium-and high-throughput 
screening), 3) in silico methods, 4) read across and 5) combination of testing methods in test 
batteries that incorporate different neurotoxicity-relevant endpoints including high-throughput 
systems. Besides validated methods, also methods currently under validation and methods at a 
research stage will be considered. The search will include publicly available peer reviewed re-
search publications and publicly available ‘grey literature’ (government reports and official insti-
tutions documents).  
These results will feed into work package 2 with the objective to make an overall evalua-
tion of the suitability of selected methods or combination of methods to support and 
complement current international regulatory requirements for NT testing. To accom-
plish this, all relevant publications will be analysed for suitable test methods based on regula-
tory requirements. These methods will be listed and described in detail with information on e.g. 
the test system (alternative organism, in vitro, in silico), the protocol used and the quality of 
the data. This information will feed into a thorough evaluation of general performance charac-
teristics (sensitivity, specificity), the potential to predict human NT and the strengths and weak-
nesses of each assay or a combination of assays.  
This comprehensive literature search on state of the art of NT test methodologies and critical 
analysis for suitability to support regulatory assessments will be made from a Plant Protection 
Products regulatory point of view, with the focus to the needs and possible strategies for future 
research and risk assessment. Specifically, an emphasis will be put onto the AOP concept. AOPs 
concerning NT published either in the peer-reviewed literature, e.g. Bal-Price et al. (2015), or 
submitted to the AOP Wiki (https://aopwiki.org/) by the start of the project, will be studied for 
key events (KE; including molecular initiating event, MIE, which is defined as a specific KE 
(Villeneuve et al, 2014), preferably common KE, relevant for NT modes-of-action. These identi-
fied KE will receive special attention in the data collection, as those are probable candidates for 
tested endpoints within an AOP-based IATA as was exampled for skin sensitization earlier (Leist 
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& Hartung, 2013). To ensure relevance of the KE measured in the methods included in the final 
recommendation, we will perform a pre-screen on mode-of-actions (MoAs) of the identified 
neurotoxic compounds. Only the compounds with a proposed cellular and/or molecular MoA will 
be pursued in the further method evaluation because for a compound with unknown MoA one 
cannot judge if the in vitro system predicts NT correctly. 
The 3rd objective will provide a report summarising the strategy, results and methods evaluation 
of the literature review. In addition, founded on AOP-based KE and possibly additional end-
points identified as KE in AOPs yet to be created, a recommendation for a possible IATA for NT 
testing will be made. 
 
2. Methodology 
2.1. Compound selection and mode-of-action analyses 
We exclusively consider methods that are used with compounds known to be neurotoxic in hu-
mans that have a known mode-of-actions (MoA). The reason for this decision was that by this 
procedure we can easily identify if a method correctly predicts an endpoint relevant for the 
compound and thus reduce uncertainty in method evaluation. Exceptions are computational 
models (‘in-silico-related’), studies that focus on method development/characterization 
(‘method-related’) and methods that model the blood brain barrier (‘BBB-related’) because 
these studies are not a priori compound-related.   
Primary selection of the compounds was based on two publications by Grandjean & Landrigan, 
2006, 2014, an EFSA supporting publication by Choi et al, (2016) and chapter 16-22 of the 
‘Handbook of Neurotoxicology’ (Chang, 1995). The list of compounds within the (Grandjean & 
Landrigan, 2006, 2014) publications contains all environmental chemicals that have been identi-
fied as toxic to the human brain until 2013, based on information from the Hazardous Sub-
stance Data Bank (HSDB) of the US National Library of Medicine. The compounds within Choi et 
al. (2016) include additional chemicals that induce Parkinsonian’s symptoms (Appendix A). 
Natural neurotoxins were identified from the ‘Handbook of Neurotoxicology’. In this book all 
compounds with a described MoA were selected. Additionally we screened the list of all natural 
neurotoxins named in the ‘Handbook of Neurotoxicity’ and identified compounds of clinical rele-
vance which were then included based on expert judgment (Appendix B). For these seven com-
pounds we performed a separate MoA analysis. 
In the next step, MoA analyses for neurotoxicity were performed for 248 individual compounds, 
23 compound classes and 212 natural neurotoxins (Appendix A+B) assembled in the four 
sources described above. Therefore, the compounds were distributed among the experts and 
each compound was reviewed by one expert. In case of uncertainty, e.g. due to multiple MoA 
or insufficient information in the literature, a second expert reviewed the compound. In the 
MoA analyses we focused on the different levels of organization: molecular, cellular, organ and 
organism and searched for causality between the different levels. Such causality between some, 
but not all levels was then called a ‘partial MoA’, while complete causality across all levels was 
needed for a ‘full MoA’. As a first information source we used the Toxnet Database ‘Hazardous 
Substance Data Bank’ (HSDB). Within HSDB we performed a search using the Chemical Ab-
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stracts Service (CAS) number of each compound. Retrieved data on compounds was then 
screened for neurotoxicity MoA as described above. If information from HSDB was not sufficient 
for defining at least a partial MoA, we performed a search in PubMed combining the key word 
‘neurotoxicity’ with search terms related to MoA (e.g. mode of action, mechanism, key event) 
here primarily focusing on review articles. This ‘MoA search’ was then combined with a ‘com-
pound search’ of the respective compound. The ‘MoA search’ was done in title and abstract and 
the ‘compound search’ in the title of the articles (Appendix E). Depending on the amount of ar-
ticles retrieved we extended the search by performing the search for each compound in title 
and abstract or by directly combining the ‘neurotoxicity search’ with the ‘compound search’. The 
selection of articles screened for MoA analyses was then performed by expert judgement. For 
compound classes, we used the following approach: Databases of regulatory organisations or 
governmental organisations or registry dealing with toxicology were screened manually in the 
following order: EFSA > World Health Organization: Environmental Health Criteria (EHC), a se-
ries of monographs prepared by the International Program on Chemical Safety (IPCS) 
(IPCS/WHO reports, used by EFSA for example to define the cumulative assessment group-
CAG) > HSDB. In case an EFSA document was not available, websites from EPA, JECFA, COT 
(UK) and ATSDR were searched. By this procedure, we prepared a list containing the available 
species of a variety of compound classes (Appendix A) and gathered information on neurotoxic 
MoA of compounds of each class including e.g. metabolites common to a class, a released 
metal or only certain species. We then developed the MoA depending on the outcome of these 
analyses and according to the strategy described above. For compound classes without infor-
mation on single species we performed the search for the individual compounds that are listed 
in Appendix A and for the most common names of each compound class.  
Information on MoA of a compound/compound class was collected in the ‘MoA analysis sheet’. 
Here we collected information on the effects described for each compound and classified them 
based on the different levels of biological organization (molecular, cellular, organ, organism), 
the species and the method types (in vitro, in vivo) that were used to identify the effect (Ap-
pendix C shows the layout of the MoA analysis sheet). Based on the collected information each 
expert concluded if the data on causality between at least two levels of organization was suffi-
cient to call it a MoA as described above. In case a MoA was considered as ‘partial’, the com-
pound was labelled as ‘Yes - Partial’ in the MoA sheet or if it was a full MoA, the label was ‘Yes’ 
in the sheet. For a brief overview, we summarized the positive results of the MoA analyses for 
all single compounds and compound classes (Appendix A), as well as for all natural neurotoxins 
(Appendix B) naming the name of the compound/compound class, CAS-number and indicated if 
a (partial) MoA was identified. Compounds with no identified MoA were excluded for the next 
step, the search strategy (2.). 
With regards to the upcoming data collection of the full texts, which is the step after searching 
for articles containing compounds with identified MoA, we sorted the identified compounds by 
MoA groups called ‘MoA/endpoint categories’. In these categories, MoA are collected that share 
common key events (KE). These categories associated with neurotransmission (cholinergic, 
GABAergic, glycinergic, glutamatergic, adrenergic, serotonergic, dopaminergic, neurotransmis-
sion in general), ion channels/receptors (sodium channels, potassium channels, calcium chan-
nels, chloride channels, other receptors), and cellular endpoints (mitochondrial dysfunc-
tion/oxidative stress/apoptosis, redox cycling, altered calcium signaling, cytoskeletal alterations, 
neuroinflammation, axonopathies, myelin toxicity, delayed neuropathy, enzyme inhibition) and 
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other (Appendix D). These MoA categories will be used as ‘Endpoint Categories’ in the data col-
lection sheet.  
 
2.2. Search strategy 
The search procedure consisted of four independent search strategies for searches related to 
compounds, in silico methods, new in vitro methods and methods for mimicking the BBB, which 
are described in detail below. The corresponding four search strings are listed in Appendix E. 
1st search strategy (‘compound-related’): 
The first strategy consists of search strings that are designed to find articles that use alternative 
methods (cellular, cell free and alternative organisms) for assessing neurotoxicity of compounds 
and compound classes with an identified MoA as described under 2.1. This search combines the 
‘neurotoxicity search’ with the ‘alternative method search 1’ and the ‘compound search’ by the 
Boolean operator ‘AND’. The ‘neurotoxicity search’ is designed to identify all articles that are re-
lated to any adverse effects to the nervous system. The ‘alternative method search 1’ is de-
signed to identify all articles that use alternative methods and combines one search string for in 
vitro models, one for cell free models, one for alternative organism based models and one with 
keywords associated to alternative methods in general (e.g. alternative approach, test method, 
testing battery). For the compound search all synonyms as listed in the ChemIDplus 
(https://chem.sis.nlm.nih.gov/chemidplus/)1 database together with the CAS number were 
combined by the Boolean operator ‘OR’. Synonyms with less than four letters were excluded 
because of the high probability of false positive search results. This first search strategy was 
performed for each compound/compound class and search results were distributed to the indi-
vidual experts who identified the respective compounds’ MoA. 
For some compounds the number of retrieved articles was too high for a manual screening and 
most of these articles did not meet our inclusion criteria. Therefore for compounds/compound 
class with >500 search results we performed an additional alternative method related search 
(‘alternative method search 2’) to retrieve only those articles that focus on the use and devel-
opment of alternative methods for neurotoxicity testing. 
2nd search strategy (‘in silico-related’): 
The second strategy was designed to retrieve all in silico models/methods useful for the as-
sessment of neurotoxicity. For this search the ‘neurotoxicity search’ was combined with the ‘in 
silico search’ that consists of key words associated with in silico models/methods such as QSAR, 
in silico or read across by the Boolean operator ‘AND’. 
3rd search strategy (‘method-related’):  
The third search strategy was designed to retrieve all publications on well-characterised alterna-
tive models for NT testing that do NOT study the effect of our preselected compounds, but are 
                                                     
 
1 https://chem.sis.nlm.nih.gov/chemidplus/ 
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dedicated to basic neurotoxicity model description/development. This search combines the ‘neu-
rotoxicity search’ with an adapted version of the ‘alternative method search 1’ and the ‘alterna-
tive method search 2’. We adapted the ‘alternative method search 1’ by removing all general 
alternative methods-related keywords and by searching for ‘in vitro’ instead of ‘in vitro’ com-
bined (AND) with keywords such as ‘model’, ‘assay’ or ‘test’ as in the ‘Alternative method search 
1’ used for the 1st search strategy. The ‘alternative method search 2’ consists of keywords re-
lated to model development and characterization such as ‘assay validation’, ‘assay develop-
ment’, ‘test assay’, or ‘screening method’.  
 
4th search strategy (‘BBB-related’):  
The fourth search strategy was designed to retrieve publications that focus on the use or devel-
opment of BBB models. This search combines a ‘BBB search’ with the ‘alternative method 
search 1 for BBB search’ and the ‘alternative method search 2 for BBB search’. The ‘BBB search’ 
was designed to retrieve all studies with a focus on BBB or BBB models. The ‘alternative 
method search 1 for BBB search’ combines keywords from the search strings for in vitro mod-
els, cell free models, alternative organism based models and the in silico search. The ‘alterna-
tive method search 2 for BBB search’ adds keywords like ‘fabrication’, ‘microtechnology’, or ‘en-
gineering’ to the ‘alternative method search 2’. 
The information collected covered a time span from the 1st of January 1990 to 2017 (between 
April and July, depending on when the searches were performed). The searches were per-
formed in the two major bibliographic databases, Web of Science® (WoS; 
http://apps.webofknowledge.com) and PubMed (http://www.ncbi.nlm.nih.gov/pubmed). The 
searches in PubMed were performed in ‘Title/Abstract’ which includes a search in title, abstract 
and author keywords of the article. The search in WoS was performed in the search field ‘Topic’ 
which includes a search in title, abstract, author keywords and keywords plus® of the article. 
The only exception were the keywords ‘BBB’, ‘brain barrier’ and ‘brain blood barrier’ of the ‘BBB 
search’ which were only searched for in the title in both databases. Publications from the search 
in WoS were limited to English language articles and the document types ‘review’ and ‘meeting 
abstract’ were excluded.  
For the 1st search strategy we performed one search for each compound/compound class. For 
the other search strategies it was one search for each strategy. After each search all duplicate 
articles (based on exact match of title and year were deleted from the search. All articles were 
exported from EndNote, imported into a shared Mendely database and distributed to the ex-
perts. Because Mendeley has an automatic identification of duplicate articles, additional dupli-
cates that were not recognized by Endnote were automatically deleted after import to Men-
deley. Here, it was not possible to reconstruct which articles were deleted. Therefore there are 
slight discrepancies between the amount of articles in Endnote and the amount of articles in 
Mendeley. Appendix A gives detailed information on the number of articles retrieved after each 
search. 
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2.2.1. ‘Grey’ literature search 
Data mining for ‘grey literature’ was performed by a different strategy than scientifically pub-
lished information involving a peer-review process.  
We searched all websites listed in Appendix F in the ‘Search’ function of the respective websites 
with the keywords ‘neurotoxicity’ or, if a search function was not available or only provided a 
google or PubMed search, scanned the website for information on alternative neurotoxicity 
methods. All information on promising methods from the Website search were collected and 
sorted with regard to the specific topics: in vitro, in vivo alternative organisms, in silico and bio-
logical barrier model (Appendix F). 
Additionally, personal contacts were utilized to contact organizations/consortiums currently in-
volved in neurotoxicity method development. Therefore, we designed an email that contained 
the question of unpublished methods for neurotoxicity testing, which was sent to the personal 
contacts by each of the partners. Specifically, 
 VITO contacted: University of Amsterdam (J. Legradi), EPA (Stefanie Padilla) 
 IUF contacted: Coordinator of ESNATS (Jürgen Hescheler), Coordinator of EU-ToxRisk 
(Bob van de Water), EURL-ECVAM (Anna Price), EPA (Kevin Crofton), ZEBET (Gilbert 
Schönfelder), HESI (Michelle Embry), CAAT-US (Helena Hogberg), CAAT-Europe (Marcel 
Leist)   
 UMIL contacted: ALTTOX (community blog), Swiss Centre for applied human toxicology 
(Florianne Tschudi-Monnet), Department of Environmental and Occupational Health Sci-
ences, University of Washington (Lucio Costa/Gennaro Giordano), Institute for Risk As-
sessment Sciences, Utrecht University (Remco Westerink), Department of Neuroscience, 
Karolinska Institute (Sandra Ceccatelli), Istituto Superiore di Sanità (Luisa Minghetti) 
Emails were sent to the organizations/consortiums, all information on promising methods was 
sorted with regard to the specific topics: in vitro, in vivo alternative organisms, in silico, blood 
brain barrier model. 
The language restrictions for ‘grey’ literature are in concordance with the languages spoken by 
the consortium members (English, German, Dutch, Spanish and Italian). 
 
Grey literature search for in silico: 
The result of the first screening of websites offering in silico models or tools is presented in Ap-
pendix F.  This selection included publicly available and commercial websites. These websites 
were further explored and if needed, contacted via the online contact point to obtain more in-
formation.   
During the full paper text screening, additional in silico models came up, as some of the pub-
lished algorithms have been developed to a web-based or a stand-alone QSAR model.  
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2.3. Selection  
2.3.1. Selection based on title and abstract 
The manual study selection process was performed with the Mendeley reference managing 
software using a Mendeley Institutional Edition account as this software made it possible for all 
experts to share the same database. 
The selection process based on title and abstract was an unmasked assessment in which each 
expert screened titles and abstracts of a set of pre-selected articles and made a decision on in-
clusion or exclusion according to the pre-defined selection criteria (see list below). If there was 
an uncertainty in the decision, the article was tagged as ‘un’ (uncertain) and a second expert 
reviewed the same article. Both experts discussed and agreed on a final decision. For documen-
tation of this selection, the ID of the article (PMID, DOI, or ISBN) and the first author of each 
publication were transferred to an Excel sheet. In this sheet, ‘yes’ for included or ‘no’ for ex-
cluded was documented together with the reason for exclusion (Appendix G). 
The decision process in the study selection for title abstract screening was based on the follow-
ing exclusion criteria: 
For all articles from 1st search strategy: (compound-related) 
1. Study does not deal with neurotoxicity 
2. Secondary literature (review, meeting abstract, etc.) 
3. Duplicate 
4. No compound with known MoA tested 
5. DNT study 
6. Wrong species (not human, mouse, rat, chicken, C. elegans, sea urchin, zebra fish, 
xenopus, drosophila) 
7. Test method not in agreement with MoA 
8. Test method not able to measure NT endpoint 
9. Only mixture tested 
10. In vivo study 
11. Not possible to study this endpoint with brain cells in vitro 
12. Article language is not English  
13. Retracted publication 
For the exclusion criteria 4, 7 and 9 we had the following exceptions: 
Articles that focus on the development and characterization of promising alternative models for 
neurotoxicity testing or biological barriers that would be excluded based on these criteria could 
be included if the expert judges these methods as valuable for the projects objectives. These 
articles are tagged by ‘om’ (only method) or ‘bb’ (biological barrier model) in the Mendeley li-
brary. 
Articles that focus on in silico models should not be excluded based on exclusion criteria 4, 7 or 
9. These articles are tagged by ‘comp’ (computational model) in the Mendeley library. 
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For all articles from 2nd search strategy (in-silico-related) 
1. Study does not deal with neurotoxicity 
2. Secondary literature (review, meeting abstract, etc.) 
3. Duplicate 
4. No compound with known MoA tested (not for computational models) 
5. DNT study 
6. Wrong species (not human, mouse, rat, chicken, C. elegans, sea urchin, zebra fish, 
xenopus, drosophila; not for computational models)  
7. Test method not in agreement with MoA (not for computational models) 
8. Test method not able to measure NT endpoint 
9. Only mixture tested, or other test items than chemical compounds (not for computational 
models) 
10. In vivo study (not for computational models) 
11. Not possible to study this endpoint with brain cells in vitro (not for computational models) 
12. Articles language is not English 
13. Artificial neural network (unless for neurotoxicity) 
14. General considerations on AOP for NT 
15. General considerations on computational tools 
For the exclusion criteria 4, 7 and 9 exist the same exceptions as mentioned above.  
 
For all articles from 3rd search strategy (method-related) 
1. Study does not deal with nervous system 
2. Secondary literature (review, meeting abstract, etc.) 
3. Duplicate 
4. DNT study 
5. Wrong species (not human, mouse, rat, chicken, C. elegans, sea urchin, zebra fish, 
xenopus, drosophila) 
6. Test method not able to measure NT endpoint 
7. In vivo study 
8. Not possible to study this endpoint with brain cells in vitro 
9. Articles language is not English 
10. Study does not focus on development/characterization of a valuable alternative test meth-
od/model 
11. No method for NT testing 
 
For all articles from 4th search strategy (BBB-related): 
1. Secondary literature (review, meeting abstract, etc.) 
2. Duplicate 
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3. Wrong species (not human, mouse, rat, chicken, C. elegans, sea urchin, zebra fish, 
xenopus, drosophila) 
4. In vivo study 
5. Articles language is not English 
6. Study does not focus on development/characterization or use of alternative test meth-
od/model 
7. No valuable alternative method 
 
Application of all these criteria led to a total of 1803 articles out of 9066 studies that qualified 
for full text screening.  
For the full-text screening, full-text copies of selected references were obtained by a manual 
search. Therefore a search for the PMID, DOI or the whole title of the articles was performed in 
PubMed, WoS, or google scholar by using the ‘search for PDF’-function or in the local library. In 
case the articles were not retrieved we contacted the corresponding author of the study by 
email. In case of non-resonance, the study was not evaluated. 
Each PDF with the full text was attached to the respective Mendeley reference. 
 
 
2.3.2. Selection based on full text 
The selection process based on full text was an unmasked assessment in which each expert 
screened the full text of a set of pre-selected articles and made a decision on inclusion or exclu-
sion according to the pre-defined selection criteria (see list below). If there was an uncertainty 
in the decision, the article was tagged as ‘un’ (uncertain) and a second expert reviewed the 
same article. Both experts discussed and agreed on a final decision. For documentation of this 
selection, the ID (PMID, DOI or ISBN) and the first author of each publication were transferred 
to an Excel sheet (the Data collection sheet). In this sheet, ‘yes’ for included or ‘no’ for excluded 
was documented together with the reason for exclusion (Appendix H). 
The decision process in the study selection for full text screening was based on all selection cri-
teria for the title abstract screening and the following additional full text exclusion criteria: 
For all articles from 1st search strategy: (compound-related) 
1. The study does not give sufficient experimental detail to assess the described methods 
2. Study on neuroprotection  
3. Only single dose 
4. Manipulated test system 
5. No quantification of endpoints  
6. No full text 
7. Tumor cells 
8. Life stage = not alternative (e.g. zebrafish beyond 5 days post-fertilisation) 
9. Not whole organism method (e.g. expression of sodium channels in Xenopus oocytes in 
vitro method) 
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Dose-response increases the likelihood of a causal association, for this reason evaluations based 
on single dose only were not taken into account, with the exception of those studies considered 
particularly relevant by the expert judgement. In this case, comments to justify have been 
added to the DCS. In general, studies based on at least 3 doses were considered, not to be too 
restrictive.  
 
Studies on neuroprotection were excluded when based on single dose only of the tested com-
pound. 
 
Tumor cells have genetic differences from neuronal cells and physiologically may diverge from 
normal cells in various respects. The analysis therefore mainly focused on: 
- stem/progenitor cells, which also allows for the possibility of generating human CNS neurons 
with normal properties 
- primary cells, which accurately represent mature neurons 
- immortalized cells 
 
Manipulated test systems were excluded since they physiologically may diverge from normal 
cells in various respects. 
 
Quantification of the result allows comparison to other experimental group and statistical analy-
sis necessary to support the plausibility of the study design and data. 
 
 
For all articles from 2nd search strategy (in-silico-related) 
No additional full-text criteria for in silico. 
 
For all articles from 3rd search strategy (method-related) 
1. The study does not give sufficient experimental detail to assess the described methods 
2. Study on neuroprotection  
3. Manipulated test system 
4. No full text 
5. Tumor cells 
6. No particularly new/relevant test method 
 
 
For all articles from 4th search strategy (BBB-related): 
1. The study does not give sufficient experimental detail to assess the described methods 
2. Manipulated test system 
3. No full text 
4. study does not focus on development/characterization of BBB alternative model 
5. published before 2016 
6. No innovative BBB model 
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For studies that focus on the use or development of BBB models we identified four reviews that 
give an overview of established in vitro BBB models up until 2016 (Banerjee et al, 2016a; Helms 
et al, 2016a; Palmer et al, 2013; Wolff et al, 2015b). Starting from these reviews the full text 
screening was only performed for studies that were published in 2016 and 2017. From these we 
selected only those studies that use or develop innovative BBB models. 
 
For all studies that were included based on full text selection we performed an assessment of 
the methodological quality (see below).   
 
 
2.3.3. Selection of ‘grey’ literature 
In general the consortium agreed that ‘work in progress’, e.g. granted projects on method vali-
dation, ring trials, etc. are important for EFSA to recognize. However, methods, which are de-
veloped and presented in various media, but have not yet undergone scientific peer review e.g. 
through a standard scientific publication process should not be taken forward in the process on 
the same grounds as publications from the peer-reviewed literature since such data can be pre-
liminary and open to final adjustments. Due to this fact, the partners used additional criteria for 
the selection of relevant unpublished methods.  
Selection criteria: 
 
 Information on granted projects currently being performed 
 Information containing preliminary results of on-going projects not yet finished 
 
 
2.4. Assessment of methodological quality 
The assessment of methodological quality was performed according to the description in the 
project outline. In short, collected all necessary information on: 
I:  Test substance identification 
 II:  Test system/organism characterisation 
 III:  Study design description 
IV:  Study results and data analysis documentation  
V:  Plausibility of study design and results 
using the ToxRTool. This publicly available tool to assess the reliability of toxicological data is 
based on the approach of Klimisch et al, (1997)2 and will assign a quality score to each study by 
the use of a QA sheet for each publication selected based on the criteria for full text evaluation. 
According to this score, the study is assigned to the following categories: 
 
1. Reliable without restriction (15-18 for in vitro; 18-21 for in vivo alternative or-
ganisms) 
2. Reliable with restrictions (11-14 for in vitro; 13-17 for in vivo alternative organ-
isms) 
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3. Not reliable (<11 for in vitro; <13 for in vivo; or not all red criteria met) 
 
The ToxRTool and the instructions were distributed among all experts. Each expert saved the 
individual QA sheet (Excel-format) for each study including the title of the study, authors and 
year, the score given in each criterion, the final category assigned and possible comments for 
documentation. Studies that obtained a score <11 (in vitro) or < 13 (in vivo), or zero points for 
one of the following criteria:   
 
1. Was the test substance identified? 
2. Is the test system described? 
3. Are doses administered or concentrations in application media given? 
4. Are frequency and duration of exposure as well as time-points of observations explained? 
5. Were negative controls included (give also point, if not necessary, see explanations)? 
6. Were positive controls included (give also point, if not necessary, see explanations)? 
7. Is the study design chosen appropriate for obtaining the substance-specific data aimed at 
(see explanations for details)? 
 
were excluded from the data collection process and method evaluation, unless the expert 
judges the study as valuable. In this case there will be an argumentation why the study should 
not be excluded in the comment section of the data collection sheet. The result of the category 
assigned as well as the total points received per study were documented in the data collection 
sheet (Appendix D). 
 
Information from all included studies were collected in the different data collection sheet for 
either in vitro methods, for alternative organisms, or for in silico approaches. The number of all 
articles retrieved after each search and selection process is summarized in a flow chart in Figure 
1. 
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Figure 1 Graphical summary of publication selection. 
 
2.5. Data Collection   
The data collection sheet is designed to summarize all information from the selected scientific 
papers that are relevant for an evaluation and comparison of the different test systems with re-
gard to the endpoints they are able to assess. For the ‘compound-related’ studies we only col-
lected information on effects that are in accordance with the described MoA. In case of negative 
compounds all endpoint effects were collected.  
Information that was collected from ‘compound-related’ scientific papers: 
Publication ID, first author, journal and year.  
 To identify each publication.   
Selection based on full text (decision 1st reviewer, Argumentation for exclusion) 
Decision 1st reviewer 
 Decision based full text screening and quality assessment (yes/no). 
 
Method type. 
 To distinguish the different method types, in vitro, cell free, organelle, alternative organ-
isms, in silico or a combination of these. In case one publication presents data on more 
than one method type the information is collected in the respective data collection 
sheet. 
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Test system classification/characterisation (test system, species, strain, age of cell 
source or age of alternative organism, cell type, brain region, culture age, serum 
use)  
 To classify the test system that is used in each publication. Each test system will be en-
tered in a separate row.  
 Serum use can alter chemical properties in vitro and thus may change the biological re-
sponse to a chemical. To identify the reason for different effects of test systems after 
chemical exposure it can be crucial to know if the system was treated in the presence of 
serum (yes/no). 
Endpoint assessment. 
Endpoint category. 
 Endpoint categories were pre-defined by MoA analyses as outlined in Appendix D.   
 
Endpoint. 
 The biological or chemical process, response or effect assessed by a test method that is 
grouped into an endpoint category.   
Multiple endpoints. 
 To see if the test method was used to analyse multiple endpoints (yes/no). In case mul-
tiple endpoints were studied, each endpoint with each compound has to be entered in a 
separate row. 
Analytical/test method. 
 The process or procedure used to obtain information on the endpoint. The analytical 
method describes the method that is used to do the endpoint measurement.  
Endpoint-specific controls. 
 Control that selectively and reproducibly modulates the endpoint by a known MoA 
(yes/no). 
Compound testing information (compound name, CAS number, use of multiple test 
compounds, compound classification a priori, concentration range, exposure dura-
tion). 
 Each compound with each endpoint in one test system will be entered in a separate 
row.  
Multiple test compounds. 
 Is more than one compound used in the study (yes/no)? If yes, for each compound a 
new row has to be filled, yet only for those compounds that have a defined MoA. 
Compound classification a priori  
 Negative or positive compound? 
Information on compound effect.  
Effect analysis 
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 Describes how an effect on this endpoint is analysed (e.g. EC50, concentration-response, 
induction/reduction).  
Hazard. 
 Indicates if the endpoint is affected (yes/no). 
Classification. 
 Gives a classification of the compound according to the prediction for this compound in 
the test method (true positive, true negative, false positive, false negative). 
Effect concentration. 
 Gives the concentration range in which the endpoint is affected. 
Data analysis. 
 Describes how the data was analysed (quantitative, qualitative, statistical).  
n = 
 Gives the number of biological replicates (one ‘n’ means one independent experiment). 
Additional information. 
 
Throughput. 
 Indicates if a test system with this specific endpoint is adaptable for high/medium 
throughput (yes/no).  
Reliability score.  
 Gives the rating based on the ToxRtool for reliability, calculated after criteria evaluation 
using the QA sheet. 
Reliability category.  
 Gives the Klimish Category (1-4) based on the ToxRtool rating. 
Comments. 
 
For all ‘method-related’ and ‘BBB-related’ studies the data collection sheet was adapted to col-
lect information with the focus on method type, test system classification/characterisation and 
endpoint assessment (Appendix H). 
 
For the evaluation of ‘in-silico-related’ studies, a section on general information is compiled, fol-
lowed by the quality criteria that are based on the five OECD criteria for QSAR validation (OECD 
report 69 on QSAR validation for regulatory use): 
0. General information 
1. Defining the endpoint  
2. Defining the algorithm 
3. Defining the applicability domain (AD) 
4. Internal and external validation 
5. Providing a mechanistic interpretation 
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3. Results and Discussion 
 
3.1. In vitro 
Data retrieved from 228 publications concerning neurotoxicity of chemicals with known MoA 
during the years 1990-2017 were collected in a data collection sheet and analyzed in multiple 
ways. Because most publications contain several endpoint evaluations measured with different 
methods, different endpoints, different test systems or different compounds, it was not effective 
for the evaluation to work with ‘number of publications’. Therefore, we evaluated the numbers 
of times a test system was used for each endpoint evaluation and/or chemical during the rest of 
this report. E.g., when 5 compounds are evaluated in the same publication for two endpoints 
and one test system, this will result in 10 citations for this one test system. In the end, each of 
these citations is then evaluated with respect to the assay performance for each compound and 
each endpoint. Thus, the number of citations for each test system or cell type category is 
higher than the amount of total publications. For each of this test system/endpoint meas-
ure/compound evaluation one line in the ‘Data Collection Sheet’ was filled. This resulted in 977 
citations within 228 publications, while 1123 publications were excluded according to the de-
fined criteria.  
First, we analyzed the total number of citations over time (Figure 2a). It is obvious, that citation 
numbers fluctuate from year to year irrespective of species or cell type. Next, the usage of cells 
from different species over time was studied. The graph (Figure 2b) shows that rat cells are the 
most cells used over time, followed by mouse and human cells and only few publications were 
included in the data analyses from chicken and Xenopus. Rat cells have been used since the 
1990ies, and since 1993 mouse citations became more frequent. Usage of human cells in our 
selection of articles started in 2002, but really accelerated from the year 2013. Rat and mouse 
cells show fluctuations throughout the whole period. Publications with cells from chicken and 
Xenopus were sporadic with no new chicken publication since 2011. The Xenopus model was 
still used lately. With regards to the cell type (Figure 2c), we found citations for primary cells 
starting from the beginning of the analysis period in 1990. Tumor cells were found to be used 
starting from the early 1990ies. The latest development is the usage of stem-/progenitor cells 
for neurotoxicity evaluation in the early 2000s. 
For the general strategy, publications containing in vitro studies for assessment of NT (n = 228) 
were grouped according to species (human, rat, mouse, chicken and Xenopus), cell type 
(stem/progenitor cells, primary cells, tumor/immortalized cells) and individual test systems (Ap-
pendix I1). Brain regions that primary cells were derived from are specified. These data are 
then evaluated with regards to their performances for certain MoA represented by endpoint 
categories as described in the methods section. A comprehensive list of the MoA analyses can 
be found in Appendix D. Questions addressed within the data evaluation are: 1. In vitro meth-
ods from which species addresses which endpoint categories? 2. What is the predictive capacity 
of each cell type and individual test system for each endpoint category? Which MoA/endpoint 
category can be correctly assessed by which test system?  
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Figure 2 Number of NT citations between the years 1990 and 2017 in total (a) and subdivided for species (b) and for 
cell types (c) amongst the selected publications. 
 
After grouping according to species, we counted 131 citations with human, 644 with rat, 174 
with mouse, 18 with chicken and 10 with Xenopus cells (Figure 3). Of these, 92, 633 and 118 
belonged to the category of stem/progenitor cells, primary cells and immortalized cells, respec-
tively, for all species (Figure 5).  
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Figure 3 Within 228 original NT (selected) in vitro publications published since 1991, a total of 977 citations were 
found for the species human, rat, mouse, chicken and Xenopus. Thereby, some publications contain multiple species 
and are thus counted multiple times. 
 
Species-specific analyses of the identified cell types revealed for human cells 66 (50%), 11 
(8.5%) and 49 (37.7%) citations for stem/progenitor cells, primary cells and immortalized cells, 
respectively; for mouse cells 19 (10.9%), 117 (67,2%),  and 27 (15.5%) citations for 
stem/progenitor cells, primary cells and immortalized cells, respectively; for rat cells 7 (1.1%), 
479 (74.4%), and 42 (6.5%) citations for stem/progenitor cells, primary cells and immortalized 
cells, respectively; for chicken cells 16 (88.9%) and 2 (11.1%) citations for primary cells and 
primary tissue, respectively; and 10 (100%) citations for Xenopus primary cells (Figure 4). 
While due to obvious availability reasons human primary cells are hardly ever employed in in 
vitro NT studies (11; most of them NSC methods, one primary astrocyte method), most data is 
produced with rat primary cells (479) followed by mouse primary cells (117), human 
stem/progenitor (66) and tumor/immortalized cells (49), rat and mouse tumor/immortalized 
cells (42 and 27) and mouse stem/progenitor cells (19; Figure 4). The overrepresentation of 
primary rodent cells is due to historical reasons. However, within the recent years also the 
number of human stem/progenitor cell-based methods is clearly on the rise (Figure 4a). 
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Figure 4 Within 228 original NT (selected) in vitro publications published since 1990, a total of 977 citations were 
found for the species human, rat, mouse and chicken. These are analyzed for usage of stem/progenitor cells, primary 
cells and immortalized cells in each species. Given are numbers of citations of each cell type. 
 
 
Analyzing the species distribution within the different cell types, it is obvious that most data 
is generated with primary cells of rat 479 (75.7%) > mouse 117 (18.5%) > chicken 16 (2.5%) 
> human 11 (1.7%) > xenopus 10 (1.6%) origin. For the cell type stem-/progenitor cells, the 
ranking is different. Here, mostly human with 66 (71.7%) citations followed by mouse 19 
(20.7%) and few rat 7 (7.6%) citations were counted. Similarly, immortalized cells were of hu-
man 49 (41.5%) > rat 42 (35.6%) < mouse 27 (22.9) origin. Also primary tissues from rat 114 
(90.5%) > mouse 8 (6.3%) and a couple from human 2 (1.6%) and chicken 2 (1.6%) were uti-
lized (Figure 4). Also the cell free methods were sparse; human and mouse studies 3 citations 
each (Figure 4). On the total scale, of the 977 citations, 633 (64.8%) citations were from prima-
ry cells, here 479 (49% from total) from rats. This illustrates impressively, that of the studies 
selected, we have the greatest part of information generated with primary rat cells. 
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Figure 5 NT in vitro studies (228) employing stem/progenitor, primary, immortalized and tumor cells from human, 
rat, mouse, chicken and Xenopus. Given are the distributions of species within each cell type category with the num-
bers of citations.  
 
In addition to the cell-based methods, there are a number of studies using cell free, organelle-
based systems. Species distribution of organelles is shown in the pie graph (Figure 5). Here the 
rat dominance is obvious. For understanding the test systems behind, we provide Table 1, 
where all the different systems for the individual species are listed. While for human, recombi-
nant proteins are the only test systems used, rodents employed cell membrane (28 citations), 
mitochondria (24 citations), microsomes, synaptosomes (rat) and also recombinant protein 
(mouse). In the rat, the highest number of citations was recorded for synaptosomes (41 cita-
tions). Studies with organelles from the other species were negligible. 
 
 
Table 1:  Overview over the types of organelles used from different species 
 # citations 
Human 5 
neuronal tau-40 protein in phosphate buffer  2 
recombinant  AChE 3 
Mouse 9 
cell membrane 2 
mitochondria 3 
recombinant  AChE 3 
synaptosomes 1 
Rat 101 
cell membrane 26 
microsome 8 
mitochondria 18 
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mitochondrial suspension from liver 3 
synaptosomal mitochondria 5 
synaptosomes 41 
Total 113 
 
When looking at the tissue origin of the primary cells, they were derived from different brain 
regions. The regional distribution of cells across species is shown in Figure 6. In rat, across the 
479 citations for primary cells most cultures were generated from cerebral cortex (241 citations) 
followed by hippocampus (50 citations), mesencephalon (55 citations), cerebellum (40 cita-
tions), whole brain (46 citations) and striatum (29 citations). In mouse, across the 117 cita-
tions, cerebral cortex (44 citations) and mesencephalon (36 citations) were the most widely 
used. In humans, only 2 citations use primary cells generated from whole brain. In chicken, 
forebrain was the most frequently used brain area (10 citations) followed by cerebellum (5 cita-
tions). In Xenopus, no brain region was used because isolated receptors were expressed in 
Xenopus oocytes. 
 
 
 
Figure 6 Brain region distribution of primary neural cells and primary tissues (see Figure 5) within the different spe-
cies.  
 
Next, we evaluated which test systems underlie the different cell types. Table 2 summarizes 
the Test Systems found across the different species. Amongst the rat primary cells, the by far 
most frequently used cell type within this investigation, primary neurons are the most frequent-
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ly used test system (194 citations, 40.5% of rat primary cells). Also for mouse test systems, 
primary neurons were the ones with the highest number of citations (62, 53% of all mouse 
primary cells). For human cultures, hiPSC-derived neurons were highest cited (49 citations, 
75.4% of all human stem-/progenitor cells). Although for chicken there were only 18 citations in 
total, also here the primary neuronal cultures dominate (10 citations, 62.5% of all primary 
chicken cells). Glia cells were not cited that often, here for human 2 (4.1%) primary glia cul-
tures, for mouse 3 (2.6%) primary glia cultures and for rat 55 (11.5%) primary glia cultures 
were found. Only from the rat microglia cultures were identified (7 citations, 1.5% of all rat 
primary cells). Isolated glia is rarely published, however, mixed neuronal/glia cultures can be 
found more frequently. This makes sense because the interplay of neurons and glia often de-
termines toxicity, thus a co-culture model of multiple cell types seems useful. Here, 8 citations 
(12.1% of stem-/progenitor cells) with hiPSC-derived mixed cultures, 15 (12.8% of mouse pri-
mary cells) mouse mixed neuron and glia cultures and 84 (17.5% of rat primary cells) of those 
cultures derived from rat were identified (Table 4). Although there are a large variety of test 
systems in this data set, it is obvious that for most test systems publications are few, and only 
for some publications are sufficient for deeper data analyses. 
 
Table 2:  Test systems from each cell type utilized for NT in vitro publications. The # citations 
indicates the frequency of model citation, including distinct endpoint (categories) and chemi-
cals. 
 # citations 
Human 130 
Immortalized cells 49 
CHME-5 (microglia) 3 
LUHMES 32 
mesencephalic cells (MESC2.10) 9 
ReNcell CX cells 5 
primary cells 11 
NSC derived culture 8 
primary glia 2 
sigmoid colon tissue 1 
stem/progenitor cells  65 
iPSC derived mixed culture (neurons+glia) 8 
iPSC derived neurons 49 
NPCs 1 
undifferentiated neurospheres 8 
primary tissue 2 
neuronal tau-40 protein in phosphate buffer  2 
cell free 3 
recombinant  AChE 3 
Mouse 173 
Immortalized cells 27 
2.3D (neuroepithelial cells differentiated into astrocytes and neurons) 1 
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BV-2 15 
CRL-2534, astrocyte type III 2 
GT1-7 cells (hypothalamic cell line) 2 
HT-22 5 
N9 microglia 1 
SN4741 1 
primary cells 116 
brain slices 1 
cerebellar granule cell 3 
cerebellar granule neurons 3 
dorsal root ganglia/spinal cord cultures 2 
isolated mouse hemidiaphragm muscles  1 
mixed culture (dopaminergic neurons+astrocytes) 22 
mixed culture (neurons+microglia) 1 
mixed culture (spinal cord - skeletal muscle) 1 
murine brain microvascular endothelial cells 1 
neuron/astrocyte contact co-culture 1 
primary glia 3 
primary neurons 62 
mixed neuron and glia cultures 15 
Dorsal root ganglia 1 
stem/progenitor cells  19 
ESC 3 
ESC derived glutamatergic neurons 9 
ESC derived neurons 7 
primary tissue 8 
brain homogenate 2 
cell membrane 2 
Mitochondria 3 
Synaptosomes 1 
cell free 3 
recombinant  AChE 3 
Rat 567 
Immortalized cells 38 
E18 neuroblast 2 
HAPI 8 
N27 27 
RBE4 5 
primary cells 408 
astrocyte rich culture 11 
brain slices 33 
cell membrane 4 
cerebellar granule cell 13 
cerebellar granule neurons 9 
dopaminergic neurons 1 
   
  
 
 
www.efsa.europa.eu/publications 31 EFSA Supporting publication 2018:EN-1410 
 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to 
the rights of the authors. 
 
hippocampal CA1 pyramidal neurons  1 
oligodendrocyte progenitors 1 
primary glia 55 
primary microglia 7 
primary neurons 194 
primary oligodendrocytes 1 
purkinje neurons 2 
re-aggregating brain cell cultures 59 
trigeminal ganglion neurons 1 
mixed neuron and glia cultures 84 
Dorsal root ganglia 3 
stem/progenitor cells  7 
differentiated mesencephalic NPCs 4 
differentiated striatal neural NPCs 3 
tumor cells 2 
PC6-3 2 
primary tissue 112 
brain homogenate 17 
cell membrane 22 
Microsome 8 
Mitochondria 18 
mitochondrial suspension from liver 3 
synaptosomal mitochondria 5 
Synaptosomes 41 
Chicken 18 
primary cells 16 
cerebellar bergmann glia 5 
primary neurons 10 
Spheroids 1 
primary tissue 2 
brain homogenate 2 
Xenopus 10 
primary cells 10 
neurolemma in Xenopus Oocytes 6 
sodium channels in Xenopus Oocytes  4 
Total 898 
 
 
In addition, cell free systems and organelles were used in our study collection. Here, the rat is 
the predominant species with 114 citations over 11 (mouse) and 5 (human; Table 2). In total, 
we recorded 132 citations with such systems. 
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Before the data collection, we assessed the MoA for 258 individual neurotoxic compounds and 
23 compound classes (Appendix A, B and D). These MoA analyses were performed rather strin-
gently, meaning that if a relation between levels of organization was not causally linked, the po-
tential MoA was not included. This procedure might have resulted in elimination of valid studies 
but reduced the probability of inclusion of false-positive studies. According to these MoA, we 
defined endpoint categories where endpoints assessed in the studies were grouped into. The 
list of endpoints grouped into endpoint categories can be found in Appendix D. One endpoint 
category was ‘negative’. This one was not retrieved from the MoA analyses, but resembles the 
negative NT compounds that we identified during the screening process. Because performance 
of test systems concerning negative compounds is crucial, we inserted them into the endpoint 
categories. In addition, we grouped studied endpoint categories by species (Figure 7).  
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Figure 7 Distribution of # citations across endpoint categories within the different species. Endpoint categories were 
derived from the compounds’ MoAs. 
 
When evaluating the collected 1223 publications, only the studies that were in agreement with 
the identified MoA of the neurotoxic compounds were included leading to the 977 citations. This 
procedure guarantees, that an effect observed in the in vitro system is a ‘true’ effect and allows 
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the categorization into ‘true positives’ and ‘false negatives’. A list of compounds contributing to 
endpoint category evaluations is given in Appendix D. In addition, negative compounds identi-
fied in the studies were classified into ‘true negatives’ and ‘false positives’. Appendix I2 summa-
rizes the total number of citations for each endpoint category divided by species as well as the 
number of true and false positives and negatives for each endpoint category and species. In the 
following sections, especially the false negatives will be analysed in the individual studies’ con-
texts for verification of results. 
 
Human 
 
These analyses show that for 131 human citations, 89 were true positives and 22 true nega-
tives. 8 false positives were identified and 12 false negatives. Of the 12 false negatives, 10 cita-
tions were studies in stem-/progenitor cells and 2 citations studies in immortalized cells. Going 
one level deeper into the data, i.e. analyzing the cell types (Table 3) and test systems (Appen-
dix I3) that the false positives were generated with, reveals that the 11 false negatives be-
longed to the endpoint categories ‘mitochondrial dysfunction/oxidative 
stress/apoptosis’ (11 citations) and ‘axonopathies’ (1 citation).  
Table 3:  Total number of citations for endpoint categories grouped for human cell types. Pre-
dictivity analyses were performed for each endpoint category and cell type by analysing true 
positives (t.p.), false positives (f.p.), true negatives (t.n.) and false negatives (f.n.). 
 
f.n. f.p. t.n. t.p. total # 
Human 12 8 22 89 131 
cell free 
   
3 3 
Stimulation of Cholinergic Neurotransmission 
   
3 3 
Immortalized cells 2 
  
47 49 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 2 
  
35 37 
Redox Cycling 
   
11 11 
Stimulation of dopaminergic Neurotransmission 
   
1 1 
primary cells 
   
11 11 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
   
10 10 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
primary tissue 
   
2 2 
Cytoskeletal Alterations 
   
2 2 
stem/progenitor cells  10 8 22 25 65 
Axonopathies 1 
  
1 2 
Cytoskeletal Alterations 
   
2 2 
Inhibition of Cholinergic Neurotransmission 
   
2 2 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 9 
  
16 25 
Negative 
 
8 22 
 
30 
Neuroinflammation 
   
1 1 
Other 
   
1 1 
Redox Cycling 
   
3 3 
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False negative data for the endpoint categories ‘mitochondrial dysfunction/oxidative 
stress/apoptosis’ was generated with LUHMES cells (2 citations), which belong to the immor-
talized cells, with hiPSC-derived neurons (4 citations) or mixed cultures (2 citations) and to un-
differentiated neurospheres (3 citations).   
 
These false negatives in the LUHMES cells were the endpoint LDH leakage upon treatment 
with MPP+ within 1 study (Smirnova et al, 2016). However, LUHMES cells had 30 true positives 
for this endpoint. These 30 citations were derived from 5 publications using a total of 4 com-
pounds (cyanide, methylmercury, MPP+ and rotenone). True positives for MPP+ came from the 
same study by Smirnova et al, (2016), yet measured viability via the resazurin assay. Thus, it is 
not the test system producing a false negative, but the test method. Interestingly, in the 
LUHMES cell system rotenone produced true positives for both, the LDH leakage and the 
resazurin assay (Smirnova et al, 2016). Thus, the LDH assay cannot be per se judged as non-
applicable for assessing cell death in LUHMES cells. Possibly, it is a matter of detection time be-
cause apoptotic cells primarily do not release LDH because they are forming apoptotic bodies, 
which are then eliminated by immune cells. From a total of 32 compounds tested, this cell sys-
tem has a false negative rate of 6.25% becoming 0% when considering the LDH aspect.  
The 3 false negatives in the hiPSC-derived cells were diverse endpoint measures (electro-
physiological recording, DAPI staining, caspase 3/7 assay) with rotenone, methylmercury, 
chlropyrifos-oxon or arsenite published in 3 articles (Zagoura et al, 2017; Druwe et al, 2015; Li 
et al, 2005). With such cells, also true positives (5 citations) were identified using hiPSC-derived 
mixed cultures and 5 citations using hiPSC-derived neurons. Compounds were also rotenone 
(Zagoura et al, 2017b), and here again, one study compiled positive and negative endpoints 
measures for the same test system and compound: while effects on DAPI staining and electro-
physiological recordings were negative, immunocytochemistry and qPCR were positive. Hence, 
rotenone administered for 24 hours had no acute cytotoxic effect on the cells, yet induced Nrf2 
translocation, reduced Keap cytoplasmic localization, and subsequently induced the Nrf2-
dependent gene NQOR1. Moreover, rotenone induced GFAP and reduced tyrosin hydroxylase 
immunoreactivity (Zagoura et al, 2017b). These data suggest that the hiPSC-derived mixed cul-
tures detect rotenone effects on neurons and glia and thus the false negative is not a ‘real’ false 
negative, just reflects the ability of the cells to compensate for rotenone effects on mitochon-
dria, at least for 24 hours. Considering the Zagoura et al. study as not a ‘real’ false negative, 
the false negative rate of hiPSC-derived mixed cultures is 0%. 
Also methylmercury and chlorpyrifos-oxon had true positive and false negative citations in one 
study (Druwe et al, 2015). In this study not mixed cultures, but pure hiPSC-derived neurons 
(iCell neurons) were used. Methylmercury and chlorpyrifos-oxon reduced a protease marker 
of cell viability, yet did not activate caspase-3/7. For arsenite, neither was affected (false nega-
tives). It is possible that the false negative effects are due to lack of astrocytes in the cultures 
because astrocytes are crucial for neuronal protection, yet can also confer to neurotoxicity 
(Kubik & Philbert, 2015; Maurer & Philbert, 2015). Other studies measured effects of 
methylmercury on mitochondria function and LDH leakage (true positives; Wilson et al, 2014). 
No caspase activity was measured here. This work uses hES-derived neurons purchased from 
Aruna Biomedical, Inc. (Athens, GA, USA), also in absence of glia. Interestingly, 12 positive and 
negative NT compounds used in this study produced true positive data for mitochondria-
related/cytotoxicity endpoints for 6-hydroxydopamine, acrylamide and methylmercury, true 
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negative data for the same endpoints for saccharin, nadolol, metformin, amoxicillin, while for 
celecoxib and ascorbic acid mitotracker was true negative, but MTT was false positive. 
Diphenhydramin was false positive for both tests, mitotracker and MTT. From a total of 9 com-
pounds tested, this cell system has a false negative rate of 44.44%. 
Also false negative data was collected from studies in undifferentiated NPC, a cell type rep-
resenting the NPC niche in the adult hippocampus. However, one of the false negative citations 
was due to timing, i.e. 2-13 hours rotenone exposure did not activate caspase-3, while 24 hours 
exposure produced a true positive result (Li et al, 2005). The two additional false negatives be-
longed to non-activation of caspase-9. Caspase-9 is the first caspase interacting with cyto-
chrome c released from the mitochondria and should be activated before caspase-3. Hence, 
timing of endpoint determination might be an issue here, and not that the cells do not undergo 
apoptosis as seen by the activated caspase-3. Because of the uncertainties and the overall low 
number in compounds studied, a predictivity analysis does not seem reasonable. 
In the endpoint category ‘axonopathies’, one true and one false positive was identified. 
Again, these belong to the same study (Wilson et al, 2015) and show different effects of 
acrylamide on hES-derived neuronal cell viability and neuronal morphology indicating that neu-
ronal morphology is a more sensitive endpoint than cell viability.  
 
 
Table 4:  List of negative compounds 
True negative     
Compound CAS# Species 
Acetaminophen 103-90-2 Mouse 
Phthalate   Mouse 
1,2 Propandiol 57-55-6 Rat 
Quinmerac 90717-03-6 Rat 
Paraquat 1910-42-5 Rat 
Salicylic acid 69-72-7 Rat 
Ibuprofene 15687-27-1 Rat 
(2,4-Dichlorophenoxy)acetic acid 2702-72-9 Rat 
Amoxicillin 26787-78-0 Human 
Celecoxib 169590-42-5 Human 
D-sorbitol 50-70-4 Human 
L-ascorbic acid 50-81-7 Human 
Metformin hydrochhloride 1115-70-4 Human 
Nadolol 42200-33-9 Human 
Saccharin 82385-42-0 Human 
Acetaminophen 103-90-2 Human 
Amoxicillin 26787-78-0 Human 
Glyphosate 1071-83-6 Human 
Rotenone 83-79-4 Rat 
Cyanide 57-12-5 Rat 
   
  
 
 
www.efsa.europa.eu/publications 37 EFSA Supporting publication 2018:EN-1410 
 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to 
the rights of the authors. 
 
    
  
 
False positives     
Compound CAS# Species 
Aniline 62-53-3 Rat 
Celecoxib 169590-42-5 Human 
Diphenhydramine 147-24-0 Human 
L-ascorbic acid 50-81-7 Human 
Nadolol 42200-33-9 Human 
Saccharin 82385-42-0 Human 
 
Of the negative compounds documented within this review with human models (Table 3), 22 
citations were true negatives and 8 citations false positives. Looking at the compounds be-
hind these data, saccharin or nadolol altered neuronal morphology (false positive), while it did 
not alter mitochondrial transmembrane potential (assessed by mitotracker), cytotoxicity (LDH 
release) or cell viability (MTT assay) and was thus a true negative on these endpoints in hES-
derived neurons (Wilson et al, 2015). Similarly, celecoxib reduced cell viability (false positive), 
yet had no effect on mitochondrial transmembrane potential or neuronal morphology (true neg-
ative). L-ascorbic acid altered cell viability and neuronal morphology with no effect on mito-
chondrial transmembrane potential (Wilson et al, 2015). Acetaminophen and glyphosate behave 
as a true negative in the caspase and protease marker cell viability assays (Druwe et al, 2015) 
and also amoxicillin is negative in all tested endpoints (Druwe et al, 2015; Wilson et al, 2015). 
Sorbitol and metformin did not alter any tested endpoint either (true negative; Wilson et al, 
2015). In contrast, there are compounds like diphenhydramine, which is stated as a non-toxic 
compound, but produces effects in all endpoints tested (cell viability, mitochondrial 
transmembrane potential, neuronal morphology) and accordingly is a false positive. However, 
antihistamines like diphenhydramine are known to have acute CNS effects in humans  (Simons 
E, 1994). Therefore, the a priori classification of diphenhydramine by the authors might have 
been incorrect (Wilson et al, 2015). 
Taken together, these analyses show that for the cell types, the number of false negatives and 
false positives (Table 4) seems over-estimated. Most of the false-negatives are due to multiple 
cytotoxicity/cell viability assays, where most of the time the LDH assay is the least sensitive. Ef-
fectively, when cells undergo apoptosis, LDH is not, or to a later time point released because 
apoptotic cells are primarily eliminated via apoptotic bodies (Figure 8). Of the false positives 4 
might be due to a priori misclassification. 
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Figure 8 The process of apoptosis. By Aaron Smith, Michael AF Parkes, Georgia K Atkin-Smith, Rochelle Tixeira, Ivan 
KH Poon - Wikiversity:Draft:WikiJournal of Medicine/Cell disassembly during cell death, CC BY 4.0, 
https://commons.wikimedia.org/w/index.php?curid=59865845 
 
Performance of human test systems is summarized in the following bar graphs. For each spe-
cies, these are divided into one graph with true positives and negatives on the top and one 
graph with false positives and negatives on the bottom. The data has to be regarded with cau-
tion, especially for the false negatives as discussed above.  
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Figure 9 Performance analyses of human cell types with regards to the ability to identify compounds of the respective 
endpoint categories correctly. The false negatives of the endpoint category have to be regarded with caution (see 
discussion above). 
 
This graph (Figure 9) demonstrates that immortalized cells, which are mainly LUHMES cells and 
also a few citations with immortalized mesencephalic cells (MESC2.10; Appendix I3) are valu-
able to assess few endpoint categories with a very good prediction for these endpoints. Primary 
cells are hardly ever used and are due to ethical and practical reasons not suited for testing 
purposes. Stem-/progenitor cell-based methods dominate the different endpoint categories, but 
compared to the sum of endpoint categories relevant for neurotoxicity evaluation, these are 
only a few. False compound classification is in reality less than shown in this graph as already 
stated above. Thus, stem-/progenitor cell-based test systems have the ability to assess multiple 
endpoint categories and seem suited for neurotoxicity evaluation. Clearly more research is 
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needed to enlarge the endpoint categories with these cell models as they are unlimitedly avail-
able and bear no ethical concerns.  
 
 
Mouse 
Over a total of 174 mouse citations, 163 resulted true positive, 2 true negative and 9 false 
negative. Endpoint categories reporting false negative are ‘mitochondrial dysfunc-
tion/oxidative stress/apoptosis’ (6 citations), ‘Redox-cycling’ (2 citations) and ‘stimula-
tion of cholinergic transmission’ (1 citations). Several endpoints have been considered in 
these categories.  
Table 5:  Total number of citations for endpoint categories grouped for mouse cell types. Pre-
dictivity analyses were performed for each endpoint category and cell type by analysing true 
positives (t.p.), false positives (f.p.), true negatives (t.n.) and false negatives (f.n.). 
 
f.n. f.p. t.n. t.p. total # 
Mouse 9 
 
2 163 174 
cell free 
   
3 3 
Stimulation of Cholinergic Neurotransmission 
   
3 3 
Immortalized cells 2 
  
25 27 
Axonopathies 
   
1 1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
   
12 12 
Redox Cycling 2 
  
10 12 
Stimulation of Glutamatergic Neurotransmission 
   
2 2 
primary cells 7 
 
2 107 116 
Activation of Sodium Channels 
   
9 9 
Altered Calcium Signaling 
   
1 1 
Axonopathies 
   
1 1 
Enzyme Inhibition 
   
1 1 
Inhibition of Chloride Channels 
   
1 1 
Inhibition of Cholinergic Neurotransmission 
   
4 4 
Inhibition of GABAergic Neurotransmission 
   
7 7 
Inhibition of Sodium Channels 
   
2 2 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 6 
  
58 64 
Redox Cycling    1 1 
Negative (compound used as negative) 
  
2 
 
2 
Neuroinflammation 
   
6 6 
Neurotransmission in General 
   
1 1 
Other 
   
2 2 
Stimulation of Cholinergic Neurotransmission 1 
  
8 9 
Stimulation of dopaminergic Neurotransmission 
   
1 1 
Stimulation of GABAergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic Neurotransmission 
   
4 4 
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primary tissue 
   
8 8 
Effects on Other Neuronal Receptors 
   
2 2 
Inhibition of dopaminergic Neurotransmission 
   
1 1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
   
3 3 
Stimulation of Cholinergic Neurotransmission 
   
2 2 
stem/progenitor cells  
   
19 19 
Altered Calcium Signaling 
   
1 1 
Inhibition of Cholinergic Neurotransmission 
   
12 12 
Inhibition of Glycinergic Neurotransmission 
   
3 3 
Other 
   
2 2 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
 
In the endpoint category ‘mitochondrial dysfunction/oxidative stress/apoptosis’, diel-
drin results as false negative for general cell death in mouse mesencephalic mixed glia-neuron 
cells when determined by counting cells visualized by DAPI-staining. When assessing specific 
cytotoxicity for DA- or GABAergic neurons by means of TH+ and GAD+ neurons count respec-
tively, the compound is a true positive. This points to the relevance of the test system and 
again here, similar to the human studies, in light of the whole study, lack of general cytotoxicity 
cannot be considered as a false negative for the test system (Sanchez-Ramos et al, 1998). Dif-
-carboline studies found 3 false negative citations in 2 publications (Hamann et al, 
2006; 2008). All three were 9-methyl-beta-carboline xHCl, which belongs to the -carboline 
compound class, yet is not a neurotoxic, but a neuroprotective member of this class (Hamann 
et al, 2008). Hence, primary mesencephalon cells from mouse brain do not have any ‘real’ false 
negatives in the endpoint categories ‘mitochondrial dysfunction/oxidative 
stress/apoptosis’. 
In the endpoint category ‘Redox-cycling’, paraquat resulted as false negative for ROS produc-
tion measured with DCF on BV2 microglial cells, when measurements were performed within 5h 
and for viability (assessed by MTT test) within 24h (Miller et al, 2007). Both these parameters 
cell death phenomenon (Miller et al, 2007). These results are consistent with what is observed 
in neuronal cultures from mice (mesencephalon and hippocampal immortalized neurons) and 
N9 immortalized microglia, where viability and oxidative stress are affected within 24 h but at 
higher concentrations (300-  (Zhao et al, 2017; Lee et al, 2015a). Thus, is not the test 
system that produces the false negative but the experimental conditions chosen. 
In the endpoint category ‘stimulation of cholinergic transmission’, glyphosate produced a 
false negative result in cortical mouse cultures grown on MEAs (Vassallo et al, 2017). This was 
in agreement with cortical rat cultures of different laboratories in the same study as well as in 
other studies (McConnell et al, 2012; Valdivia et al, 2014; Alloisio et al, 2015). In this study, 
chlorpyrifos oxon, deltamethrin and domoic acid were identified as true positives. Chlorpyrifos 
oxon is in the same endpoint category than glyphosate. In addition, glyphosate did not produce 
a single positive hit in this data collection. Hence, time and dose/concentration have to be ques-
tioned for the identified MoA. It can also be considered that the identified MoA might not be 
solely responsible for glyphosate toxicity. 
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Taken together, the false negatives identified in the data evaluation, were for the most part not 
‘real’ false negatives, giving the mouse systems have a very good predictivity. Over all, per-
formance of mouse test systems is summarized in the following bar graphs. For each species, 
these are divided into one graph with true positives and negatives on the top and one graph 
with false positives and negatives on the bottom. The data has to be regarded with caution, es-
pecially for the false negatives as discussed above.  
 
 
Figure 10 Performance analyses of mouse cell types with regards to the ability to identify compounds of the respec-
tive endpoint categories correctly. The false negatives of the endpoint category have to be regarded with caution 
(see discussion above).  
 
Figure 10 illustrates that in the mouse over all there are very few false positive or false negative 
studies identified. Immortalized mouse cells, which are mainly BV-2 cells, similar to human im-
mortalized cells, have the ability to study few endpoint categories with a very good prediction 
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for these endpoints. Primary cells dominate mouse studies. 18 endpoint categories are studied 
with this cell type, few false negatives that are discussed above and do not really classify as 
false when going back into the studies. Stem-/progenitor cell-based methods of mouse are few. 
These are used for studying cholinergic neurotransmission-related endpoints, as are also cell 
free methods. Data of primary mouse cells will serve as a good reference when working with 
and comparing data to human stem-/progenitor cell-based methods. Such species comparisons 
were previously performed with mouse and rat tumor cells (Schmuck & Ahr, 1997; Canete & 
Diogene, 2010, 2008, Hong et al, 2016, 2013; Huff & Abou-Donia, 1995; Case et al, 2016; 
Zhang et al, 2007; Campanha et al, 2014) and can be transferred to human stem-/progenitor 
cell-based methods. Such analyses can validate human in vitro methods for a variety of end-
points relevant for different neurotoxicity MoA. 
 
Rat 
Evaluating rat citations, of the 644 total citations, 529 were true positives and 22 true nega-
tives. 85 false negatives were identified and 8 false positive. Of the 85 false negatives, 65 cita-
tions were studies in primary cells and 16 citations studies in primary tissue. Going one level 
deeper into the data, i.e. analyzing the cell types (Table 6) and test systems (Appendix I5) that 
the false negatives were generated with, reveals that the 85 false negatives mainly belonged to 
the endpoint categories ‘mitochondrial dysfunction/oxidative stress/apoptosis’ (32 cita-
tions) and ‘neuroinflammation’ (11 citation). These distribute between the cell types primary 
cells and primary tissue. The remaining are scattered across a large variety of endpoint catego-
ries. 
 
Table 6:  Total number of citations for endpoint categories grouped for rat cell types. Predic-
tivity analyses were performed for each endpoint category and cell type by analysing true posi-
tives (t.p.), false positives (f.p.), true negatives (t.n.) and false negatives (f.n.). 
 
f.n. f.p. t.n. t.p. total # 
Rat 85 8 22 259 644 
Immortalized cells 4 
  
38 42 
Altered Calcium Signaling 
   
1 1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
   
17 17 
Neuroinflammation 
   
2 2 
Redox Cycling 4 
  
18 22 
primary cells 65 1 17 334 408 
Activation of Sodium Channels 5 
  
18 23 
Altered Calcium Signaling 
   
5 5 
Axonopathies 
   
10 10 
Cytoskeletal Alterations 4 
  
1 5 
Inhibition of Adrenergic Neurotransmission 
   
2 2 
Inhibition of Cholinergic Neurotransmission 3 
 
2 4 9 
Inhibition of dopaminergic Neurotransmission 1 
  
2 2 
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f.n. f.p. t.n. t.p. total # 
Inhibition of GABAergic Neurotransmission 5 
  
33 38 
Inhibition of Glycinergic Neurotransmission 
   
4 4 
Inhibition of Sodium Channels 
   
1 1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 21 
 
2 176 199 
Myelin Toxicity 
   
2 2 
Negative (compound used as negative) 
 
1 15 
 
16 
Neuroinflammation 11 
  
20 31 
Neurotransmission in General 1 
  
5 6 
Other 
   
4 4 
Redox Cycling 3 
 
1 39 43 
Stimulation of Cholinergic Neurotransmission 9 3 4 38 54 
Stimulation of dopaminergic Neurotransmission 
   
9 9 
Stimulation of GABAergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic 
Neurotransmission 3 
  
10 13 
primary tissue 16 
  
98 114 
Activation of Sodium Channels 
   
6 6 
Altered Calcium Signaling 2 
  
12 14 
Axonopathies 
   
5 5 
Effects on Other Neuronal Receptors 3 
  
9 12 
Enzyme Inhibition 
   
4 4 
Inhibition of dopaminergic Neurotransmission 
   
6 6 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 11 
  
35 46 
Redox Cycling  2 2 
Neurotransmission in General 
   
2 2 
Stimulation of Cholinergic Neurotransmission 
   
12 12 
Stimulation of dopaminergic Neurotransmission 
   
2 2 
Stimulation of GABAergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic 
Neurotransmission 
   
2 2 
stem/progenitor cells  
   
7 7 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
   
5 5 
Redox Cycling 
   
2 2 
 
False negative data for the endpoint categories ‘mitochondrial dysfunction/oxidative 
stress/apoptosis’ was generated with primary glia (4 citations), primary microglia (2 cita-
tions), primary neurons (9 citations), re-aggregating brain cell cultures (3 citations), isolated mi-
tochondria (9 citations) or synaptosomes (2 citations).   
The false negatives in the primary glia cells (astrocytes) concern acrylonitrile cytotoxicity 
measured via MTT and LDH assays, lipid peroxidation measured by F2-isoprostanes and Nrf2 
protein expression. Acrylonitrile caused a strong induction of the cellular glutathione content 
(Caito et al, 2013). Therefore, these cells are able to compensate oxidative damage by increas-
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ing defense mechanisms. As there is no cell damage involved, this test system is not suited as a 
stand-alone NT test system due to its limited sensitivity towards ROS. 
The 2 false negatives in the primary microglia cells concern acrylonitrile cytotoxicity meas-
ured via MTT and LDH assays. Acrylonitrile causes lipid peroxidation measured by F2-
isoprostanes and Nrf2 protein expression. Acrylonitrile caused an induction of the cellular gluta-
thione content, yet, GSH levels in microglia are much lower than in primary astrocytes suggest-
ing the higher susceptibility of microglia towards ROS compared to astrocytes (Caito et al, 
2013). Although there is no cell death involved, this test system shows signs of oxidative stress, 
yet it is not suited as a stand-alone NT test system due to its limited cell type composition. 
The 9 false negatives in the primary neuronal cultures concern 5 different studies. D-
amphetamine induces apoptotic cell death in primary fetal cortical cultures with decreasing bcl-
XL and increasing bcl-XS. Yet, bax gene expression is unaltered (false-negative; (Stumm et al, 
1999). This cannot be considered as a ‘real’ false negative because here bcl-XL/S are the driving 
factors for apoptosis that the cell system is able to detect. The low-concentration study by 
Nogueira et al, (2014) show that D-amphetamine promoted significant mitochondrial dysfunc-
tion and elicited neuronal death in primary mixed neuronal/glial cultures. Moreover, in some 
cultures caspase 3 activity was activated. The 4 false negatives in this study are based on ex-
perimenting with exposure time and concentration. In total, this test system is well suitable for 
studying D-amphetamine-induced ROS mitochondrial dysfunction and apoptotic cell death at 
exposure levels that are relevant for human exposure. Also Hondebrink et al, (2016) studied the 
effects of D-amphetamine on neuronal cell death. However, they measured neutral red uptake 
30 min after exposure, which is far too short for detecting cell death. As these well-
characterized, mixed neuronal/glial cultures are used for measuring electrical activity using mul-
tiwell microelectrode arrays (MEA), this cell model is well suited for neurotoxicity analyses. In 
the study by (Gao et al, 2002) one false negative was detected, i.e. no reduction of TH-positive 
neurons in neuron-enriched cultures derived from mesencephalon by rotenone treatment. Be-
cause the neuron/glia co-cultures are responsive to rotenone-induced reduction in TH+ cells, 
neuron-enriched cultures are not best-suited for this MoA. Glia, especially microglia presence 
enhances rotenone toxicity. Also lead produced false negative results in neuron-enriched pri-
mary cultures because it did not induce cytotoxicity (Fujimura & Usuki, 2012). However, it 
caused neuronal degeneration. Three different MoA were identified for lead (Appendix D), 
which do not always include cell death. Thus, it is questionable if this false negative result is a 
‘real’ result or if lead is acting via a MoA not involving cell death. Studies with primary neuronal 
cultures also identified 163 true positives. Considering that not all of the 9 false negative cita-
tions are ‘real’, primary rat neuronal cultures have a false negative rate < 10%. In primary glia 
and microglia this is higher with 18% and 40%.  
The 9 false negative data for the endpoint category ‘mitochondrial dysfunc-
tion/oxidative stress/apoptosis’ in isolated organelles include rat brain as well as liver mi-
tochondria. Here, lack of effect on oxygen consumption (Sayre et al, 1991), ROS formation 
(Fonck & Baudry, 2003), protein or lipid oxidation (Taskiran et al, 2007) were the reasons for 
categorization. Rat brain or liver mitochondria have 37.5% and 100% false negative rate. 
The 11 false negative data for the endpoint category ‘neuroinflammation’ were derived 
from one study (Cookson & Pentreath, 1994a) using toluene, isopropanol, hexane, acrylamide, 
MPTP, tin and lead for the endpoints astrocyte death and astrogliosis in primary astrocyte cul-
tures. This paper studied altogether 20 positive compounds with a false negative rate of 55%. 
Interestingly, out of all these studies, there was only one citation identified as false positive. 
This study by Defranchi et al, (2011) identified 6 compounds (1,2-propandiol, quinmerac, 
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paraquat, salicylic acid, ibuprofene, 2,4-dichlorophenoxy acetic acid) as true negatives, yet 
found aniline as a false positive and 5 compounds as true positives (tin, toluene, cicotine, 
fipronil, carbaryl) for disturbance of neuronal network activity of mixed neuronal/glia cultures 
growing on MEAs. 
Performance of rat test systems is summarized in the following bar graphs. For each species, 
these are divided into one graph with true positives and negatives on the top and one graph 
with false positives and negatives on the bottom. The data has to be regarded with caution, es-
pecially for the false negatives as discussed above.  
 
Over all, across the highest number of false negatives, where most of are in the end no false 
negatives with regards to the whole test system evaluation, concerns measures for cytotoxicity. 
In in vitro toxicology, choosing the right cytotoxicity assay, or a combination of different ones is 
not trivial and needs to be chosen wisely (Méry et al, 2017). It is recommended to use a larger 
variety of measures for the endpoint cell death because cells can die by different modes, which 
are sometimes difficult to distinguish, and it is thereby essential that the measurement of cell 
death involves complementary methodologies. Another important point concerns the timing of 
experimentation as apoptosis often occurs very quickly, whereas necrosis is much slower; thus, 
the use of cytotoxicity and viability assays is necessary so as to correctly assess different cell 
death pathways (Kepp et al, 2011). 
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Figure 11 Performance analyses of rat cell types with regards to the ability to identify compounds of the respective 
endpoint categories correctly. The false negatives of the endpoint category have to be regarded with caution (see 
discussion above).  
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Figure 11 illustrates that most endpoint categories (23) are studied in rat and that the rat is the 
best studied species of the five species evaluated in this report. There are hardly any immortal-
ized rat cells used, the few studies on the same endpoint categories than in human and mouse 
immortalized cells relating to apoptosis and cell death. Rat primary cells dominate these studies 
and all 23 endpoint categories can be assessed with this cell type. Most false classifications fall 
again in the apoptosis-cell death endpoint category. Of these, primary neuronal cultures (which 
often are neuronal-glia co-cultures) perform better than pure astrocyte or microglia cultures. 
Stem-/progenitor cell-based methods of rat are even fewer than from mouse and negligible. 
Such data of primary rat cells will – similar or in addition to the primary mouse cells - serve as a 
good reference when working with and comparing data to human stem-/progenitor cell-based 
methods. As already stated above, such species comparisons were previously performed with 
mouse and rat tumor cells  (Schmuck & Ahr, 1997; Canete & Diogene, 2010, 2008, Hong et al, 
2016, 2013; Huff & Abou-Donia, 1995; Case et al, 2016; Zhang et al, 2007; Campanha et al, 
2014) and can be transferred to human stem-/progenitor cell-based methods. Such analyses 
can validate human in vitro methods for a large variety of endpoints relevant for different neu-
rotoxicity MoA identified in this analysis. 
Chicken and Xenopus 
The analyses were also performed for methods based on chicken and Xenopus. The few 
Xenopus studies had no false negative, only true positive data. Thus, negative compounds are 
missing in the experimental set-up. Yet, the measurements of direct effects of compounds on 
overexpressed receptors is straight-forward and confirms MoA of DDT, terfluthrin, deltamethrin, 
-conotoxin, chorotoxin and tetradotoxin. Although not in a physiological context, these meth-
ods seem useful as a screen for molecular initiating events (MIEs). Unfortunately, the through-
put of this test system is low. Table 7 summarizes the individual test systems of the xenopus 
assays and Figure 13 shows its performance. 
Table 7:  Total number of citations for endpoint categories grouped for Xenopus cell types. 
Predictivity analyses were performed for each endpoint category and cell type by analysing true 
positives (t.p.), false positives (f.p.), true negatives (t.n.) and false negatives (f.n.). 
 
true positive total # 
primary cells 10 10 
neurolemma in Xenopus Oocytes 6 6 
Activation of Sodium Channels 2 2 
Inhibition of Calcium Channels 1 1 
Inhibition of Chloride Channels 1 1 
Inhibition of Sodium Channels 2 2 
sodium channels in Xenopus Oo-
cytes  4 4 
Activation of Sodium Channels 4 4 
total 10 10 
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Figure 12 Performance analyses of Xenopus cell types with regards to the ability to identify compounds of the re-
spective endpoint categories correctly. The false negatives of the endpoint category have to be regarded with caution 
(see discussion above).  
 
Data analyses for 18 chicken citations revealed 15 true positives and 3 false negatives. Most 
true positive citations (10) were acetylcholinesterase inhibition using parathion and paraoxon in 
presence of S9 mix (Sawyer et al, 1992), in the endpoint category ‘enzyme inhibition’. As in 
the other species, false negatives are due to lack of ROS-related endpoints in the endpoint 
category ‘mitochondrial dysfunction/oxidative stress/apoptosis’ upon chicken cerebellar 
granule cells arsenic exposure. However, reduced GSH was measured indicating the compensa-
tory abilities of the test system (Castro-Coronel et al, 2011). Table 8 summarizes the individual 
test systems of the chicken assays and Figure 14 shows its performance. 
 
Table 8:  Total number of citations for endpoint categories grouped for chicken cell types. 
Predictivity analyses were performed for each endpoint category and cell type by analysing true 
positives (t.p.), false positives (f.p.), true negatices (t.n.) and false negatives (f.n.). 
 
false 
negative 
true 
positive total# 
primary cells 3 13 16 
cerebellar bergmann glia 3 2 5 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 2 2 4 
Other 1 
 
1 
primary neurons 
 
10 10 
Enzyme Inhibition 
 
10 10 
Spheroids 
 
1 1 
Activation of Chloride Channels 
 
1 1 
primary tissue 
 
2 2 
brain homogenate 
 
2 2 
Delayed Neuropathy 
 
1 1 
Stimulation of Cholinergic Neurotransmission 
 
1 1 
Total 3 15 18 
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Figure 13 Performance analyses of chicken cell types with regards to the ability to identify compounds of the respec-
tive endpoint categories correctly. The false negatives of the endpoint category have to be regarded with caution 
(see discussion above).  
 
Summary evaluation of the false negatives across all species and cell types/test systems reveal 
that measures for cytotoxicity are the main issue identifying false negatives incorrectly. In in vi-
tro toxicity evaluation, choosing the right cytotoxicity assay, or a combination of different ones 
is not trivial and needs to be chosen wisely (Méry et al, 2017). It is recommended to use a lar-
ger variety of measures for the endpoint cell death because cells can die by different modes, 
which are sometimes difficult to distinguish, and it is thereby essential that the measurement of 
cell death involves complementary methodologies. Another important point concerns the timing 
of experimentation as apoptosis often occurs very quickly, whereas necrosis is much slower; 
thus, the use of cytotoxicity and viability assays is necessary so as to correctly assess different 
cell death pathways (Kepp et al, 2011). Hence, if multiple viability/cytotoxicity assays display 
contradictive results, the negative one should not be taken as a false negative.  
 
 
 
 
 
   
  
 
 
www.efsa.europa.eu/publications 51 EFSA Supporting publication 2018:EN-1410 
 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to 
the rights of the authors. 
 
Cell Types and Endpoint categories 
 
 
Figure 14 Endpoint categories covered by the different cell types and tissues across the species human, mouse, rat, 
chicken and xenopus from true positive and true negative data. Information on test systems behind the cell types is 
given in Appendix I1.  
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After performance analyses of the different cell types, now the analyses determine the endpoint 
categories that each cell type from each species can successfully evaluate. Here, the primary 
MoA analyses that we performed before data collection is extremely helpful, because every true 
positive and negative result has physiological relevance. This means, that every cell type/test 
system positive in this evaluation is suitable for neurotoxicity testing of this endpoint category 
summarizing certain MoA (Appendix D). The donut graphs in Figure 14 summarize these end-
point categories for each cell type. The specific Test systems behind can then be found in Ap-
pendix I1. 
This way of presenting the data shows on the first glimpse that some cell types are capable of 
studying a large variety of endpoint categories (primary mouse and rat cells) and that others 
are more limited in their abilities. Human stem-/progenitor cells, the cell type with the largest 
promise for human cell-based neurotoxicity tests, are on the way to become useful for neuro-
toxicity testing applications. However, clearly more work is needed to establish methods that 
can detect as many endpoint categories in human stem-/progenitor cells as in the rodent pri-
mary cells.  
 
Published in vitro methods beyond chemical testing 
The literature was also mined for studies that are promising methods, yet are not targeted to 
chemical testing. We identified 123 studies and included 34 of them (Appendix H). Because we 
already found a high number of rodent studies evaluating NT endpoints, we concentrated on 
promising studies using human systems. 8 publications were found; of those, 3 studies employ 
hiPSC-derived neural cells, 2 hESC-based neuronal cells, 3 NSC-derived neurons and 2 primary 
astrocytes. Because working with ESC is of ethical concern and thus not applicable for regula-
tory purposes, these studies were not included into the evaluation. 
Malik et al, (2014) evaluated effects of a compound library with pharmaceuticals on iPSC, iPSC-
derived neurons and fetal astrocytes. The set-up in a screening format is very useful (Figure 
15). hiPSC-derived neurons were seeded at a density of 30,000 cells/well and assayed on day 
-positive. In the same study, also hiPSC, NSC and fe-
tal astrocytes were used as test systems. There are two drawbacks of the study. For one, there 
does not seem to be glia cells in the cultures and secondly, the only endpoint assessed was cy-
totoxicity. Co-culture systems of multiple cell types have a higher physiological relevance and 
increase application domains of assays. With regards to cytotoxicity evaluation, our data set 
analysed above clearly show that there are a high number of misclassified compounds due to 
cytotoxicity measures. Therefore, it is not advisable to use only cytotoxicity screens as stand 
alone assays for NT evaluation.  
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Figure 15 Flow chart depicting how hiPSC-derived neurons were used for compound testing in a 96-well format. Cy-
totoxicity of pharmaceuticals was assessed. (from: Malik et al. 2014) 
 
Seidel et al, (2017) use three different hiPSC lines (2 IMR-90 lines and the 4603c27 line) for dif-
ferentiation into NPC. After timely defined cultivation of NPC they are differentiated into the 
neural lineage producing neurons and also astrocytes in a controlled and defined manner. 
Readout in this study is MEA activity, an endpoint warranted for NT testing because a broad 
number of endpoint categories can be assessed when different neuronal receptors are present 
in the cells. This study shows reactivity towards dopamine, GABA, serotonin, acetylcholine and 
glutamic acid, not to norepinephrine. One drawback of the study is the quantification of MEA 
measurements. Instead of using different chips or experiments as individual ‘n’ numbers, single 
electrodes were used as the statistical unit. Therefore, reproducibility and standardization be-
tween experiments cannot be assessed. 
A recent study by Tukker et al, (2016) used different commercially available hiPSC-derived, ma-
ture neurons with and without astrocyte co-culture in comparison to rat primary cortical neu-
rons. Readouts are MEA activity and calcium signalling. Calcium transients of individual iCell 
neurons are generated upon treatment with glutamate, GABA and acetylcholine. Glutamate and 
GABA strongly reduced mean spike rate. Limitations of the pure neuronal cultures are absence 
of bursting and absence of astrocytes. Moreover, more thorough characterization of the cell 
system is necessary. Similar to the study by Seidel et al, (2017), statistical analyses are an is-
sue. Here, one well of a 48-well plate is the statistical unit, not electrodes. However, reproduci-
bility and standardization between experiments can also not be assessed with this statistical 
procedure.  
hiPSC-derived neuronal differentiation was also performed by (Yan et al, 2016), who differenti-
ated the hiPSC line iPSK3 to embryoid bodies that further developed to 3D NPC aggregates. 
These aggregates were plated for neuronal differentiation and used for changing biomolecule-
dependent neuronal patterning of brain organoids. This is an interesting approach, especially 
with regards to brain region-specific differentiation. Others have used the concept of producing 
NPC as an intermediate cell population with a distinct proliferation capacity to generate reliable 
terminal differentiated neural tissue (neuron-glia and neuron subtype proportions) in managea-
ble time intervals (Li et al, 2011; Hofrichter et al, 2017). More work is needed here to under-
stand if such methods can be used for reproducible generation of brain region-specific neural 
cultures with human cells. 
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Figure 16 Generation of neural cell types from banked human blood. (from Lee et al, 2015) 
 
An interesting report from Lee et al, (2015) employed banked human blood as a direct cell 
source for reprogramming into NPC (Figure 16). Neuronal cultures generated by this method 
are well-characterized, express a variety of neuronal and glia markers. The NPCs differentiate 
into central (dopaminergic) and peripheral (nociceptive) neurons, the latter were used for che-
motherapy-induced neurotoxicity evaluation. This is an interesting concept also showing the 
plethora of differentiation protocols available. Most hiPSC-derived neural cells use fibroblasts. 
However, also other body cells can be used for reprogramming into hiPSC or direct iNPC.  
Another cell type that is clearly underrepresented for toxicity studies, yet is of high importance, 
are oligodendrocytes. Oligodendrocytes can be generated from primary human NPC (Baumann 
et al, 2015; Dach et al, 2017), however, to differentiate standardized, large amounts of oli-
godendrocytes, hiPSC-based methods are preferred. While most oligodendrocyte differentiation 
protocols take a long period of time (60-150 days; e.g.) and show limited efficiency (Wang et 
al, 2013; Douvaras et al, 2014; Djelloul et al, 2015), a recent protocol published in PNAS allows 
rapid and efficient generation of oligodendrocytes from hiPSC (Ehrlich et al, 2017).  
In summary, most studies using differentiating hiPSC do characterize neurons. This is a highly 
important topic and overall hiPSC have the ability to differentiate into a variety of neuronal sub-
types. In contrast, information on glia, i.e. astro- and oligodendroglia is sparse. For regulatory 
applications, defined protocols need to be established, that in a reproducible way generate neu-
ral cells from hiPSC, cover a large variety of compounds’ MoA for NT assessment in a reason-
able time frame that are applicable to multiwell plate testing. The EU-Joint Research Center 
goes into this direction by publishing standard operating procedures for their hiPSC cultivation 
and differentiation procedures in the DB-ALM database online (https://ecvam-
dbalm.jrc.ec.europa.eu/methods-and-protocols/method-summary/differentiation-of-induced-
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pluripotent-stem-cells-into-post-mitotic-neurons-and-glial-cells-(mixed-culture)/key/m_1961; 
protocol number 165 and 166) as well as the accompanying research paper (Zagoura et al, 
2017a). More studies in this way are needed to produce hiPSC-based cultures tailored for neu-
rotoxicity evaluation in vitro. 
 
3.1.1. Grey literature search 
 
The grey literature search for in vitro and ao methods did not retrieve any additional informa-
tion that was not already published. Results of the grey literature search are summarized in Ap-
pendix F.   
Next to the grey literature search a promising approach for defined neurotoxicity testing was 
published as poster at the SOT meeting in March 2018 (Saavedra et al. 2018; NeuCyte, CA, 
USA), yet this work has not been published as a primary research paper. The specialty of this 
approach lies in the direct reprogramming of hiPSCs into highly functional neurons of defined 
subtypes and into glia cells. These cells are then seeded in a defined ratio of excitatory neu-
rons, inhibitory neurons and astrocytes onto MEAs, thereby providing a defined human neu-
ronal/glial co-culture platform for comprehensive electrophysiological measurements using 
MEAs (SynFire iN Cell Technology). When combining defined ratios of glutamatergic to 
GABAergic neurons together with astroglial cells, robust neuronal activity, including synaptically 
driven spontaneous synchronized network bursting can be recorded at 3-4 weeks post seeding 
(Figure 17). 
 
Figure 17 Combination of iN technology with human primary glial supporter cells on 48-well MEA plates to develop a 
pure human neural co-culture system consisting of glutamatergic excitatory neurons (140K cells/well), GABAergic 
inhibitory neurons (60K cells/well), and astrocytes (70K cells/well). Reproducible formation of spontaneous 
synchronized neuronal network activity can be detected 3-4 weeks after plating. 
 
6. Summary
New iPSC-Based Neural In Vitro Approach for Seizure Liability Testing
L. Saavedra, A. Fua, V. Dang, J. Davila, and D. Haag
NeuCyte, Sunnyvale, CA.
5B. Neural Responses to Test Compounds: Analysis by MEA Parameters
1. Abstract
Standard animal models have shown insufficiencies in predicting adverse effects of therapeutic compounds particularly on the
CNS, mostly because of limited concordance with human neurotoxicity. The high attrition rate of new drugs in clinical studies is
largely attributed to CNS-related safety failures unidentified in pre-clinical testing. One of the most common issues
encountered during safety assessment over the past 5 years is the induction of seizures at relevant therapeutic
concentrations. Moreover, GABAA receptors as primary mediators of inhibitory neu otransmission, represent a vul erable
target for neurotoxic environmental chemicals, many of which lead to seizures in humans. Therefore, new human in
vitro assays are urgently needed for de-risking of new drugs and higher throughput testing of multitude of chemicals with
daily human exposure. Based on direct reprogramming of induced pluripotent stem cells (iPSCs) into highly functional neurons
of defined subtypes, we developed a pure human neuronal/glial co-culture platform for comprehensive electrophysiological
measurements using multi-electrode arrays (MEAs). When combining defined ratios of glutamatergic to GABAergic neurons
together with astroglial cells, robust neuronal activity, including synaptically dri n spontaneous synchronized network
bursting can be recorded at 3-4 weeks post seeding. Due to parallel acquisition of multiple parameters, our platform allows
detailed characterization of neurotoxicity effects of test compounds. Here, we optimized our platform to specifically and
quantitatively assess chemically-induced seizure-like activity in a semi high-throughput setting. As part of the HESI NeuTox
Group, we tested a set of 11 compounds with clinically reported seizurogenic effects in patients, which partially remained
undetected in r dent-based testing. Importantly, our human system was able to identify specific alterations in neuro al
activity of all test compounds in a dose-dependent manner, and determine seizure-like firing patterns in the most potent
subset. We also used our platform to test a set of environmental neurotoxicants with well-established effects on human
GABAARs, and successfully identified changes in activity indicative of seizurogenic effects over a large range of concentrations.
Hence, we report the development and proof of concept of a novel iPSC-based neuronal/glial in vitro approach for the
assessment f seizure liabilities of chemical compounds in a huma -relevant c ll context.
2. SynFire iPSC-Derived Neural (iN) Cell Technology
We combined our iN technology with human primary glial supporter cells on 48-well MEA plates to develo pure human
neural co-cultur system consisting of glutamatergic excitatory neurons (140K cells/well), GABAergic inhibitory neurons (60K
cells/well), and astrocytes (70K cells/well). Reproducible formation of spontaneous synchronized neuronal etwork activity
can be detected 3-4 weeks after plating.
After seeding, cultures were allowed to mature for 21-22 days. Spontaneous neuronal activity was assessed by using the Axion
Maestro syste as follows: baseline activity was r c rded for 15 min, right after an equilibration period of 20 min. Then, a et
of 11 proco vulsan compounds, 2 negative con r ls, the vehicle in which all the test compounds were dissolved (DMSO
0.1%), were added to individual wells according to the following plate layout. Neuro al responses after dosing wer recorded
for 75 min.
3. Experimental Design
DMSO 0.1%
Positive Control: BIC 3uM
Compound 1 [1-5 Doses] 
Compound 2 [1-5 Doses] 
4. Human iN-glia Cell Characterization
5. Results
MAP2
MAP2
MergeDapi
Synapsin1
GFAP
Dapi Merge
A
B
Characterization of our human induced neurons by immuno-staining (A) Pan-neuronal marker Map2 / Astroglia marker GFAP /
Nuclear staining Dapi. (B) Pan-neuronal marker Map2 / Synaptic marker Synapsin1 / Nuclear staining Dapi. (C) Pan-neuronal
marker β3-Tubb (TuJ1) / Inhibitory neuron GABAA receptor, α1 / Nuclear staining Dapi. (D) Pan-neuronal marker Map2 /
Vesicular GABA transporter VGat/ Nuclear staining Dapi.
C
MAP2
β3-Tub
VGat
GABA Dapi
Dapi
Merge
MergeD
5a. Data Binning Analysis
After processing the baseline (15 min) and the dosing (75 min) recordings using the AxIS software, the wMFR values were
binned into 10 min segments across both baseline and dosing periods for each test compound. This analysis allows for
detection of the time window in which the vehicle DMSO has equilibrated after dosing. That period (15 min) was used for
compound normalization and comparisons against baseline.
5c. Clustering Analysis
Heat Map and Clustering Analysis: MEA Parameters (rows) are centered; unit variance scaling is applied to rows. Compounds in increasing
doses (columns) are clustered using correlation distance and average linkage.
Compounds Solvent Concentrations 
(uM)
Mode of Action Seizurogenic
Picrotoxin (PTX) DMSO 0.3, 1, 3, 10, 30 antagonist of GABAA receptors Yes 
Pentylenetetrazol 
(PTZ)
DMSO 10, 30, 100, 300, 
1000
antagonist of GABAA receptors Yes 
Pilocarpine DMSO 0.3, 1, 3, 10, 30 muscarinic receptor agonist Yes 
Linopirdine DMSO 1, 3, 10, 30, 100 selective KCNQ channel blocker Yes
4-Aminopyridine 
(4-AP)
DMSO 0.3, 1, 3, 10, 30 potassium channel blocker Yes 
Chlorpromazine DMSO 0.1, 0.3, 1, 3, 10 D2 receptor antagonist Yes
Amoxapine DMSO 0.3, 1, 3, 10, 30 blocks dopamine receptors, and the 
reuptake of norepinephrine and 
serotonin 
Yes
Phenytoin DMSO 1, 3, 10, 30, 100 sodium channel blocker No 
Maprotiline DMSO 0.1, 0.3, 1, 3, 10 inhibits reuptake of norepinephrine Yes 
Clozapine DMSO 0.1, 0.3, 1, 3, 10 targets D2 receptors and an 
antagonist of 5-HT2A receptor 
Yes
Amoxicillin DMSO 1, 3, 10, 30, 100 inhibitor of bacterial wall 
biosynthesis
No
Acetaminophen DMSO 1, 3, 10, 30, 100 COX-1 and 2 inhibitor 
(prostaglandin production blocker)
No 
Bicuculline (BIC) DMSO 3 antagonist of GABAA receptors Yes
DMSO Vehicle 0.1% ----- No
A. Single Plate Assay (48-well MEA
plate). Two compounds per plate, 5
concentrations, 4 replicates. DMSO
and one positive control, 4
replicates each, were also included.
B. Test Compounds Table showing
the concentrations used per
compound and their modes of
action.
A B
Electrode Grid
MEA Parameter Description
Weighted mean firing rate (wMFR) Total number of spikes divided by the total time of the analysis, and 
normalized against the number of active electrodes
Burst frequency Total number of single-electrode bursts divided by the duration of the 
analysis
Burst duration Average time from the first spike to last spike in a single-electrode burst
Number of spikes per burst Average number of spikes in a single-electrode burst
Mean inter-spike-interval (ISI) within 
burst
Mean inter-spike interval (time between spikes) in a single electrode burst 
Inter-burst-interval (IBI) Average time between the start of single-electrode bursts (time between 
bursts)
ISI Coefficient of Variation The coefficient of variation (standard deviation/mean) of the inter-spike 
interval, the time between spikes, for an electrode. This is a measure of spike 
regularity and bursting
Network burst frequency Total number of network bursts divided by the duration of the analysis
Network burst duration Average time from the first spike to last spike in a network burst
Number of spikes per network burst Average number of spikes occurring in a network burst
Network Normalized Duration IQR Interquartile range of network burst durations. This metric provides a 
measure of network burst duration regularity.
Synchrony Index A unitless measure of synchrony between 0 and 1. Values closer to 1 indicate 
higher synchrony.
Standard parameters for
assessment of neuronal
network activity assessed in
this study are depicted in
the table. Recordings were
performed on Axion’s
Maestro system using the
AxIS software. Acquired raw
data was processed using
the following settings:
Neural Broadband as Analog
Mode setting, Butterworth
filter (high pass 200 Hz, low
pass 5KHz) as Digital Filter
setting, Adaptive Threshold
Crossing of 8 SD as Spike
Detector setting, ISI
Threshold as Burst Detector
setting, and Envelope
algorithm as Network Burst
setting.
5d. Cell Viability Assays
% LDH Release and % Cell Survival per compound across
concentrations. No significant differences when compared to
vehicle DMSO.
*
*
*
*
*
*
*
* *
*
*
*
* *
*
*
*
* *
*
*
*
*
*
*
*
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*
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*
*
*
*
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*
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*
*
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*
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*
*
**
*
*
*
*
*
*
**
*
*
For each MEA parameter, measurements from vehicle- or compound-treated wells were normalized to their respective baseline values. All
parameters are expressed as percent change. Significance for Bicuculine (+ Ctrl) relative to DMSO (Vehicle) was determined via Student's T-
test (n = 4, *p<0.05). Significance for test compounds relative to DMSO (Vehicle) was determined via One-Way ANOVA (n = 4, *p<0.05).
• NeuCyte’s SynFire neural cells allow for a fully defined human neural co-
culture which is ideal for in vitro neurotox assessment.
• Upon exposure to the Hesi Neutox MEA group test compounds, our neural 
co-culture system show reproducible and robust dose dependent changes 
in spike rates, bursting and network firing parameters.  These changes 
were not seen in the negative control compounds acetaminophen and 
amoxicillin.  
• By focusing on a select set of network firing parameters we have begun to 
identify firing patterns resembling ictal discharges as they occur during 
status epilepticus. 
• Clustering of the data allows for grouping of compounds by firing patterns.
• More seizuregenic and non-seizuregenic compounds with well defined 
modes of action need to be tested to further optimize our seizure 
prediction capacity.  
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Due to parallel acquisition of multiple parameters, the platform allows detailed characterization 
of neurotoxicity effects of test compounds. Specifically in this work the platform was used to 
specifically and quantitatively assess chemically-induced seizure-like activity in a semi high-
throughput setting by studying the following defined MoA: Inhibition of GABAA receptors, stimu-
lation of muscarinic AChR, potassium channel blockage, D2 receptor antagonism, norepineph-
rine and serotonine re-uptake inhibition and 5-HT2A receptor antagonism. Therefore, 11 com-
pounds with clinically reported seizurogenic effects in patients were studied, which partially re-
mained undetected in rodent-based testing. The human system identified specific alterations in 
neuronal activity of all test compounds in a concentration-dependent manner, and determined 
seizure-like firing patterns in the most potent subset. Hence, this is a proof-of-concept study of 
a novel iPSC-based neuronal/glial in vitro approach for the assessment of seizure liabilities of 
chemical compounds in a human-relevant cell context. The defined cellular context of this work 
is so far unique, eliminates variability due to individual experiment hiPSC differentiation and 
thus deserves more MoA analyses in the future. 
 
3.2. Cell based blood brain barrier models  
 
The blood brain barrier (BBB) plays a critical role for any chemical-induced neurotoxic action to 
the CNS as it determines the availability of a potential neurotoxicant at the target organ. BBB 
permeability therefore presents a key characteristic to be considered in the evaluation of the 
neurotoxic potential of a chemical in humans. This is especially true when the NT potential of a 
compound is determined based on an alternative model (in vitro, alternative organism) that 
does lack or is very limited in the representation of pharmacokinetics of the CNS. 
Anatomically the BBB consists of brain microvascular endothelial cells (BMECs), the non-cellular 
basement membrane (BM) and cells from the neurovascular unit, astrocytes, pericytes, micro-
glia and neurons (Aday et al., 2016; Banerjee et al., 2016; Figure 18B). The barrier function of 
the BBB consists of several key characteristics. Tight and adherent junctions expressed by 
BMEC seal the gap between two adjacent cells and prevents the paracellular diffusion of hydro-
philic compounds (Figure 18D). Efflux transport systems like the ABC-type transporters trans-
port hydrophobic molecules out of the cell back into the lumen and thereby prevent them from 
reaching the CNS. The high metabolizing capacity of astrocytes metabolizes hydrophobic com-
pounds that permeated into the neurovascular unit (Banerjee et al, 2016b; Helms et al, 2016b). 
In addition to several mechanisms that prevent the penetration of chemicals into the CNS, there 
are several influx transport systems that provide the CNS with necessary nutrients but might 
also cause the influx of undesired chemicals. Influx mechanisms are thereby the carrier-
mediated transport, receptor-mediated endocytosis and transcytosis and adsorptive-mediated 
endocytosis and transcytosis (Palmer and Alavijeh, 2013; Figure 18D).  
For an alternative model to correctly predict the BBB permeability its key structure and mecha-
nism need to be represented in vitro. Therefore, an ideal in vitro model should form tight junc-
tions, express transporters, enzymes, macromolecular and immune cell trafficking and signalling 
and be suitable for rapid screening of BBB permeability of potential CNS toxicants.   
 
There are a number of well-characterized cell-based models that are able to assess the BBB 
permeability of a chemical as summarized in two reviews from Helms et al. (2016) and Wolff et 
al. (2015). These models are mainly developed from rat, mouse, bovine, porcine as well as hu-
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man material and are based on primary-, tumor/immortalized- or stem/progenitor cells. The 
most common set up is thereby a transwell cell culture system with either mono-culture, non-
contact co-culture, contact co-culture or a triple culture. In addition, several microchip-based 
BBB models have been developed in the last 10 years. 
 
 
Figure 18: Blood–Brain Barrier (BBB): structure and function. (A) Schematic picture of the blood brain 
barriers. (B) Schematic picture of the BBB’s structure in magnification. The lumen surrounded by 
endothelial cells (ECs) that are in close association with pericytes, astrocytic end feet and neurons all 
separated by the basal membrane. (C) different routes of transport across the BBB into the CNS. (D) 
Structure of Tight junctions (Aday et al., 2016). 
 
The most simplistic cellular BBB model is the mono-culture, which consists of a uniform layer of 
brain endothelial cells (BECs) that is seeded on a semipermeable membrane filter (Figure 19A). 
This model has been generated from different cell types and various species. Key advantages of 
a mono-culture model are its simplicity and cost effectiveness as well as the suitability for high-
throughput permeability screening (Banerjee et al, 2016b). Major drawbacks, however, are the 
absence of other influencing cellular components like pericytes, astrocytes or microglia as well 
as inadequate barrier properties as demonstrated by low transendothelial electrical resistance 
(TEER) compared to co-cultures (Banerjee et al, 2016b). The use of astrocyte conditioned me-
dia or dynamic models that introduce shear stress to the system both increase barrier proper-
ties (Siddharthan et al, 2007). Kim (2009) demonstrated that shear stress, together with astro-
cyte-conditioned medium can increase the TEER of primary human brain microvascular endo-
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thelial cells (HBMECs) by a factor of 3, from 500 to 1500 ohm/cm2. The use of astrocytes or 
pericytes co-cultured with brain endothelial cells (BECs) in general increases tight junction char-
acteristics and improves the paracellular barrier properties (Nakagawa et al, 2007). Because of 
the lack of astrocyte or pericytes induction, results from mono-cultures should generally be re-
garded with caution whereas co-culture systems that consider the interactions between endo-
thelial cells ECs and the surrounding brain microenvironment are more promising models.  
 
Co-culture models mostly combine endothelial cells with astrocytes or pericytes. Thereby two 
set ups are commonly used. In both set ups BEC are grown on the luminal side of a transwell 
membrane, whereas the second cell type (astrocytes or pericytes) are grown either on the bot-
tom of the well (non-contact co-culture; Figure 19B) or directly on the abluminal side of the 
membrane (contact co-culture; Figure 19C). Similar to mono-cultures, co-culture models have 
also been generated from multiple cell types and species including different combinations of 
both. The key advantage of co-culture models is their ability to represent an astrocyte or peri-
cyte induction with increased TEER values and improved permeability. They are, however, more 
complex in their overall handling causing high variations in research results and a limited 
throughput of permeability screening. Another disadvantage is that the thickness of semiper-
meable membrane inserts is much thicker than the basal membrane in vivo (Banerjee et al, 
2016b). Similar to the mono-cultures the introduction of shear stress improves barrier function 
compared to static co-cultures models (Booth & Kim, 2012).   
 
A B 
C D 
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Figure 19 Common configuration of transwell culture system. (A) mono-culture with cells BECs seeded on 
the luminal site of a semipermeable membrane filter. (B) non-contact co culture with astrocytes seeded 
on the abluminal site on the bottom of the well. (C) contact co-culture with astrocytes seeded on the 
abluminal site of the semipermeable membrane. (D) triple-culture with pericytes seeded on the abluminal 
site of the semipermeable membrane and astrocytes seeded on the abluminal site on the bottom of the 
well (from Helms et al., 2016). 
 
 
An extension of the co-culture models are triple-cultures that most commonly contain endothe-
lial cells and astrocytes as first and second cell type. As a third cell type neurons have been 
used traditionally but have been substituted by pericytes in recent years (Wolff et al, 2015a). 
The classical set up of triple-culture models in a transwell format is demonstrated in Figure 19D. 
A key advantage of the triple culture model is the higher level of resemblance with in vivo brain 
physiology. It was for example demonstrated that triple-cultures of endothelial cells, astrocytes 
and neurons show a higher expression of zonula occludens-1 (ZO-1) and faster synthesis of oc-
cludin, both key proteins of tight junctions, with an overall higher TEER (Schiera et al, 2003; 
Xue et al, 2013). Overall triple-cultures show considerable improvement in BBB phenotype and 
paracellular permeability compared to co-culture models (Banerjee et al, 2016b). They are, 
however, very complex, more expensive and often show low reproducibility with a high varia-
tion of data, which makes them less suited for high throughput permeability screening. 
 
In a study by Nakagawa et al. (2007) seven different models and set ups of either rat brain 
capillary endothelial cells in mono-culture, in co-culture with astrocytes or pericytes as contact 
or non-contact culture, or as triple-culture with pericytes and astrocytes (contact and non-
contact) are compared based on their barrier tightness. The authors show that a triple-culture 
with pericytes as contact and astrocytes as non-contact culture gives the best TEER and that all 
co-culture models show increased TEER and decreased permeability of the marker sodium fluo-
rescein compared to the mono-culture model. In a follow up study Nakagawa et al. (2009) 
characterize the triple-culture with pericytes as contact- and astrocytes as non-contact-culture. 
They identify the expression of several crucial transport systems and demonstrate a good corre-
lation (R2=0.89) between the in vitro and in vivo permeability of 19 compounds. The observa-
tion by Nakagawa et al. (2007) could not be reproduced in a similar study that compared a 
similar set ups of immortalized human cerebral microvascular endothelial cells (hCMEC/D3) co-
cultured with human cerebral astrocytes and/or human brain vesicular pericytes (HBVP). Here 
the overall TEER was noticeably lower than observed in Nakagawa et al. (2007; 40-60 com-
pared to 50-400 ohm/cm2) and the triple-cultures did not show improved TEER compared to 
mono-culture (Hatherell et al, 2011).  
 
The comparison of these two studies demonstrates some of the major limitations in comparing 
different BBB models and identification of a suitable model. For one, not all studies provide 
TEER values and permeability of tracer substances. However, a number of studies demonstrate 
that TEER values alone are not sufficient to determine the quality of the BBB (summarized in 
Wolff et al., 2015) which is why both values should be assessed and ideally accompanied with a 
correlation of permeability data from the BBB model and in vivo data from compounds with dif-
ferent properties related to their ability to enter the CNS. Another important aspect is species 
differences in BBB permeability. There are several studies that demonstrate different expression 
of transporters, tight junctions, and receptors between the BBB of rodents and primates 
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(Uchida et al, 2013, 2011; Shawahna et al, 2011; Ito et al, 2011; Hoshi et al, 2013). Positron 
emission tomography studies for example indicate differences in pharmacokinetics of P-gp sub-
strates. Thereby the substrates [18F]-altanserin and [11C] -R205171 have a 4.5- and 8.6-fold 
greater penetration efficiency in human BBB compared to rodents (Syvänen et al, 2008). An-
other example is the tight junction protein claudin-5 which in human brain microvessels is two-
fold lower expressed than in those of rats and other primates (Shawahna et al, 2011). These 
species differences ultimately cause differences in the paracellular and transporter/receptor 
based transport. It is therefore desirable to find suitable in vitro BBB models that are based on 
human cells. 
 
A general limitation of human models is to acquire primary human material on a regular basis, 
which makes the establishment of BBB models based on primary human BEC difficult. For hu-
man primary material that is offered commercially, there is often only sparse documentation on 
the source of the material. Nevertheless some BBB models based on primary human brain en-
dothelial cells are presented in the literature (reviewed in Wolff et al., 2015). A primary model 
of human BMECs co-cultured in a dynamic in vitro set up with human astrocytes demonstrated 
good TEER (200-700 ohm/cm2) and good correlation with in vivo permeability data (R2 = 0.93) 
of 7 compounds (Cucullo et al, 2011). This study additionally demonstrates that a dynamic sys-
tem reaches a higher TEER, better correlation of compound permeability compared to in vivo 
data and increased tight junctions formation as well as the expression of multidrug resistance 
transporters.  
 
Human based models that circumvent aforementioned limitation can be based on immortalized 
brain endothelial cells or pluripotent stem cell (PSC), (including induced PSC), - derived BECs. 
The most common, easy to use and best-characterized immortalized line are human cerebral 
microvascular endothelial cells (hCMEC/D3). In its basic state TEER values from these cells are 
not comparable with the in vivo situation or animal based models. This model therefore offers 
barrier function for only large molecules, whereas small molecules relatively easily permeate the 
barrier (Helms et al, 2016b). Although there are several articles that show limited barrier func-
tion of this cell model (Eigenmann et al, 2013; Hatherell et al, 2011) different culture condition 
for example dynamic culture system and/or co-culture with pericytes and/or astrocytes might 
improve the barrier function and make this a useful model for permeability screening. A study 
that compared four immortalized capillary endothelial cell lines (hCMEC/D3, hBMEC, TY10 and 
BB19) concluded that hBMEC proved to be the most suitable and promising immortalized cell 
for a human in vitro BBB model in terms of barrier tightness and paracellular permeability. The 
TEER values however were low compared to previously described models and no correlation of 
permeability data with in vivo data was demonstrated. 
 
In contrast to immortalized cells, PSC- derived brain endothelial cells have been shown to form 
a good barrier function with expression of tight junction proteins, a TEER between 250 and up 
to 5000 ohm/cm2 depending on the culture condition and sucrose permeability’s comparable to 
porcine and bovine models and below values for primary and immortalized human models 
(reviewed in Helms et al., 2016). In a study by Lippmann et al. (2012) the authors present a 
BBB model based on human PSC- derived endothelial cells in non-contact co-culture with pri-
mary rat astrocytes. This model demonstrated well -organized tight junctions, appropriate ex-
pression of nutrient transporters and polarized efflux transporter activity. The TEER was meas-
ured to be around 1,450 ohm/cm2 and permeability was in good correlation with in vivo data 
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(R2 = 0.98) of a group of 7 compounds. The same authors demonstrated in a study from 2016 
that retinoic acid treated iPSC derived BMEC that were co-cultured with primary human brain 
pericytes as well as astrocytes and neurons derived from human neural progenitor cells (NPCs) 
were able to form a BBB model with a TEER of up to 5,000 ohm/cm2 and low sucrose perme-
ability (Lippmann et al, 2015). The TEER however was very dependent on the type of iPSC that 
was used an could drop to below 500 ohm/cm2. Other recent studies generated models based 
on adult human endothelial progenitor cells (Ponio et al, 2014) and hematopoietic 
stem/progenitor cells (Cecchelli et al, 2014). Especially the latter study generated a stable and 
reproducible human BBB model with good correlation with in vivo permeability data of 9 com-
pounds (R2=0.84). These studies demonstrate that the generation of BBB models based on 
PSC-derived BECs with superior barrier function compared to other human BBB models is in 
principal possible, making this an promising method for future permeability screening.  
 
Until now, there is no model that can be recognized as the gold standard for predictable high-
throughput screening application for BBB permeability. Nevertheless, several models have been 
proven useful. Primary BMECs isolated from animal brain tissue have shown to form tight barri-
ers with low permeability and several models show good correlation with in vivo data (reviews 
in Helms et al., 2016; Wolff et al., 2015); however these comparisons are limited and the num-
ber of drugs tested very small (<10). The increasing knowledge on species differences lead to 
the general view, that human based systems are better suited for the prediction of BBB perme-
ability in vivo (Aday et al, 2016). Primary human BMECs and immortalized human cells possess 
only moderate barrier properties (Helms et al, 2016b). These barrier properties can be im-
proved when cells are co-cultured with astrocytes or pericytes or by the introduction of shear 
stress in a dynamic system. Recent research demonstrates that PSC- derived BMEC in co-
culture with astrocytes, pericytes and/or neurons and under specific culture conditions form a 
very tight barrier that are able to produce TEER values comparable to in vivo data (Lippmann et 
al, 2015). Because of the short time period these cells are available they still lack some valida-
tion regarding functional expression of transporters, efflux pumps and receptors. There is also 
still some uncertainty in the reproducibility regarding culture condition, stability of the culture, 
culture set up and the type of PSC that is used. Nevertheless, PSC- derived BMEC are a promis-
ing model for chemical or drug permeability screening and need further characterization and 
development. In addition promising and established human based models should undergo vali-
dation of the transport and permeability properties using a large set of compounds and drugs 
with very different properties regarding in vivo BBB permeability and sufficient in vivo data.  
 
 
3.3. In silico 
3.3.1. Introduction: 
Chemical substances can only exert neurotoxic effects if they are able to reach the brain. Before 
they can reach the brain, they have to cross the blood-brain barrier (BBB or BB). As previously 
described, the BBB is a very complex physical barrier that determines which substances are al-
lowed to enter the brain.  In this section computational (in silico) models for estimating BBB 
passage and for predicting neurotoxicity as such are discussed. 
The selection procedure described in the methodology section resulted in 1365 publications. 
The title-abstract screening resulted in 169 publications for the full-text screening.  The full-text 
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screening resulted in 54 publications. Details of the publications are presented in the Data Col-
lection Sheet (DCS), rows 3 to 56. The publications are arranged in alphabetical order by first 
author’s last name. The columns of the DCS sheet are structured according to the 5 OECD prin-
ciples for Quantitative-Structure-Activity relationship (QSAR) models for regulatory use (OECD 
guidance No 69 on QSAR validation).  
Additionally, websites offering QSAR models for hazard assessment were explored. Fourteen 
websites were found to contain in silico tools useful for NT evaluation. 
A QSAR is a quantitative relationship between a biological activity (e.g., toxicity), which may be 
qualitative (yes/no) or quantitative, and one or more molecular descriptors that are used to 
predict the activity. A molecular descriptor is a structural or physicochemical property of a 
molecule, or part of a molecule, which specifies a particular characteristic of the molecule and is 
used as an independent variable in a QSAR (Worth et al., 2011)3. 
 
3.3.2. Models on blood-brain-barrier (BBB) permeation and neurotoxicity: 
A total of 39 publications with in some cases more than one model per publication is the result 
of the full paper screening on BBB passage (Table 10). All models consider the passive diffu-
sion; four of the papers include additional descriptors to also cover active transport. Most of the 
models are quantitative (calculate log BB = log ((Cbrain/Cblood)); some are qualitative, indicating 
whether the substance is able to reach the central nervous system (CNS) or not (CNS+/-, or 
BB+/-) with a defined cut-off value). The algorithms are developed by means of a wide range 
of machine learning methods, going from univariate and multivariate linear regression genera-
tion with a small number of parameters (e.g. Bujak et al, 2015) to the development of complex 
(non)-linear regressions with artificial neural networks (ANN) (e.g. Yan et al, 2013) and other 
machine learning methods such as support vector machine (SVM) (e.g. Golmohammadi et al, 
2017), partial least square (PLS; (Cuadrado et al, 2007) and random forest analysis (RFA) (e.g. 
(Polishchuk et al, 2016). In the field of machine learning, the computer has the ability to "learn" 
from data (i.e. progressively improve performance on a specific task), without being explicitly 
programmed. The model developer chooses the number and kind of parameters (descriptors), 
the computer calculates their weights (coefficients) and the intercept. At the end an algorithm 
or final model (e.g. ANN), which is in fact a very complex algorithm with linear and non-linear 
correlations, is derived. These machine learning techniques can also be used to generate a 
qualitative outcome (BBB permeation: yes/no).  
An overview of the compliance of the models with the five OECD criteria for QSAR-model 
evaluation is presented in Table 10. In general the models comply very well with the exception 
of the description of the applicability domain (OECD principle 3). For models without a pub-
lished algorithm, the compliance with criterion 2, i.e. an unambiguous algorithm, is unclear. For 
two models algorithms are not present but they may be in the supplementary information. For 
complex models, it is not possible to publish the algorithm in a paper. Transparency on the ex-
act training data and architecture of the method (e.g. neural network, number of layers and 
nodes in the ANN) (to ‘reproduce’ the model) or availability of the final model (represents the 
algorithm), and the assurance that the model is not overfitted (too many variables present, 
leading to a low validation performance) are important factors in view of the 2nd OECD principle 
                                                     
 
3 Applicability of QSAR analysis in the evaluation of developmental and neurotoxicity effects for the assessment of the toxicological 
relevance of metabolites and degradates of pesticide active substances for dietary risk assessment. Scientific report submitted to 
EFSA. Final version 31/05/11 
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on QSAR model validation.  A linear model is generally considered as unambiguous algorithm 
(OECD report 69 on QSAR validation). 
 
Table 9:  Compliance of the QSAR models with the five OECD criteria: 
 
OECD Principle Result (details available in the DCS sheet 
1. Defining the  end-
point 
BBB permeation: 39 models 
CNS membrane toxicity (IC12.5 for membrane fluidity): 1 model 
Acute neurotoxicity: 6 models (EC30 effective concentration at 30% of 
the maximum possible effect) 
Acetylcholinesterase (AChE) and neurotoxic esterase inhibition: 2 
models 
Neurotoxicity effect towards ryanodine receptors (neurons): 2 models 
Formation of Reactive Oxygen Species (ROS): 1 model 
Three biochemical endpoints for cytotoxicity: 1 observed SAR (not a 
model) 
Decrease in cell dopamine content: 1 observed SAR (not a model) 
CNS/hyperactivity: 1 observed SAR (not a model) 
2. Defining the algo-
rithm 
Algorithm available: 27 publications  
Final models (complex algorithms): 18 models (the models or their ar-
chitecture and training set should be available via the supplementary 
information of by other means, to fulfil the 2nd OECD criterion ‘unam-
biguous algorithm’)) 
Not applicable: SAR observations: 3 models (line 14, 48 and 52) 
3D models, no algorithm: 3 models 
An algorithm could not be built: 1 publication (Stenberg et al. 2011) 
Not available: 2 models (maybe in the supplementary information but 
that is not indicated) (line 31, and 38) 
 and 50) 
Descriptors: described from in detail to general, mostly calculated; 
Number of descriptors: from unknown to 72 
3. Defining the appli-
cability domain 
Domain explicitly mentioned: 4/37 
Chemical indication/description of the training set chemicals: all mod-
els 
Limits of applicability: 4 publications provide physical chemical prop-
erty boundaries of the training set chemicals; the other publications 
define no limits of applicability. Predictions for substances outside the 
training set property boundaries may be less accurate. 
4. Internal/external 
validation 
Yes for all models 
Coefficient of determination (R² or r²) range: 0,54-0,99  
Cross validation correlation coefficient(Q²): 0,50-0,98  
Accuracy range: 73-97%(where available) 
5. Mechanistic basis BBB permeation: passive diffusion; 4 models additionally include ac-
tive transport for which the mechanistic basis is protein binding activ-
ity 
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Ryanodine receptor (RyR) mediated mechanisms and associated neu-
ronal signalling: influenced by altered calcium regulation  
 
The fitness of an algorithm or model is measured as the coefficient of determination (R² or r²) 
and internal cross-validation coefficient (Q²).  Commonly applied criteria for reliability and pre-
dictability are R² > 0.6 and Q² > 0.5 which were set by  Tropsha et al, (2003). Other authors 
considered a QSAR model to have an acceptable predictive power if q² > 0.65 and R² > 0.65. 
The R² ranges from 0,54 to 0,99 (where available) and Q² ranges from 0,50 to 0,98 (where 
available). Most of the models are above the 0.65 limit. Moderate q² values may indicate that 
the model might only perform marginally in predicting the logBB of compounds outside the 
training set.  
The accuracy, which is the ratio of correctly predicted positives and negatives to the total num-
ber of predicted compounds, gives an idea about the predictivity of the model. The accuracy of 
the studied models varies from 73 to 97% (where available). 
 
A significant disadvantage of an ANN is the amount of training data needed. Experimental data 
on BBB or neurotoxicity are scarce. This may contribute to the explanation as to why the per-
formance of an ANN model is not always better than the performance of a simple linear regres-
sion.  
 
Two properties often returning as important factors linked to passive BBB diffusion are lipo-
philicity (LogP) and charge (total polar surface area). It has been appreciated in drug design for 
many years that drugs with logP values of 1.5-3.0 seem to have optimal abilities to diffuse 
through biological membranes (Burns & Weaver, 2004). The total polar surface area of a mole-
cule however, is negatively correlated with passive diffusion.  Also heteroatoms seem to have a 
negative impact on diffusion.  
 
Note: Two authors developed a BBB-model from dynamic membrane computer simulations. 
Four models consider, besides passive passage, also active transport such as by the efflux 
pump P-glycoprotein (P-gp) (Chen et al, 2009; Garg & Verma, 2006; Iyer et al, 2002 and 
Suenderhauf et al, 2012) Whether a substance is actively transported through the BBB depends 
on the properties of that substance, but may also be influenced by the presence of another 
substance that acts as transport inhibitors. One model, trained with alcohols, estimates the im-
pact on Na+/K+-ATPase and AchE activity (indicators of CNS membrane fluidity). A linear rela-
tionship between membrane fluidity and the octanol-water partitioning coefficient (log P) is 
found, indicating a significant effect of the alcohols on membrane fluidity. Based on these re-
sults, the authors suggest that the alcohols inhibit the Na+/K+-ATPase and AchE activity 
through a direct toxic action on the enzymes and/or through changing the membrane fluidity 
(El Yazal et al, 2001). This research touches the issue of mixture toxicity: active transport of 
chemicals into the CNS may be influenced by the presence of chemicals inhibiting membrane 
fluidity directly or indirectly. 
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3.3.3. Grey literature search: 
Based on the gathered information, all websites of the first screening were retained in the final 
selection, with the exception of ToxMatch and Accelrys; ToxMatch does not cover the neurotox-
icity endpoint or BBB permeation, and Accelrys offers a modelling environment, where the user 
can store his own developed models.  
The finally collected models and tools are presented in the DCS sheet rows 56 to 69. The mod-
elled endpoints are BBB permeation and neurotoxicity. Furthermore tools for read a cross were 
identified and one database that is searchable for in silico- and experimental results on neuro-
toxicity was found: the e-Chem portal developed by the OECD (row 70 in the DCS). The result 
of the in silico grey literature search is as follows:  
 BBB permeation: 7 models 
 Neurotoxicity: 3 models 
 Read across tools: 3 
 Database: 1. 
More details and the links to the models/tools are presented in the DCS sheet, rows 56 to 70 
(first column: grey lit 1 to 15).  
Some models have been developed to serve new-drug designers, although the websites do not 
state that the models are restricted to predictions for drugs. Other models explicitly state that 
they cover ‘any’ chemical.   
It would be interesting to make a comparative study on the prediction of neurotoxicity or BBB 
permeation of pesticides and other chemical substances by these website-models and the best 
performing algorithms. 
 
3.4. Alternative organisms 
For 140 publications on methods with alternative organisms for neurotoxicity of chemicals with 
known MoA during the years 1990-2017, full texts were screened and relevant information in 
line with inclusion criteria was collected in a data collection sheet (Appendix H). For those re-
tained for further analyses, a quality sheet was also completed to assess the reliability. Howev-
er, a majority of publications was excluded based on main criteria such as 1) a study on DNT, 
2) a study on neuroprotection (often in combination with the 3rd exclusion criterion), 3) only 1 
single concentration of compound tested or 4) life stage was not an alternative stage. The latter 
exclusion criterion was only applicable for the zebrafish model, as often neurotoxicity studies 
were performed with juvenile or adult life stages which according to EU Directive are considered 
experimental animals.  
Only 23 different publications representing alternative whole organism models with the fruit fly 
Drosophila melanogaster (n=7), the nematode worm Caenorhabditis elegans (n=12) or the 
zebrafish Danio rerio (n=4) were retained for further analysis in multiple ways. Each of the pub-
lications can cover multiple biological endpoints for neurotoxicity and studying one or more dif-
ferent test compounds. The latter resulted in a total of 119 citations (or hits) corresponding to 
these 23 papers. The time course for these publications and citations is presented in Figure 20.  
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a)  
 
b) 
 
Figure 20 a) number of publications, covering multiple citations by endpoints and compounds for methods with alter-
native organisms as a function of year and b) number of citations with distribution for 3 alternative species across 
the past 20 years.  
 
The analysis of total number of publications and of citations over time (Figure 20) did not show 
a real trend, but overall the numbers were rather low to find patterns. With respect to the 
number of citations there is high variability from year to year, but the high number of citations 
e.g. for 2004, 2008 and 2013 is rather due to few publications where multiple endpoints or 
compounds were simultaneously studied (Cole et al, 2004b; Rajini et al, 2008; Hosamani, 
2013). 
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The graph on contribution of the different alternative model species (Figure 20b) clearly 
demonstrates that the nematode worm, C. elegans is used most based on the number of cita-
tions throughout the past 20 years.  
The review clearly showed that C. elegans is most important alternative organisms for neuro-
toxicity studies, as can be derived from the number of publications which represent 52% (n= 
12 publications), and the number of citations which goes up to 64% (n=76). This is followed by 
Drosophila as 2nd most important organism (7 publications, 24 % of citations) and least use of 
the zebrafish model (4 publications, 12% of citations) as alternative for neurotoxicity (Figure 21 
a & b).  
a) 
 
 
b) 
 
Figure 21 a) number of publications for alternative whole organism approaches grouped by species and b) distribu-
tion of citations by species as a % of total.  
 
These data are then evaluated with regard to their performance within species group for certain 
MoA represented by endpoint categories as described in the methods section. A comprehensive 
list of the identified MoA for the list of neurotoxic compounds in relation to endpoint categories 
is available in Appendix D.  
This further evaluation will only make use of individual citations (single rows in DCS sheet), 
grouped by species addressing endpoint categories. For endpoint categories, the list of specific 
endpoints studied will be listed as can be derived from the DCS for each of the species studied 
for selected neurotoxic compounds. Questions to be addressed within the data evaluation are: 
1) which endpoint categories and specific endpoints are represented by each of the alternative 
model species, and 2) what is the predictive capacity of each alternative organism for each 
endpoint category considering the identified MOA and for each of the selected neurotoxic chem-
icals in the compound list?  
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When evaluating the publications, only those citations that were in agreement with the identi-
fied MoA (1 or more) of the selected neurotoxic compounds were included in the DCS leading to 
the 119 citations. This procedure guarantees that an effect observed in model organism is a 
‘true’ effect and allows the categorization into ‘true positives’ or ‘false negatives’. In addition, 
negative compounds (though exceptional for alternative organism) which were identified in the 
studies have been classified into ‘true negatives’ or ‘false positives’.  
In the following graphs (Figure 22 a,b,c), the major endpoint categories studied for respectively 
C. elegans, Drosophila and zebrafish are shown. For each of the species, a difference is seen 
with respect to the main endpoint categories studied. It is not clear from the current review 
with limited number of publications whether these differences are rather occasional and biased 
due to the low number or whether there is a biological or technological background with respect 
to e.g. availability of methods to measure the endpoints.  
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c) 
 
Figure 22 Distribution of # citations across endpoint categories within the different species, respectively a) C. ele-
gans, b) Drosophila, and c) zebrafish. Endpoint categories were derived from the compounds’ MoAs.  
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More detail on endpoints within categories and their predictive capacity using C. elegans is 
summarized in the next table (Table 10) and an overview for the compounds tested is present-
ed in a bar chart (Figure 23). 
The major endpoint category studied with C. elegans is inhibition of cholinergic transmission (48 
citations), which is represented by specific endpoints as measurements of AChE activity (15 ci-
tations) and motor activity (22 citations). Especially the latter endpoint confirms the added val-
ue of a whole organism approach which is lacking in studies using in vitro assays (cell culture 
models). The predictive capacity for this endpoint category is high with 96% true positive re-
sults in C. elegans. Only for 1 compound (glyphosate), for both motor activity and AChE inhibi-
tion a false negative score was obtained. Effects on motor activity were dedicated to low pH of 
test solutions at high glyphosate levels, which did not occur after pH correction, and no effect 
on AChE activity was observed (Cole et al, 2004b). The 2nd most important endpoint category 
for C. elegans was ‘multiple’. This category was identified throughout the analysis of methods 
for those cases where an endpoint (e.g. motor activity disturbance in alternative organisms), 
might be the result of different MOAs, which relate to more than 1, thus multiple, endpoint cat-
egories for some compounds. For this category, a high true positive score of 83.3 % was ob-
tained for the main endpoint ‘motor activity’ (10/12 citations). Copper chloride and 
mebendazole were both considered as negative compounds by the authors for this assay. The 
results showed no effect for mebendazole for C. elegans motor activity and thus confirmed as 
true negative. On the other hand, disturbance of motor activity (locomotion and feeding behav-
ior) was observed after exposure to copper chloride which scored false positive. The effects 
were however less than other known neurotoxic metals (Pb and Al).  
Within the 3 other endpoint categories, respectively mitochondrial dysfunction & oxidative 
stress (8 citations), axonpathies (4 citations) and inhibition of dopaminergic neurotransmission 
all assays resulted into 100% true positive results.  
The prediction of C. elegans assays for a diversity of compounds is presented as a bar chart for 
individual compounds tested (Figure 23). For a total of 76 citations, representing 27 compounds 
of different chemical classes, 96% true prediction was obtained for 72 positive neurotoxic com-
pounds and 1 negative compound.  
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Table 10:   Total number of citations for endpoint categories and specific endpoints, 
grouped for C. elegans. Predictivity analyses were performed for each endpoint category and 
specific endpoint by analyzing true positives, false positives, true negatives and false negatives. 
C. elegans 
Endpoint category (and specific endpoints) 
false  
negative 
false  
positive 
true  
negative 
true  
positive 
Axonopathies 
   
4 
Aggregation of α-synuclein protein 
   
1 
Learning ability 
   
1 
Motor activity 
   
1 
Sensory function 
   
1 
Inhibition of Cholinergic Neurotransmission 2 
  
48 
AChE activity 1 
  
15 
Activity feeding behaviour 
   
1 
Motor activity 1 
  
22 
Viability 
   
10 
Inhibition of dopaminergic Neurotransmission 
   
1 
Localisation of dopaminergic neurons 
   
1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
   
8 
Mitochondrial Membrane Potential 
   
1 
Mitochondrial structure 
   
1 
Motor activity 
   
3 
Neurodegeneration 
   
1 
Oxygen consumption rate 
   
1 
RNAi of respiratory chain genes 
   
1 
Multiple 
 
1 1 11 
Metabolomics  
   
1 
Motor activity 
 
1 1 10 
Grand Total 2 1 1 72 
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Figure 23: Total number of citations for each of the test compounds evaluated for C. elegans assays. Predictivity 
analyses were performed for each compound, considering different endpoints resulting into true positives, false posi-
tives, true negatives and false negatives. 
 
 
More detail on endpoints within categories and their predictive capacity using Drosophila from 8 
different publications with 29 citations is summarized in the next table (Table 11) and an over-
view for the compounds tested (n=4) is presented in a bar chart (Figure 24). 
The major endpoint category studied with Drosophila is mitochondrial dysfunction/oxidative 
stress/apoptosis (13 citations), which is represented by 13 different specific endpoints (Figure 
22; Table 11) with 100% true positive results. Also the endpoint category redox cycling, with 7 
citations, resulted in 86% true positive results. Only 1 citation for endpoint oxidative stress 
(catalase assay) in Drosophila exposed to paraquat gave a false negative result among true 
positive results for other endpoints as motor activity (geotaxis) and morphological damage to 
dopaminergic neurons (Chaudhuri et al, 2007). 
  
Except for 26 citations with paraquat, only 3 other neurotoxic compounds were tested with Dro-
sophila assays, but all these resulted into true positives (Figure 24). No negative compounds 
were evaluated. Overall, the Drosophila assays across all endpoints and compounds resulted in-
to 96% true prediction.  
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Table 11:  Total number of citations for endpoint categories and specific endpoints, grouped 
for Drosophila. Predictivity analyses were performed for each endpoint category and specific 
endpoint by analyzing true positives, and false negatives. 
Drosophila 
Endpoint category (and specific endpoints) 
false  
negative 
true  
positive 
Inhibition of GABAergic Neurotransmission 
 
2 
Nerve firing 
 
2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
 
13 
AChE activity 
 
1 
Activity of anti-oxydant enzymes 
 
1 
Assay for Citric Acid Cycle Enzymes 
 
1 
BuChE activity 
 
1 
Electron Transport Enzymes: Complex I-III and Complex II-III Activi-
ty 
 
1 
Hydroperoxide generation 
 
1 
Lipid peroxidation 
 
1 
Mg2+ ATPase Activity 
 
1 
Mitochondrial Membrane Potential 
 
1 
Reduced GSH content 
 
1 
ROS generation  
 
1 
Superoxide generation 
 
1 
Tissue Iron Levels 
 
1 
Multiple 
 
5 
DNA damage in brain 
 
1 
Histopathological brain damage 
 
1 
Motor activity 
 
2 
Oxidative stress 
 
1 
Neuroinflammation 
 
2 
Oxidative stress 
 
2 
Redox Cycling 1 6 
Metabolomics  
 
1 
Morphology dopaminergic neurons 
 
1 
Motor activity 
 
2 
Number of DA neurons 
 
1 
Oxidative stress 1 1 
Grand Total 1 28 
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Figure 24 Total number of citations for each of the test compounds evaluated for Drosophila assays. Predictivity 
analyses were performed for each compound, considering different endpoints resulting into true positives and false 
negatives. 
 
 
For the limited number of different publications (4), for 6 positive compounds tested resulting 
into 14 citations for the zebrafish model, the data analysis on endpoints within categories and 
their predictive capacity is presented in the next table (Table 12) and an overview for the com-
pounds tested is presented in a bar chart (Figure 25). 
 
The major endpoint category (Figure 22; Table 12) studied with zebrafish was inhibition of do-
paminergic transmission (11 citations), with 3 specific endpoints (motor activity, morphology 
and tyrosine hydroxylase labeling of dopaminergic neurons). The majority of citations were part 
of only 1 publication with the study of 3 compounds, respectively paraquat, rotenone and MPTP 
(Bretaud et al, 2004). Except for the endpoint motor activity and tyrosine hydroxylase labeling 
for MPTP, all other endpoints and compounds resulted into false negative scores. So far there is 
no good explanation for this discrepancy.  
On the other hand, for 5 citations in 3 other papers, the endpoint motor activity and 3 different 
endpoints covering the category axonopathies resulted in 100% true positive results. No nega-
tive compounds were evaluated for the zebrafish assays. Overall, the zebrafish assays across all 
endpoints and compounds resulted into 50% true prediction, and 50% false prediction.  
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Table 12:  Total number of citations for endpoint categories and specific endpoints, grouped 
for zebrafish. Predictivity analyses were performed for each endpoint category and specific 
endpoint by analyzing true positives, and false negatives. 
Zebrafish 
Endpoint category (and specific endpoints) 
false 
 negative 
true  
positive 
Axonopathies 
 
3 
Apoptosis 
 
1 
Myelin basic protein (MBP) 
 
1 
Structure of myelin fibers 
 
1 
Inhibition of dopaminergic Neurotransmission 7 4 
Morphology dopaminergic neurons 3 
 Motor activity 2 3 
Tyrosine hydroxylase labeling for Dopaminergic neurons 2 1 
Grand Total 7 7 
 
 
 
 
Figure 25 Total number of citations for each of the test compounds evaluated for zebrafish assays. Predictivity analy-
ses were performed for each compound, considering different endpoints resulting into true positives and false nega-
tives. 
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Summary alternative organisms related to MOA of neurotoxic compounds 
The review resulted in a rather low number of publications, in total 23, representing 3 non-
mammalian whole organism models which were retained for the analysis of methods covering a 
diversity of endpoint categories related to identified MOA of neurotoxic compounds. The latter 
allowed evaluating methods using C. elegans, Drosophila or zebrafish covering 119 citations. 
We can summarize the results of the review through comparison of performance for each of the 
model systems to predict mode of action of compounds, based on endpoint categories tested 
(Figure 26). 
The majority of data were available for C. elegans with 76 citations, representing 27 com-
pounds (25 positive, 2 negative). The main endpoint category was inhibition of cholinergic 
transmission, with specific endpoints for AChE activity and motor activity. The latter endpoint 
confirms the need for the use of a whole organism approach. Often automated video tracking 
methods are used which allow medium to high-throughput assessment. The overall true predic-
tion using the C. elegans was very high (96%) for a large group of compounds of different 
chemical classes (Figure 26a).  
For the Drosophila model, 7 publications with 29 citations were evaluated with majority dedi-
cated to paraquat (26 citations). The major endpoint category studied in the fly was mitochon-
drial dysfunction/oxidative stress/apoptosis. These and other endpoints studied, resulted in 97 
% true prediction, but only 4 compounds, positive for neurotoxicity were part of the studies 
(Figure 26b) 
The zebrafish model represented the lowest number of publications (4) and citations (14) for 6 
chemical compounds, classified as positive for neurotoxicity. Predictive capacity was least of the 
3 alternative species with only 50% true prediction and 50% false prediction (Figure 26c). The 
latter bad result is based on tests performed within only 1 publication.  
Overall, we can conclude that the whole organism approaches using C. elegans and Drosophila 
both provide high true prediction of MOA (96-97%). Most data resulted from studies with the 
nematode worm which seems widely used, applied for a diversity of numerous compounds and 
a lot of protocols are available both for mechanistic studies (molecular and cellular events) as 
well as medium to high-throughput methods for effect assessment, or adverse outcome such as 
motor activity. New developments related to lab-on-chip approaches and standardization of pro-
tocols might be needed to consider this assay as a low cost, and fast screening tool within an 
IATA for neurotoxicity assessment. As the C. elegans nervous system is a simplified system, fur-
ther needs for research might go to the zebrafish model, representing a vertebrate organism 
with known high gene conservation compared to mammals. It appeared in this review that this 
model has not yet been sufficiently studied as an alternative model organism for neurotoxicity, 
though promising assays for developmental neurotoxicity and assays with juvenile and adult 
fish exist. Beyond the period of embryo development (2-3 dpf), when major brain structure and 
cellular features are present (Nishimura et al, 2015), exposure studies to neurotoxic compounds 
for many more endpoints are required to demonstrate the validity of this model. However, ex-
posure and endpoint analysis should be finished within 5-6dpf when the model is not yet con-
sidered an experimental model. The whole animal approaches, which offer advantages to study 
complex processes such as molecular, cellular and signaling events in the CNS and PNS need 
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further consideration to fill gaps identified using in silico & vitro approaches, and enhance in vi-
vo predictions.  
Another recommendation, applicable to any of test methods (ao, in vitro,..)  to be evaluated re-
fers to the need to include also negative compounds for performance testing and assessment of 
prediction.  
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Figure 26 summary of results, based on endpoint categories and % prediction by analyzing true positives, true nega-
tives, false positives and false negatives across compounds tested for each of the alternative model species, respec-
tively a) C. elegans, b) Drosophila, and c) zebrafish.  
 
4. Readiness analyses 
A readiness check of testing methods was performed according to the procedure described in 
Bal-Price et al, (2018). Here, 13 criteria for evaluation are sorted into three phases. Each area 
has various sub items and the number of points that can be obtained is indicated in Appendix J. 
Phase I (green) includes the basic features of the test method as they would be provided by 
academic researchers. They include biological plausibility of the test method, features of the 
test system, and the availability of controls. A high number of points can be obtained for test 
system description (10 out of 35), as this is very important at early stages of test development. 
However, still two thirds of the points come from other areas not to be neglected. The second 
phase (blue) relates to the implementation of a test for practical applications in industry or for 
regulatory purposes. Here, the relation to a testing strategy, good robustness, and the availabil-
ity of a prediction model are important. The third phase (yellow) is optional as not each test 
method is used for a screening approach. Notably, not all points apply to all tests. In the pre-
liminary rating scheme suggested here, these items are then scored positive automatically. 
Each phase is evaluated independently, and then categorized into one of four readiness classes 
(A-D). In the figure, an example is given for the rating of the cMINC (UKN2) test method. It 
would score as ‘A’ (largely ready) in phase I, and as ‘B’ in phase II. For phase III, it would score 
as ‘A’ (Figure 27). 
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Figure 27 Set-up and example of a test system readiness check as published in Bal-Price et al. 2018.  
 
During the review of the studies, 8 publications were marked as applicable to a readiness check 
(Smirnova et al, 2016; Zagoura et al, 2017a; Cookson & Pentreath, 1994b; Krug et al, 2013; 
Zurich et al, 2013; van Vliet et al, 2007; Nicolas et al, 2014; Sirenko et al, 2014). Scoring of 
these studies was performed across phase I, II and III as indicated above. The results of this 
scoring are shown in Table 13 and the detailed score results in Appendix K. These analyses 
show that there is not a high readiness level within the test systems evaluated. The highest 
score for phase I is a ‘B’, indicating that there is room for improvement even on the basic scien-
tific description level of the methods. Also scores for phase II across all evaluations do not ex-
ceed ‘B’, most studies scoring ‘C’ or ‘D’. The best category was phase III concerning screening. 
Here, most studies reached an ‘A’. Overall, the study with the highest scores (Zurich et al. 
2013) are 3D primary rat cultures, followed by studies using 2D (Krug et al. 2013) or 3D (Smir-
nova et al. 2016) immortalized human LUHMES cells, and a hiPSC model (Zagoura et al. 2016). 
 
Table 13:  Scores for readiness of in vitro test systems from 8 publications. 
1st author 
 
Smirno
va 
Zagour
a 
Cookso
n Krug Zurich 
van 
Vliet Nicolas Sirenko 
Year 2016 2016 1994 2013 2013 2007 2014 2014 
Phase I - 21 20 17 23 20 11 10,5 12,5 
ALTEX preprint  
published February 23, 2018, version 2 
doi:10.14573/altex.1712081 
 
12 
 
12c AOP Information contributed to an AOP 
KE/MIE; element of a KE testing 
battery 
 1 
13 Screening hits   4 
13a Hit definition Transparent, pre-defined criteria 
(including curve-fitting/statistical 
procedure) 
Usually, non-hits are discarded. If statements of 
non-hits are made, they need definition and power 
calculation. 
1 
13b Hit confirmation 
(prim.) 
Independent test run(s) in “same” test 
method; full concentration-response 
Often loose (soft) criteria for hits, and no correction 
for false discovery rate. Confirmation assays can 
counteract such problems; use of new cells and new 
compound stocks provides additional robustness. 
1 
13c Hit confirmation 
(sec.) 
Additional test (different from primary 
test method) confirming hit on same 
endpoint as screen 
E.g. migration may be measured by tracking cells 
(primary test) and then (secondary test) by a 
Boyden chamber method. 
1 
13d Screen 
documentation 
Acceptability criteria, performance of 
positive controls, internal robustness 
controls 
 1 
 
3.2 Scoring system for readiness criteria 
According to the OECD GD211 (OECD, 2014b), the new generation of in vitro test methods, may be very useful for some 
regulatory purposes, even if they are not officially validated. For instance, they may be used to provide additional/supplemental 
mechanistic information on top of standard testing results. Moreover, such tests may be used in companies or regulatory 
authorities for internal decision making, or for screening programs with the aim of prioritization for further testing (Browne et al., 
2017). Although there is guidance on what needs to be considered for test method validation, not many tools are available that 
provide an actual measure of readiness. 
 
 
Fig. 3: Scoring system for readiness criteria 
Overview of the scoring system for the readiness criteria. The 13 criteria are sorted into three phases. Each areas has various sub-
items and the number of points that can be obtained is indicated in Table 2. Phase I (green) includes the basic features of the test 
method as they would be provided by academic researchers. They include biological plausibility of the test method, features of the 
test system, and the availability of controls. A high number of points can be obtained for test system description (10 out of 35), as 
this is very important at early stages of test development. However, still two thirds of the points come from other areas not to be 
neglected. The second phase (blue) relates to the implementation of a test for practical applications in industry or for regulatory 
purposes. Here, the relation to a testing strategy, good robustness, and the availability of a prediction model are important. The third 
phase (yellow) is optional as not each test method is used for a screening approach. Notably, not all points apply to all tests. In the 
preliminary rating scheme suggested here, these items are then scored positive automatically (labelled in italics in Table 2). Each 
phase if evaluated independently, and then categorized into one of four readiness classes (A-D). In the figure, an example is given 
for the rating of the cMINC (UKN2) test method. It would score as ‘A’ (largely ready) in phase I, and as ‘B’ in phase II. For phase III, it 
would score as ‘A’. 
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score 
Phase I - 
grade B B C B B C C C 
Phase II - 
score 6 8 9 9 11 4 5 2 
Phase II - 
grade C C C C B D D D 
Phase III - 
score 4 3 3 4 3 0 0 0 
Phase III - 
grade A A A A A D D D 
 
For the review of studies using alternative organisms, 3 publications were retained to be suit-
able for a readiness check (Shukla et al, 2014; Cole et al, 2004a; Irons et al, 2010). Scoring of 
these studies was performed across phase I, II and III as indicated above. The results of this 
scoring are shown in Table 14 and the detailed score results in Appendix K. Some (sub)criteria, 
as defined based on in vitro methods, were not considered relevant for the organism approach 
(NR), and got the maximum score applicable (italic in appendix).  
The highest score for each of the papers in phase I is a ‘B’, indicating that similar to the in vitro 
methods, there is need to improve the methods at different levels (e.g. use of positive and 
negative controls, technical documentation). Also scores for phase II are low, with ‘B’ for the 
nematode model, and even ‘C’ for the 2 other publications. There is general lack of information 
on the prediction model, test benchmarks, robustness testing and application domain. The 
phase III scoring was little bit better with 2 studies reaching the ‘A’ score. The overall score for 
the C. elegans models (Cole et al, 2004a) was the highest, followed by the fruit fly model 
(Shukla et al, 2014) and least for the zebrafish model (Irons et al, 2010). In the latter study, 
the linkage of the relevant neurotoxic adverse outcome measurements (disturbed behaviour) to 
changes of early key events as part of AOP should have been of added value and needs further 
investigation (see also low score for criteria 4, 8 & 12).  
Table 14:  Scores for readiness of alternative organisms based test systems from 3 publica-
tions.  
1st author 
 
Shukla et al.  Cole et al.  Irons et al. 
Year 2014 2004 2010 
Species ao Fruit fly Nematode worm Zebrafish 
Phase I - 
score 
22 23 19 
Phase I - 
grade 
B B B 
Phase II - 9 11 6 
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score 
Phase II - 
grade 
C B C 
Phase III - 
score 
3 3 2 
Phase III - 
grade 
A A B 
 
 
5. Summary  
Testing for neurotoxicity of compounds including plant protection products is performed in rats 
according to the OECD Guideline 424 (Neurotoxicity studies in rodents) and 426 (Developmental 
Neurotoxicity Studies). However, both these methods use complex in vivo tests, which are often 
too laborious and expensive and might also not well reflect the human situation because of in-
ter-species variation. It is now recognised that the future of chemical safety assessment must 
move away from animal tests towards a combination of complementary approaches that ad-
dress functional mechanistic endpoints tied to adverse outcomes of regulatory concern. This 
does not only concern the EU, but also the US has just released a draft strategy to reduce the 
use of vertebrate animals in chemical testing. This Toxic Substances Control Act (TSCA) re-
quires EPA to develop a Strategic Plan by mid 2018 to promote the development and implemen-
tation of alternative test methods and strategies to reduce, refine or replace vertebrate animal 
testing (https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/alternative-test-
methods-and-strategies-reduce). On this background, this systematic review was performed 
under a contract with EFSA to evaluate information on assessment methods in the field of neu-
rotoxicity (NT). Therefore, a systematic and comprehensive literature search and collection of 
scientific literature and all other relevant grey literature and website information (in English) 
from 1990 until 2017 on the state of the art NT testing methods including in vitro test methods, 
novel and alternative non-mammalian models and in silico methods was performed. In addition, 
mode-of-action (MoA) analyses for 248 individual neurotoxic compounds, 23 compound classes 
and 212 natural neurotoxins were carried out and collected. While analysing the publications, 
only these studies were included that related to the identified MoA(s) of the respective com-
pounds. In this way, only studies with known physiological relevance were included in the final 
evaluation strongly increasing the meaningfulness of the data. However, there still were end-
points detected that did not show an anticipated effect or negative compounds having an ef-
fect. This produced false negative and false positive data. These were analysed in more detail 
and the true positives were used for defining the assays’ application domains.   
The analyses of the in vitro studies revealed: 
 From 9088 studies after the first search, 1803 were included for full text screening. From 
those we included 209 for in vitro, 39 for in silico and 23 for alternative organisms. 
 The main studies of the publication selection for in vitro studies were performed with rat 
cells, followed by mouse, human and only few studies were included working with chicken 
and xenopus cells.  
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 These contain primary cells, primary tissue, stem-/progenitor cells, immortalized cells or 
cell free methods. 
 Primary cells were generated from different brain regions with rat primary cells prepared 
from the largest number of brain regions followed by mouse and chicken. 
 Stem-/progenitor cell-based models were mainly from human the human species, here 
predominantly hiPSC. 
 According to the MoA analyses, 27 endpoint categories were defined that contain grouped 
endpoints and reflect key events (KE) of neurotoxicity. 
 In all in vitro models, ‘mitochondrial dysfunction/oxidative stress/apoptosis’ was the most 
studied endpoint 
 No test system has so far been shown to study all endpoint categories. However, multi-
plexing of endpoints within one model is advisable.  
 Multiple especially primary cells in combination are able to cover a wide spectrum of end-
point categories. 
 With regards to human stem-/progenitor cell methods, promising cell systems are on the 
way, yet there is a lot of data missing regarding their ability to detect the endpoint cate-
gories that can be studied in rodent primary cells.  
 Special attention has to be given to glia cells. These are understudied cells when it comes 
to hiPSC. Here, oligodendrocyte and microglia data are even more sparse than data on 
astrocytes. 
 More glia models and neuron-glia co-culture models are needed to multiplex endpoint 
evaluations in one system that contains interactions between the different cell types, neu-
rons and glia. 
 BBB models need further development.  
 Protocol harmonization and definition of culture and quality standards are necessary to 
reproducibly produce defined test systems based on hiPSC. 
 This systematic review report now contains usable data on cell methods and application 
domains that can be used for assembly of a NT testing strategy covering multiple NT 
MoA. Moreover, it can be used for choosing the right test system when a certain MoA of a 
compound is suspected. 
 Readiness analyses indicate that there is more specific test method development needed. 
The analyses of the in silico studies revealed: 
 The in silico part in this systematic review was dedicated to models for assessment of 
chemicals passing the blood-brain barrier or of neurotoxicity.  
 Selected 54 QSARs publications, relevant for NT, of which 39 on BBB permeation The 
QSARs available in the publications were developed from data on drugs and chemicals. 
 Two properties often returning as important factors linked to passive BBB diffusion are 
lipophilicity (LogP) and charge (total polar surface area). Lipophilicity is positively corre-
lated with passive diffusion. The total polar surface area of a molecule and heteroatoms, 
however, seem to have a negative impact on diffusion. These properties should be con-
sidered in the assessment of NT. 
 Most of the mhe models do not consider active transport, none considers metabolites of 
compounds.  
 There is limited experimental data for chemicals and pesticides on blood-brain barrier 
passage. Publications from different authors often refer to the same data sets.  
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The analyses of the alternative organism studies revealed: 
 Rather low number of publications, in total 22, representing 3 non-mammalian whole or-
ganism models.  
 A diversity of endpoint categories (in total 8 for ao) and specific endpoints related to iden-
tified MOA of neurotoxic compounds using C. elegans, Drosophila or zebrafish as ao mod-
els covering 119 citations for evaluation. 
 The majority of data were available for C. elegans with 76 citations, representing 27 com-
pounds (25 positive, 2 negative). The main endpoint category was inhibition of cholinergic 
transmission, with specific endpoints for AChE activity and motor activity, the latter con-
firming the added value of a whole organism approach among alternative models 
 The major endpoint category studied in the fly was mitochondrial dysfunction/oxidative 
stress/apoptosis. 
 Despite its role as a vertebrate model, the zebrafish assays were poorly available for neu-
rotoxicity studies. Restrictions are likely due to the limited time period to be used as a 
non-animal methods, as early life stages are considered DNT, while after 5dpf the zebraf-
ish is considered an animal. Nevertheless, the zebrafish model should be further explored 
for NT assays, especially for the period 3-5dpf when the metabolic system is developed. 
 The true prediction using C. elegans (96%) and Drosophila (97%) was very high, while 
only 50% for zebrafish, but the latter was based on only 4 publications.  
 
6. Conclusion 
This systematic review identified a variety of cell types and test systems covering a broad vari-
ety of endpoint categories. These endpoint categories are representative for the MoA of neuro-
toxic compounds identified through a MoA analysis. Most predictive and covering a large variety 
of endpoints are primary rodent cells or tissues, next to the C. elegans model. Working with tis-
sues was historically a prominent model, however, nowadays primary and stem cell models 
have superseded these tissue models.  
With regards to species-specific effects, working with human methods is warranted. Therefore, 
although primary rodent cells are capable of assessing a large variety of endpoints, they do not 
solve the species issue. This is why lately working with hiPSC-based neural methods has 
evolved. So far, we do not have enough data on these test systems to understand if they could 
possibly substitute primary rodent cells for NT testing purposes and thus momentarily the pri-
mary rodent cell is the best method we have for NT evaluation. Nevertheless, species compari-
sons with primary rodent cells to validate hiPSC methods are probably very useful. Especially 
functional endpoints like electrical activity measures on MEAs are well-studied with rat cultures, 
yet sparse with hiPSC. Another shortcoming of stem cell-based methods is the lack of brain re-
gion-specificity. Rodent cell preparations from different brain regions reflect brain region-
specific toxicities. To achieve similar results with hiPSC in vitro using human cells one needs de-
fined differentiation protocols that reflect respective brain regions. Such are sporadically avail-
able, but are not standard procedures yet. Besides neurons, glia represent targets for neuro-
toxicants. Astrocytes and microglia can protect against neurotoxicity or exacerbate chemical ef-
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fects on neurons, e.g. by releasing pro-inflammatory cytokines. Oligodendrocytes are targets for 
myelin toxins. Cell methods for glia toxicity are rare and glia endpoint categories are underrep-
resented. There is a strong need to put some method development focus on glia cells, astro-
cytes, oligodendrocytes and microglia. Preferably, one would want all these cell types in neu-
ronal-glia co-cultures. This is also true for BBB models.  
Until we possess fit-for-regulatory-purposes-hiPSC test systems for NT evaluation, i.e. covering 
endpoint categories and with this known NT MoA comprehensively, the results from this study 
can be used to select test systems according to suspected MoA for NT testing. The complemen-
tarity of assays to screen for AOP events in a reproducible way, and correctly predicted MOA 
should be considered including the best performing model systems (in vitro, ao, in silico) and 
endpoints methods identified in this review. Harmonisation of procedures and development of 
standard protocols with data interpretation will be necessary to enhance regulatory confidence 
and implementation of non-animal alternatives for neurotoxicity. Specific test method develop-
ment needs to be accelerated for using test systems in a regulatory context. 
 
 
7. Summary of recommendations 
 
7.1. General 
• There is consensus that there is a need for alternative methodologies that can more rapidly 
and cost effectively screen large numbers of chemicals for their potential to cause NT or in-
vestigate MoA to provide information on human relevance.  
• As part of an IATA, the different alternative approaches in silico, in vitro and alternative or-
ganisms should be evaluated for their performance (predictivity) for regulatory needs, while 
considering time and cost-efficiency.  
• To demonstrate performance, especially for the ao methods, but relevant for all assays, 
there is a need to identify negative compounds for neurotoxicity.  
• Test method development for regulatory purposes is needed. 
 
 
7.2. In vitro 
• Cells taken out of the in vivo context maintain certain cellular and molecular functions they 
hold in vivo. Cellular composition and dimension of in vitro models are crucial. This aspect 
needs special attention when it comes to human stem cell-derived systems.  
• Human embryonic stem cells (hESC) were employed, yet posing an ethical issue on their 
use and differences in national laws for working with such material. 
• Human hiPSC are ethically without concern and are therefore a useful alternative to embry-
onic stem cells. When using hiPSC-derived neural cultures, mixed neuron and glia cultures 
are preferred, i.e. containing astrocytes, oligodendrocytes and microglia. 
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• Easy to use, highly reproducible protocols for establishing such mixed cell, hiPSC-based in 
vitro cultures need to be produced. Reliable protocols need establishment in a systematic 
way. 
• Brain region-specific cell methods derived from hiPSC need establishment. 
• Glia role in neurotoxicity need to be implemented with a particular attention to co-culture 
systems. 
• BBB models need improvement. 
• When working with hiPSC protocols, quality assurance needs to be implemented into the 
procedures. 
• For endpoint determination, a guidance on how to use and interpret viability/cytotoxicity as-
says in NT in vitro studies is highly recommended. 
• A NT in vitro test battery covering identified and relevant MoA for NT is recommended. 
Therefore, assays as test methods with relevant controls and standard operation procedures 
have to be set up for covering most important MoA. To link the human in vitro testing to ro-
dent in vivo studies and validate the stem cell-derived systems, it is advised to include ro-
dent primary cultures into the studies. 
• Chemicals representing compound classes with defined MoA need to challenge the human 
and rat in vitro testing battery thereby producing reliable reference data. 
 
7.3. Alternative organisms 
 Both whole organism approaches using C. elegans and Drosophila showed high true pre-
diction of MOA (96-97%). Especially for the nematode worm, which seems widely used 
and applied for a diversity of compounds with a lot of protocols for mechanistic studies 
(molecular and cellular events) and motor activity are available. In order to strengthen 
the suitability of this model, standardization of protocols might be necessary and valida-
tion studies to demonstrate its wide applicability.  
 Current assays with alternative organisms show automation towards increased throughput 
methods by using lab-on-chip approaches, video tracking for motor activity, or high-
throughput detection of fluorescent signals in transgenic models (detection of MIE, re-
porter systems). These developments offer future potential for low cost, fast screening of 
large battery of compounds to be prioritized for NT assessment.  
 The zebrafish model, recognized as a highly relevant DNT model (Fritsche et al, 2015) 
and representing a vertebrate organism with known high gene conservation compared to 
mammals, needs further exploration as an alternative model organism for neurotoxicity. 
Beyond the period of embryo development (2-3 dpf), when major brain structure and cel-
lular features are present (Nishimura et al, 2015), and the liver metabolic system is active 
(Goldstone & Stegeman, 2012) a multitude of endpoints, as listed for MOA can be meas-
ured in an automated way, in multi-well set-up. 
 The whole animal approaches, which offer advantages to study complex processes such 
as molecular, cellular and signaling events in the CNS and PNS need further consideration 
to fill gaps identified using in silico & vitro approaches, and enhance in vivo predictions 
aiming to predict human neurotoxicity.  
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7.4. In silico 
 There is limited experimental data for chemicals and pesticides on blood-brain barrier 
passage. Publications from different authors often refer to the same data sets. There is a 
need to extend the data sets for neurotoxic chemicals. 
 To fully profit from the advantages of complex machine learning techniques such as Artifi-
cial Neural Networks and Support Vector Machines, the generation of new experimental 
data (log BB) for use as training set should be increased drastically. Mixture toxicity is 
considered in one model, indicating that a substance may influence the BBB-passage of 
another substance. Further research on the mechanism of mixture toxicity and additional 
experimental data on the mixture effect are needed 
 It would be interesting to make a comparative study on the prediction of neurotoxicity or 
BBB permeation of pesticides and other chemical substances by the models provided on 
websites (grey literature result) and the best-performing published algorithms. 
 
 
7.5. Possible EFSA follow-up activities 
• Experimental project sponsorship to systematically set up a NT hiPSC-based testing strategy 
with primary rodent models as references. Test methods need further development. Chal-
lenging this testing battery with a test set of chemicals from different compound classes 
covering the proposed MoAs. 
• Experimental project sponsoring evaluation of NT MoA in the zebrafish by using different 
compound classes. 
• In silico analyses of the outcomes with comparisons across the different models. 
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APPENDICES 
 
Appendices A to D can be found in the online version of this output (‘Supporting information’ section): 
http://dx.doi.org/10.2903/j.efsa.2018.1410  
 
Appendix A.  List of Compounds and compound classes identified from two publica-
tions by Grandjean and Landrigan (20061 and 20142) and an EFSA 
supporting publication by Choi et al. (20163). 
 
 
Appendix B.  List of Natural Compounds (NCs) identified from the Handbook of Neu-
rotoxicity. 
 
 
Appendix C.  MoA analysis sheet (layout) 
 
 
Appendix D.  Detailed information on Mode of Actions (MoAs) of all compounds and 
compound classes (including natural neurotoxins) with an identified 
(partial) MoA from Appendix A and B and association to a respective 
MoA/endpoint category. 
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Appendix E.  Search strings 
Neurotoxicity search 
PubMed: 
(("1990/01/01"[Date - Publication] : "2017/04/31"[Date - Publication])) AND (((((toxic*[Title/Abstract]) AND 
((((((brain[Title/Abstract]) OR CNS[Title/Abstract]) OR PNS[Title/Abstract]) OR nervous system[Title/Abstract]) OR 
neurological*[Title/Abstract]) OR neural*[Title/Abstract]))) OR neurotoxi*[Title/Abstract]))  
WoS: 
(toxic* AND (Brain OR CNS OR PNS OR nervous system OR neurological* OR neural*)) OR neurotoxi* 
 
Compound search (for Chlorpyrifos as an example compound) 
PubMed: 
"Zidil"[Title/Abstract] OR "Grofo"[Title/Abstract] OR "Brodan"[Title/Abstract] OR "Suscon"[Title/Abstract] OR 
"Durmet"[Title/Abstract] OR "Terial"[Title/Abstract] OR "XRM 429"[Title/Abstract] OR "Dursban"[Title/Abstract] OR 
"Lorsban"[Title/Abstract] OR "Pyrinex"[Title/Abstract] OR "Bonidel"[Title/Abstract] OR "Coroban"[Title/Abstract] OR 
"Lentrek"[Title/Abstract] OR "Lock-On"[Title/Abstract] OR "Spannit"[Title/Abstract] OR "Tafaban"[Title/Abstract] OR 
"HSDB 389"[Title/Abstract] OR "OMS-0971"[Title/Abstract] OR "XRM 5160"[Title/Abstract] OR 
"Piridane"[Title/Abstract] OR "Danusban"[Title/Abstract] OR "2921-88-2"[Title/Abstract] OR "AI3-
27311"[Title/Abstract] OR "Dowco 179"[Title/Abstract] OR "ENT 27311"[Title/Abstract] OR "Detmol 
ua"[Title/Abstract] OR "Dursban F"[Title/Abstract] OR "Dhanusban"[Title/Abstract] OR "Dursban R"[Title/Abstract] 
OR "Geodinfos"[Title/Abstract] OR "CCRIS 7144"[Title/Abstract] OR "Dursban 4E"[Title/Abstract] OR "Dursban 
44"[Title/Abstract] OR "Terial 40L"[Title/Abstract] OR "Killmaster"[Title/Abstract] OR "BRN 1545756"[Title/Abstract] 
OR "Detmol"[Title/Abstract] OR "suSCon Blue"[Title/Abstract] OR "Lorsban 50SL"[Title/Abstract] OR "Dursban 
10CR"[Title/Abstract] OR "Chlorpyrifos"[Title/Abstract] OR "suSCon Green"[Title/Abstract] OR 
"Chlorpyriphos"[Title/Abstract] OR "UNII-JCS58I644W"[Title/Abstract] OR "Trichlorpyrphos"[Title/Abstract] OR 
"EINECS 220-864-4"[Title/Abstract] OR "Caswell No. 219AA"[Title/Abstract] OR "Radar"[Title/Abstract] OR 
"Chlorpyrifos ethyl"[Title/Abstract] OR "Chlorpyrifos-ethyl"[Title/Abstract] OR "Chlorpyriphos-ethyl"[Title/Abstract] OR 
"Ethyl chlorpyriphos"[Title/Abstract] OR "Chlorpyriphos"[Title/Abstract] OR "Chlorpyrifos"[Title/Abstract] OR "EPA 
Pesticide Chemical Code 059101"[Title/Abstract] OR "O,O-Diaethyl-O-3,5,6-trichlor-2-
pyridylmonothiophosphat"[Title/Abstract] OR "O,O-Diethyl O-3,5,6-trichloro-2-pyridyl 
phosphorothioate"[Title/Abstract] OR "O,O-Diethyl O-(3,5,6-trichloro-2-pyridyl) phsophorothioate"[Title/Abstract] OR 
"O,O-Diethyl O-(3,5,6-trichloro-2-pyridinyl)phosphorothioate"[Title/Abstract] OR "O,O-Diaethyl-O-3,5,6-trichlor-2-
pyridylmonothiophosphat"[Title/Abstract] OR "Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridyl) es-
ter"[Title/Abstract] OR "Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester"[Title/Abstract] OR "2-
Pyridinol, 3,5,6-trichloro-, O-ester with O,O-diethyl phosphorothioate"[Title/Abstract] 
 
WoS: 
"Zidil" OR "Grofo" OR "Brodan" OR "Suscon" OR "Durmet" OR "Terial" OR "XRM 429" OR "Dursban" OR "Lorsban" OR 
"Pyrinex" OR "Bonidel" OR "Coroban" OR "Lentrek" OR "Lock-On" OR "Spannit" OR "Tafaban" OR "HSDB 389" OR 
"OMS-0971" OR "XRM 5160" OR "Piridane" OR "Danusban" OR "2921-88-2" OR "AI3-27311" OR "Dowco 179" OR 
"ENT 27311" OR "Detmol ua" OR "Dursban F" OR "Dhanusban" OR "Dursban R" OR "Geodinfos" OR "CCRIS 7144" 
OR "Dursban 4E" OR "Dursban 44" OR "Terial 40L" OR "Killmaster" OR "BRN 1545756" OR "Detmol" OR "suSCon 
Blue" OR "Lorsban 50SL" OR "Dursban 10CR" OR "Chlorpyrifos" OR "suSCon Green" OR "Chlorpyriphos" OR "UNII-
JCS58I644W" OR "Trichlorpyrphos" OR "EINECS 220-864-4" OR "Caswell No. 219AA" OR "Chlorpyrifos ethyl" OR 
"Chlorpyrifos-ethyl" OR "Chlorpyriphos-ethyl" OR "Ethyl chlorpyriphos" OR "Chlorpyriphos" OR "Chlorpyrifos" OR "EPA 
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Pesticide Chemical Code 059101" OR "O,O-Diaethyl-O-3,5,6-trichlor-2-pyridylmonothiophosphat" OR "O,O-Diethyl O-
3,5,6-trichloro-2-pyridyl phosphorothioate" OR "O,O-Diethyl O-(3,5,6-trichloro-2-pyridyl) phsophorothioate" OR "O,O-
Diethyl O-(3,5,6-trichloro-2-pyridinyl)phosphorothioate" OR "O,O-Diaethyl-O-3,5,6-trichlor-2-
pyridylmonothiophosphat" OR "Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridyl) ester" OR 
"Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester" OR "2-Pyridinol, 3,5,6-trichloro-, O-ester with 
O,O-diethyl phosphorothioate" 
 
Alternative method search 1 (combined by ‘OR’) 
In vitro: 
PubMed 
((((((model*[Title/Abstract] OR test[Title/Abstract] OR assay*[Title/Abstract] OR method*[Title/Abstract] OR tech-
nique*[Title/Abstract] OR set up[Title/Abstract] OR experiment*[Title/Abstract] OR endpoint*[Title/Abstract] OR pri-
oritization*[Title/Abstract] OR system*[Title/Abstract] OR evaluation*[Title/Abstract] OR exposure*[Title/Abstract] 
OR testing[Title/Abstract] OR tests[Title/Abstract]))) AND in vitro[Title/Abstract]))) OR ((culture*[Title/Abstract] OR 
brain slice*[Title/Abstract] OR cell based[Title/Abstract] OR cell line*[Title/Abstract] OR cell model*[Title/Abstract] 
OR cell system*[Title/Abstract] OR cellular model*[Title/Abstract] OR cellular assay*[Title/Abstract] OR cellular sys-
tem*[Title/Abstract] OR cellular method*[Title/Abstract] OR cellular technique*[Title/Abstract] OR cellular end-
point*[Title/Abstract] OR cellular exposure*[Title/Abstract] OR immortalised[Title/Abstract] OR immortal-
ized[Title/Abstract] OR IPS cell*[Title/Abstract] OR primary cell*[Title/Abstract] OR In Vitro Techniques[MeSH] OR 
tumor cell line*[Title/Abstract] OR Cells, Cultured[MeSH] OR Astrocyte*[Title/Abstract] OR ESC[Title/Abstract] OR 
glial cell*[Title/Abstract] OR iPSC[Title/Abstract] OR nerve cell*[Title/Abstract] OR neural cell*[Title/Abstract] OR 
neuroblastoma [Title/Abstract] OR neuronal cell*[Title/Abstract] OR oligodendrocyte*[Title/Abstract] OR pheochro-
mocytoma*[Title/Abstract] OR pluripotent cell*[Title/Abstract] OR schwann cell*[Title/Abstract] OR stem 
cell*[Title/Abstract] OR teratocarcinoma*[Title/Abstract] OR tumor cell[Title/Abstract] OR microglia[Title/Abstract])) 
WoS 
(("model*" OR "test OR assay*" OR "method*" OR "technique*" OR "set up" OR "experiment*" OR "endpoint*" OR 
"prioritization*" OR "system*" OR "evaluation*" OR "exposure*" OR "testing" OR "tests") AND "in vitro") OR "cul-
ture*" OR "brain slice*" OR "cell based" OR "cell line*" OR "cell model*" OR "cell system*" OR "cellular model*" OR 
"cellular assay*" OR "cellular system*" OR "cellular method*" OR "cellular technique*" OR "cellular endpoint*" OR 
"cellular exposure*" OR "immortalised" OR "immortalized" OR "IPS cell*" OR "primary cell*" OR "tumor cell line*" OR 
"Astrocyte*" OR "ESC" OR "glial cell*" OR "iPSC" OR "nerve cell*" OR "neural cell*" OR "neuroblastoma " OR "neu-
ronal cell*" OR "oligodendrocyte*" OR "pheochromocytoma*" OR "pluripotent cell*" OR "schwann cell*" OR "stem 
cell*" OR "teratocarcinoma*" OR "tumor cell" OR "microglia*" 
 
 
Cell free 
PubMed 
acellular assay*[Title/Abstract] OR biochemical assay*[Title/Abstract] OR biomimetic*[Title/Abstract] OR biosen-
sor*[Title/Abstract] OR cell free[Title/Abstract] OR cellfree[Title/Abstract] OR enzyme assay*[Title/Abstract] OR lab 
on a chip*[Title/Abstract] OR non cell assay*[Title/Abstract] OR receptor assay*[Title/Abstract] OR reporter as-
say*[Title/Abstract] OR binding assay*[Title/Abstract] OR Cell-Free System[MeSH] 
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WoS 
"acellular assay*" OR "biochemical assay*" OR "biomimetic*" OR "biosensor*" OR "cell free" OR "cellfree" OR "en-
zyme assay*" OR "lab on a chip*" OR "non cell assay*" OR "receptor assay*" OR "reporter assay*" OR "binding as-
say*" 
 
Alternative organism 
PubMed 
(invertebrate*[Title/Abstract] OR non mammal*[Title/Abstract] OR caenorhabditis[Title/Abstract] OR C. ele-
gans[Title/Abstract] OR nematod*[Title/Abstract] OR rerio[Title/Abstract] OR roundworm*[Title/Abstract] OR sea 
urchin*[Title/Abstract] OR zebra fish[Title/Abstract] OR zebrafish[Title/Abstract] OR Xenopus[Title/Abstract] OR tad-
pole[Title/Abstract] OR clawed frog*[Title/Abstract] OR Zebrafish[MeSH] OR Caenorhabditis[MeSH] OR Sea Ur-
chins[MeSH] OR Xenopus[MeSH] OR Brachydanio[Title/Abstract] OR Brachydanio rerio[Title/Abstract] OR Danio [Ti-
tle/Abstract] OR Caenorhabditis elegan*[Title/Abstract] OR Fruitfly[Title/Abstract] OR Fruit fly[Title/Abstract] OR 
Drosophila[Title/Abstract] OR Drosophila melanog*[Title/Abstract] OR Echinoid*[Title/Abstract] OR fruit 
flies[Title/Abstract] OR fruitflies[Title/Abstract] OR Drosophila[MeSH] 
WoS 
"invertebrate*" OR "non mammal*" OR "caenorhabditis" OR "C. elegans" OR "nematod*" OR "rerio" OR "round-
worm*" OR "sea urchin*" OR "zebra fish" OR "zebrafish" OR "Xenopus" OR "tadpole" OR "clawed frog*" OR "Brachy-
danio" OR "Brachydanio rerio" OR "Danio " OR "Caenorhabditis elegan*" OR "Fruitfly" OR "Fruit fly" OR "Drosophila" 
OR "Drosophila melanog*" OR "Echinoid*" OR "fruit flies" OR "fruitflies" 
 
Alternative method related (general)  
PubMed 
alternative approach*[Title/Abstract] OR alternative assay*[Title/Abstract] OR alternative method*[Title/Abstract] OR 
alternative model*[Title/Abstract] OR alternative to animal*[Title/Abstract] OR alternatives to animal*[Title/Abstract] 
OR analogue approach*[Title/Abstract] OR animalfree[Title/Abstract] OR animal-free[Title/Abstract] OR assay char-
acterisation[Title/Abstract] OR assay characterization[Title/Abstract] OR assay development[Title/Abstract] OR assay 
performance[Title/Abstract] OR assay validation[Title/Abstract] OR bio assay*[Title/Abstract] OR bioas-
say*[Title/Abstract] OR Biological Assay*[Title/Abstract] OR in vitro screening*[Title/Abstract] OR method characteri-
zation[Title/Abstract] OR method characterization[Title/Abstract] OR method development[Title/Abstract] OR method 
validation[Title/Abstract] OR model characterisation[Title/Abstract] OR model characterization[Title/Abstract] OR 
model development[Title/Abstract] OR model validation[Title/Abstract] OR non animal alternativ*[Title/Abstract] OR 
non animal alternative*[Title/Abstract] OR non testing method[Title/Abstract] OR sceening tool*[Title/Abstract] OR 
screening assay*[Title/Abstract] OR screening method*[Title/Abstract] OR screening system*[Title/Abstract] OR 
screening test*[Title/Abstract] OR test assay*[Title/Abstract] OR test batteries[Title/Abstract] OR test bat-
tery[Title/Abstract] OR test method*[Title/Abstract] OR test strategies[Title/Abstract] OR test strategy[Title/Abstract] 
OR test system*[Title/Abstract] OR testing assay*[Title/Abstract] OR testing batteries[Title/Abstract] OR testing bat-
tery[Title/Abstract] OR testing method*[Title/Abstract] OR testing strategies[Title/Abstract] OR testing strat-
egy[Title/Abstract] OR three dimensional cell culture[Title/Abstract] OR three dimensional model[Title/Abstract] OR 
throughput screening[Title/Abstract] OR Biological Assay[MeSH] 
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WoS 
"alternative approach*" OR "alternative assay*" OR "alternative method*" OR "alternative model*" OR "alternative to 
animal*" OR "alternatives to animal*" OR "analogue approach*" OR "animalfree" OR "animal-free" OR "assay charac-
terisation" OR "assay characterization" OR "assay development" OR "assay performance" OR "assay validation" OR 
"bio assay*" OR "bioassay*" OR "Biological Assay*" OR "in vitro screening*" OR "method characterization" OR 
"method characterization" OR "method development" OR "method validation" OR "model characterisation" OR 
"model characterization" OR "model development" OR "model validation" OR "non animal alternativ*" OR "non ani-
mal alternative*" OR "non testing method" OR "sceening tool*" OR "screening assay*" OR "screening method*" OR 
"screening system*" OR "screening test*" OR "test assay*" OR "test batteries" OR "test battery" OR "test method*" 
OR "test strategies" OR "test strategy" OR "test system*" OR "testing assay*" OR "testing batteries" OR "testing bat-
tery" OR "testing method*" OR "testing strategies" OR "testing strategy" OR "three dimensional cell culture" OR 
"three dimensional model" OR "throughput screening" 
 
In silico search 
PubMed 
("(Q)SAR"[Title/Abstract] OR computational*[Title/Abstract] OR in silico*[Title/Abstract] OR physico chemical prop-
ert*[Title/Abstract] OR physicochemical propert*[Title/Abstract] OR QSAR[Title/Abstract] OR read 
across*[Title/Abstract] OR structural alert*[Title/Abstract] OR structure activit*[Title/Abstract] OR 
SAR[Title/Abstract] OR SARs[Title/Abstract] OR "(Q)SARs"[Title/Abstract] OR QSARs[Title/Abstract] OR structure tox-
icity relationship*[Title/Abstract] OR QSTR*[Title/Abstract] OR Structure-Activity Relationship[Majr] OR Computer 
Simulation[Majr] OR ((Computational Biology[Majr]) AND Computational Biology[mh:noexp])) 
WoS 
("(Q)SAR" OR "computational*" OR "in silico*" OR "physico chemical propert*" OR "physicochemical propert*" OR 
"QSAR" OR "read across*" OR "structural alert*" OR "structure activit*" OR "SAR" OR "SARs" OR "(Q)SARs" OR 
"QSARs" OR "structure toxicity relationship*" OR "QSTR*" OR "Structure-Activity Relationship" OR "Computer Simula-
tion") 
 
Alternative method search 2 
PubMed 
(sensitivity[Title/Abstract] AND specificity[Title/Abstract]) OR (bioassay*[Title/Abstract] AND (in vitro[Title/Abstract] 
OR culture*[Title/Abstract]) OR (alternative approach*[Title/Abstract] OR alternative assay*[Title/Abstract] OR alter-
native method*[Title/Abstract] OR alternative model*[Title/Abstract] OR alternative to animal*[Title/Abstract] OR 
alternatives to animal*[Title/Abstract] OR analogue approach*[Title/Abstract] OR animalfree[Title/Abstract] OR ani-
mal-free[Title/Abstract] OR assay characterisation[Title/Abstract] OR assay characterization[Title/Abstract] OR assay 
development[Title/Abstract] OR assay performance[Title/Abstract] OR assay validation[Title/Abstract] OR bio as-
say*[Title/Abstract] OR Biological Assay*[Title/Abstract] OR in vitro screening*[Title/Abstract] OR method characteri-
zation[Title/Abstract] OR method characterization[Title/Abstract] OR method development[Title/Abstract] OR method 
validation[Title/Abstract] OR model characterisation[Title/Abstract] OR model characterization[Title/Abstract] OR 
model development[Title/Abstract] OR model validation[Title/Abstract] OR non animal alternativ*[Title/Abstract] OR 
non testing method*[Title/Abstract] OR screening tool*[Title/Abstract] OR screening assay*[Title/Abstract] OR 
screening method*[Title/Abstract] OR screening system*[Title/Abstract] OR screening test*[Title/Abstract] OR test 
assay*[Title/Abstract] OR test batteries[Title/Abstract] OR test battery[Title/Abstract] OR test 
method*[Title/Abstract] OR test strategies[Title/Abstract] OR test strategy[Title/Abstract] OR test sys-
tem*[Title/Abstract] OR testing assay*[Title/Abstract] OR testing batteries[Title/Abstract] OR testing bat-
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tery[Title/Abstract] OR testing method*[Title/Abstract] OR testing strategies[Title/Abstract] OR testing strat-
egy[Title/Abstract] OR throughput screening[Title/Abstract] OR Biological Assay[MeSH] OR toxicological screen-
ing[Title/Abstract] OR screening battery[Title/Abstract] OR screening batteries[Title/Abstract] OR screening 
model*[Title/Abstract] OR alternative testing method[Title/Abstract] OR alternative toxicity testing[Title/Abstract] OR 
alternative testing[Title/Abstract] OR alternative test method[Title/Abstract] OR novel method*[Title/Abstract] OR 
novel model*[Title/Abstract] OR novel system*[Title/Abstract] OR reproducibilitly[Title/Abstract] OR assay capac-
ity[Title/Abstract] OR method capacity[Title/Abstract] OR content assay*[Title/Abstract] OR content 
method*[Title/Abstract] OR content system*[Title/Abstract] OR content model*[Title/Abstract] OR content screen-
ing[Title/Abstract] OR toxicity screening[Title/Abstract] OR neurotoxicity screening[Title/Abstract] OR NT screen-
ing[Title/Abstract] OR screening model*[Title/Abstract] OR throughput model*[Title/Abstract] OR throughput 
method*[Title/Abstract] OR throughput system*[Title/Abstract] OR throughput assay*[Title/Abstract] OR throughput 
test*[Title/Abstract]) 
WoS 
("alternative approach*" OR "alternative assay*" OR "alternative method*" OR "alternative model*" OR "alternative 
to animal*" OR "alternatives to animal*" OR "analogue approach*" OR "animalfree" OR "animal-free" OR "assay 
characterisation" OR "assay characterization" OR "assay development" OR "assay performance" OR "assay validation" 
OR "bio assay*" OR "Biological Assay*" OR "in vitro screening*" OR "method characterization" OR "method charac-
terization" OR "method development" OR "method validation" OR "model characterisation" OR "model characteriza-
tion" OR "model development" OR "model validation" OR "non animal alternativ*" OR "non testing method*" OR 
"screening tool*" OR "screening assay*" OR "screening method*" OR "screening system*" OR "screening test*" OR 
"test assay*" OR "test batteries" OR "test battery" OR "test method*" OR "test strategies" OR "test strategy" OR 
"test system*" OR "testing assay*" OR "testing batteries" OR "testing battery" OR "testing method*" OR "testing 
strategies" OR "testing strategy" OR "throughput screening" OR "Biological Assay" OR "toxicological screening" OR 
"screening battery" OR "screening batteries" OR "screening model*" OR "alternative testing method" OR "alternative 
toxicity testing" OR "alternative testing" OR "alternative test method" OR "novel method*" OR "novel model*" OR 
"novel system*" OR "reproducibilitly" OR "assay capacity" OR "method capacity" OR "content assay*" OR "content 
method*" OR "content system*" OR "content model*" OR "content screening" OR "toxicity screening" OR "neurotox-
icity screening" OR "NT screening" OR "screening model*" OR "throughput model*" OR "throughput method*" OR 
"throughput system*" OR "throughput assay*" OR "throughput test*" OR ("bioassay*" AND ("in vitro" OR "cul-
ture*")) OR ("sensitivity" AND "specificity") 
 
BBB search (combined by ‘AND’) 
BBB search 
PubMed 
BBB[Title] OR brain barrier*[Title] OR brain blood barrier*[Title] OR BBB model*[Title/Abstract] OR brain barrier 
model*[Title/Abstract] OR brain blood barrier model*[Title/Abstract] OR model BBB[Title/Abstract] OR model biologi-
cal barrier*[Title/Abstract] OR model brain blood barrier*[Title/Abstract] OR model blood brain bar-
rier*[Title/Abstract]  
WoS 
"BBB" OR "brain barrier*" OR "brain blood barrier*" OR "BBB model*" OR "brain barrier model*" OR "brain blood 
barrier model*" OR "model BBB" OR "model biological barrier*" OR "model brain blood barrier*" OR "model blood 
brain barrier*" 
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Alternative method search 1 for BBB search 
PubMed 
(culture*[Title/Abstract] OR cell based[Title/Abstract] OR cell line*[Title/Abstract] OR cell model*[Title/Abstract] OR 
cell system*[Title/Abstract] OR cellular model*[Title/Abstract] OR cellular assay*[Title/Abstract] OR cellular sys-
tem*[Title/Abstract] OR cellular method*[Title/Abstract] OR cellular technique*[Title/Abstract] OR cellular end-
point*[Title/Abstract] OR cellular exposure*[Title/Abstract] OR in vitro[Title/Abstract] OR inverte-
brate*[Title/Abstract] OR non mammal*[Title/Abstract] OR caenorhabditis[Title/Abstract] OR C. ele-
gans[Title/Abstract] OR nematod*[Title/Abstract] OR rerio[Title/Abstract] OR roundworm*[Title/Abstract] OR sea 
urchin*[Title/Abstract] OR zebra fish[Title/Abstract] OR zebrafish[Title/Abstract] OR Xenopus[Title/Abstract] OR tad-
pole[Title/Abstract] OR clawed frog*[Title/Abstract] OR Zebrafish[Title/Abstract] OR Caenorhabditis[Title/Abstract] 
OR Sea Urchins[Title/Abstract] OR Xenopus[Title/Abstract] OR Brachydanio[Title/Abstract] OR Brachydanio re-
rio[Title/Abstract] OR Danio [Title/Abstract] OR Caenorhabditis elegan*[Title/Abstract] OR Fruitfly[Title/Abstract] OR 
Fruit fly[Title/Abstract] OR Drosophila[Title/Abstract] OR Drosophila melanog*[Title/Abstract] OR Echin-
oid*[Title/Abstract] OR fruit flies[Title/Abstract] OR fruitflies[Title/Abstract] OR Drosophila[Title/Abstract] OR 
(Q)SAR[Title/Abstract] OR computational*[Title/Abstract] OR in silico*[Title/Abstract] OR physico chemical prop-
ert*[Title/Abstract] OR physicochemical propert*[Title/Abstract] OR QSAR[Title/Abstract] OR read 
across*[Title/Abstract] OR structural alert*[Title/Abstract] OR structure activit*[Title/Abstract] OR 
SAR[Title/Abstract] OR SARs[Title/Abstract] OR (Q)SARs[Title/Abstract] OR QSARs[Title/Abstract] OR structure toxic-
ity relationship*[Title/Abstract] OR QSTR*[Title/Abstract] OR Cell-Free System[MeSH] OR Zebrafish[MeSH] OR 
Caenorhabditis[MeSH] OR Sea Urchins[MeSH] OR Xenopus[MeSH] OR Drosophila[MeSH] OR In Vitro Tech-
niques[MeSH] OR Cells, Cultured[MeSH] OR Structure-Activity Relationship[Majr] OR Computer Simulation[Majr])))  
WoS 
"culture*" OR "cell based" OR "cell line*" OR "cell model*" OR "cell system*" OR "cellular model*" OR "cellular as-
say*" OR "cellular system*" OR "cellular method*" OR "cellular technique*" OR "cellular endpoint*" OR "cellular ex-
posure*" OR "in vitro" OR "invertebrate*" OR "non mammal*" OR "caenorhabditis" OR "C. elegans" OR "nematod*" 
OR "rerio" OR "roundworm*" OR "sea urchin*" OR "zebra fish" OR "zebrafish" OR "Xenopus" OR "tadpole" OR 
"clawed frog*" OR "Zebrafish" OR "Caenorhabditis" OR "Sea Urchins" OR "Xenopus" OR "Brachydanio" OR "Brachy-
danio rerio" OR "Danio " OR "Caenorhabditis elegan*" OR "Fruitfly" OR "Fruit fly" OR "Drosophila" OR "Drosophila 
melanog*" OR "Echinoid*" OR "fruit flies" OR "fruitflies" OR "Drosophila" OR "(Q)SAR" OR "computational*" OR "in 
silico*" OR "physico chemical propert*" OR "physicochemical propert*" OR "QSAR" OR "read across*" OR "structural 
alert*" OR "structure activit*" OR "SAR" OR "SARs" OR "(Q)SARs" OR "QSARs" OR "structure toxicity relationship*" 
OR "QSTR*" 
Alternative method search 2 for BBB search 
PubMed 
(sensitivity[Title/Abstract] AND specificity[Title/Abstract]) OR ((in vitro[Title/Abstract]) OR culture*[Title/Abstract]) 
AND bioassay*[Title/Abstract]) OR (alternative approach*[Title/Abstract] OR alternative assay*[Title/Abstract] OR 
alternative method*[Title/Abstract] OR alternative model*[Title/Abstract] OR alternative to animal*[Title/Abstract] 
OR alternatives to animal*[Title/Abstract] OR analogue approach*[Title/Abstract] OR animalfree[Title/Abstract] OR 
animal-free[Title/Abstract] OR assay characterisation[Title/Abstract] OR assay characterization[Title/Abstract] OR as-
say development[Title/Abstract] OR assay performance[Title/Abstract] OR assay validation[Title/Abstract] OR bio as-
say*[Title/Abstract] OR Biological Assay*[Title/Abstract] OR in vitro screening*[Title/Abstract] OR method characteri-
zation[Title/Abstract] OR method characterization[Title/Abstract] OR method development[Title/Abstract] OR method 
validation[Title/Abstract] OR model characterisation[Title/Abstract] OR model characterization[Title/Abstract] OR 
model development[Title/Abstract] OR model validation[Title/Abstract] OR non animal alternativ*[Title/Abstract] OR 
non testing method*[Title/Abstract] OR screening tool*[Title/Abstract] OR screening assay*[Title/Abstract] OR 
screening method*[Title/Abstract] OR screening system*[Title/Abstract] OR screening test*[Title/Abstract] OR test 
assay*[Title/Abstract] OR test batteries[Title/Abstract] OR test battery[Title/Abstract] OR test 
method*[Title/Abstract] OR test strategies[Title/Abstract] OR test strategy[Title/Abstract] OR test sys-
tem*[Title/Abstract] OR testing assay*[Title/Abstract] OR testing batteries[Title/Abstract] OR testing bat-
   
  
 
 
www.efsa.europa.eu/publications 108 EFSA Supporting publication 2018:EN-1410 
 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to 
the rights of the authors. 
 
tery[Title/Abstract] OR testing method*[Title/Abstract] OR testing strategies[Title/Abstract] OR testing strat-
egy[Title/Abstract] OR throughput screening[Title/Abstract] OR Biological Assay[Title/Abstract] OR toxicological 
screening[Title/Abstract] OR screening battery[Title/Abstract] OR screening batteries[Title/Abstract] OR screening 
model*[Title/Abstract] OR alternative testing method[Title/Abstract] OR alternative toxicity testing[Title/Abstract] OR 
alternative testing[Title/Abstract] OR alternative test method[Title/Abstract] OR novel method*[Title/Abstract] OR 
novel model*[Title/Abstract] OR novel system*[Title/Abstract] OR reproducibilitly[Title/Abstract] OR assay capac-
ity[Title/Abstract] OR method capacity[Title/Abstract] OR content assay*[Title/Abstract] OR content 
method*[Title/Abstract] OR content system*[Title/Abstract] OR content model*[Title/Abstract] OR content screen-
ing[Title/Abstract] OR toxicity screening[Title/Abstract] OR neurotoxicity screening[Title/Abstract] OR NT screen-
ing[Title/Abstract] OR screening model*[Title/Abstract] OR throughput model*[Title/Abstract] OR throughput 
method*[Title/Abstract] OR throughput system*[Title/Abstract] OR throughput assay*[Title/Abstract] OR throughput 
test*[Title/Abstract] OR performance[Title/Abstract] OR validation[Title/Abstract] OR validity[Title/Abstract] OR pre-
diction[Title/Abstract] OR predict[Title/Abstract] OR valid[Title/Abstract] OR reproducibility[Title/Abstract] OR tans-
port model[Title/Abstract] OR predicting[Title/Abstract] OR reproducible[Title/Abstract] OR fabrica-
tion*[Title/Abstract] OR microtechnolog*[Title/Abstract] OR engeneering*[Title/Abstract]) 
WoS 
"alternative approach*" OR "alternative assay*" OR "alternative method*" OR "alternative model*" OR "alternative to 
animal*" OR "alternatives to animal*" OR "analogue approach*" OR "animalfree" OR "animal-free" OR "assay charac-
terisation" OR "assay characterization" OR "assay development" OR "assay performance" OR "assay validation" OR 
"bio assay*" OR "Biological Assay*" OR "in vitro screening*" OR "method characterization" OR "method characteriza-
tion" OR "method development" OR "method validation" OR "model characterisation" OR "model characterization" OR 
"model development" OR "model validation" OR "non animal alternativ*" OR "non testing method*" OR "screening 
tool*" OR "screening assay*" OR "screening method*" OR "screening system*" OR "screening test*" OR "test as-
say*" OR "test batteries" OR "test battery" OR "test method*" OR "test strategies" OR "test strategy" OR "test sys-
tem*" OR "testing assay*" OR "testing batteries" OR "testing battery" OR "testing method*" OR "testing strategies" 
OR "testing strategy" OR "throughput screening" OR "Biological Assay" OR "toxicological screening" OR "screening 
battery" OR "screening batteries" OR "screening model*" OR "alternative testing method" OR "alternative toxicity 
testing" OR "alternative testing" OR "alternative test method" OR "novel method*" OR "novel model*" OR "novel sys-
tem*" OR "reproducibilitly" OR "assay capacity" OR "method capacity" OR "content assay*" OR "content method*" 
OR "content system*" OR "content model*" OR "content screening" OR "toxicity screening" OR "neurotoxicity screen-
ing" OR "NT screening" OR "screening model*" OR "throughput model*" OR "throughput method*" OR "throughput 
system*" OR "throughput assay*" OR "throughput test*" OR "performance" OR "validation" OR "validity" OR "predic-
tion" OR "predict" OR "valid" OR "reproducibility" OR "tansport model" OR "predicting" OR "reproducible" OR "fabri-
cation*" OR "microtechnolog*" OR "engeneering*" OR ("bioassay*" AND ("in vitro" OR "culture*")) OR ("sensitivity" 
AND "specificity") 
 
MoA search (only PubMed) 
(MoA[Title/Abstract] OR mode of action[Title/Abstract] OR key event[Title/Abstract] OR initiating 
event[Title/Abstract] OR organ effect[Title/Abstract] OR cell effect[Title/Abstract] OR cellular effect[Title/Abstract] 
OR mechanism*[Title/Abstract]) 
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Appendix F:  Results of ‘grey’ literature search 
 
Appendix F can be found in the online version of this output (‘Supporting information’ section): 
http://dx.doi.org/10.2903/j.efsa.2018.1410 
 
Results of the QSAR screening 
QSAR Neurotoxicity 
OECD QSAR 
toolbox 
http://www.qsartoolbox.org/  
OECD 
eChemPortal 
http://www.echemportal.org/echemportal/index?pageID=0&request_locale=en 
Derek Nexus https://www.lhasalimited.org/derek_nexus/  
neurotox endpoint which also covers cholinesterase inhibition 
HazardEx-
pert 
http://www.compudrug.com/  
PASS http://195.178.207.233/PASS/index.html   
Leadscope http://www.leadscope.com/  
ADME 
Lazar https://lazar.in-silico.de/predict  
ADMET Pre-
dictor BBB 
http://www.simulations-plus.com/  
ACD/Labs http://www.acdlabs.com/products/percepta/predictors.php  
Accelrys Ac-
cord BBB 
http://accelrys.com/solutions/domains/  
Grouping and read across for neurotoxicity 
OECD QSAR 
toolbox 
http://www.qsartoolbox.org/  
Toxmatch 
(JRC) 
https://eurl-ecvam.jrc.ec.europa.eu/laboratories-
research/predictive_toxicology/qsar_tools/toxmatch  
ChemIDplus 
(Toxnet) 
https://chem.nlm.nih.gov/chemidplus/  
AIM (US-
EPA) 
http://www.epa.gov/tsca‐screening‐tools/analog‐identification‐methodologyaim‐t
ool  
Databases  searchable by the endpoint neurotoxicity 
OECD 
eChemPortal 
http://www.echemportal.org/echemportal/index?pageID=0&request_locale=en 
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Appendix G:  Study selection sheet of title/abstract screening  
 
Appendix G can be found in the online version of this output (‘Supporting information’ section): 
http://dx.doi.org/10.2903/j.efsa.2018.1410  
 
 
Appendix H:  Data collection sheet 
 
Appendix H can be found in the online version of this output (‘Supporting information’ section): 
http://dx.doi.org/10.2903/j.efsa.2018.1410  
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Appendix I:  Tables I1-I5 
 
Table I1: Test Systems grouped by species and Cell Types with respective numbers of cita-
tions. 
 
 # citations 
human 130 
immortalized cells 49 
CHME-5 (microglia) 3 
LUHMES 32 
mesencephalic Cells (MESC2.10) 9 
ReNcell CX cells 5 
primary cells 11 
NSC derived culture 8 
primary astrocytes 2 
sigmoid colon tissue 1 
stem/progenitor cells  65 
iPSC derived mixed culture (neurons+glia) 8 
iPSC derived neurons 49 
NPCs 1 
undifferentiated neurospheres 8 
cell free 3 
recombinant  AChE 3 
primary tissue 2 
neuronal tau-40 protein in phosphate buffer  2 
 
mouse 173 
immortalized cells 27 
2.3D (neuroepithelial cells differentiated into astrocytes and neurons) 1 
BV-2 15 
CRL-2534, astrocyte type III 2 
GT1-7 cells (hypothalamic cell line) 2 
HT-22 5 
N9 microglia 1 
SN4741 1 
primary cells 116 
brain slices 1 
cerebellar granule cell 3 
cerebellar granule neurons 3 
dorsal root ganglia/spinal cord cultures 3 
isolated mouse hemidiaphragm muscles  1 
mixed neuron and glia culture 15 
mixed culture (dopaminergic neurons+astrocytes) 22 
mixed culture (neurons+microglia) 1 
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mixed culture (spinal cord - skeletal muscle) 1 
murine brain microvascular endothelial cells 1 
neuron/astrocyte contact co-culture 1 
primary glia 3 
primary neurons 62 
stem/progenitor cells  19 
ESC 3 
ESC derived glutamatergic neurons 9 
ESC derived neurons 7 
cell free 3 
recombinant  AChE 3 
primary tissue 8 
brain homogenate 2 
cell membrane 2 
mitochondria 3 
synaptosomes 1 
 
rat 567 
Immortalized cells 42 
E18 neuroblast 2 
HAPI 8 
N27 27 
RBE4 5 
primary cells 479 
astrocyte rich culture 11 
brain slices 33 
cell membrane 4 
cerebellar granule cell 13 
cerebellar granule neurons 9 
dopaminergic neurons 1 
hippocampal CA1 pyramidal neurons  1 
Oligodendrocyte progenitors 1 
primary glia 55 
primary microglia 7 
primary neurons) 194 
primary oligodendrocytes 1 
purkinje neurons 2 
re-aggregating brain cell cultures 59 
trigeminal ganglion neurons 1 
mixed neuron and glia cultures 84 
Dorsal root ganglia 3 
stem/progenitor cells  7 
differentiated mesencephalic NPCs 4 
differentiated striatal neural NPCs 3 
tumor cells 2 
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PC6-3 2 
primary tissue 114 
brain homogenate 17 
cell membrane 22 
microsome 8 
mitochondria 18 
mitochondrial suspension from liver 3 
synaptosomal mitochondria 5 
synaptosomes 41 
xenopus 10 
primary cells 10 
neurolemma in Xenopus Oocytes 6 
sodium channels in Xenopus Oocytes  4 
 
chicken 18 
primary cells 16 
cerebellar bergmann glia 5 
primary neurons 10 
spheroids 1 
primary tissue 2 
brain homogenate 2 
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Table I2: Total number of citations for endpoint categories grouped according to species. In 
addition, predictivity analyses were performed for each endpoint category and species giving 
the true as well as false positives and negatives. 
 
f. n. f. p. t. n. t. p. total 
Chicken 3 
  
15 18 
Activation of Chloride Channels 
   
1 1 
Delayed Neuropathy 
   
1 1 
Enzyme Inhibition 
   
10 10 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 2 
  
1 4 
Other 1 
   
1 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
130 Human 12 8 22 88 
Axonopathies 1 
  
1 2 
Cytoskeletal Alterations 
   
4 4 
Inhibition of Cholinergic Neurotransmission 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 11 
  
60 72 
negative 
 
8 22 
 
30 
Neuroinflammation 
   
1 1 
Other 
   
1 1 
Redox Cycling 
   
14 14 
Stimulation of Cholinergic Neurotransmission 
   
4 4 
Stimulation of dopaminergic Neurotransmission 
   
1 1 
Mouse 9 
 
2 162 173 
Activation of Sodium Channels 
   
9 9 
Altered Calcium Signaling 
   
2 2 
Axonopathies 
   
2 2 
Effects on Other Neuronal Receptors 
   
2 2 
Enzyme Inhibition 
   
1 1 
Inhibition of Chloride Channels 
   
1 1 
Inhibition of Cholinergic Neurotransmission 
   
16 16 
Inhibition of dopaminergic Neurotransmission 
   
1 1 
Inhibition of GABAergic Neurotransmission 
   
7 7 
Inhibition of Glycinergic Neurotransmission 
   
3 3 
Inhibition of Sodium Channels 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 6 
  
73 79 
negative 
  
2 
 
2 
Neuroinflammation 
   
6 6 
Neurotransmission in General 
   
1 1 
Other 
   
4 4 
Redox Cycling 2 
  
11 13 
Stimulation of Cholinergic Neurotransmission 1 
  
14 15 
Stimulation of dopaminergic Neurotransmission 
   
1 1 
Stimulation of GABAergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic Neurotransmission 
   
6 6 
Rat 85 8 22 529 644 
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Activation of Sodium Channels 5 
  
24 29 
Altered Calcium Signaling 2 
  
18 20 
Axonopathies 
   
15 15 
Cytoskeletal Alterations 4 
  
1 5 
Effects on Other Neuronal Receptors 3 
  
9 12 
Enzyme Inhibition 
   
4 4 
Inhibition of Adrenergic Neurotransmission 
   
2 2 
Inhibition of Cholinergic Neurotransmission 3 2 
 
4 9 
Inhibition of dopaminergic Neurotransmission 
   
8 8 
Inhibition of GABAergic Neurotransmission 5 
  
33 38 
Inhibition of Glycinergic Neurotransmission 
   
4 4 
Inhibition of Sodium Channels 
   
1 1 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 32 
 
2 235 269 
Myelin Toxicity 
   
2 2 
negative 
 
1 15 
 
16 
Neuroinflammation 11 
  
22 33 
Neurotransmission in General 1 
  
7 8 
Other 
   
4 4 
Redox Cycling 7 
 
1 61 69 
Stimulation of Cholinergic Neurotransmission 9 3 4 50 66 
Stimulation of dopaminergic Neurotransmission 
   
11 11 
Stimulation of GABAergic Neurotransmission 
   
2 2 
Stimulation of Glutamatergic Neurotransmission 3 
  
12 15 
Stimulation of Adrenergic Neurotransmission  1  1 
Stimulation of Serotonergic Neurotransmission  1   1 
Xenopus 
   
10 10 
Activation of Sodium Channels 
   
6 6 
Inhibition of Calcium Channels 
   
1 1 
Inhibition of Chloride Channels 
   
1 1 
Inhibition of Sodium Channels 
   
2 2 
total 109 16 46 806 977 
 
 
 
 
Table I3: Total number of citations for endpoint categories grouped according to human test 
systems. Predictivity analyses were performed for each endpoint category, species and test sys-
tem giving the true as well as false positives and negatives. 
 
 
f. n. f. p. t. n. t. p. total 
cell free 
   
3 3 
recombinant  AChE 
   
3 3 
Stimulation of Cholinergic Neurotransmission 
   
3 3 
Immortalized cells 2 
  
47 49 
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CHME-5 (microglia) 
   
3 3 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
3 3 
LUHMES 2 
  
30 32 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 2 
  
30 32 
mesencephalic cells (MESC2.10) 
   
9 9 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
2 2 
Redox Cycling 
   
6 6 
Stimulation of dopaminergic Neurotransmission 
   
1 1 
ReNcell CX cells 
   
5 5 
Redox Cycling 
   
5 5 
primary cells 
   
11 11 
NSC derived culture 
   
8 8 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
8 8 
primary glia 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
2 2 
sigmoid colon tissue 
   
1 1 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
primary tissue 
   
2 2 
neuronal tau-40 protein in phosphate buffer  
   
2 2 
Cytoskeletal Alterations 
   
2 2 
stem/progenitor cells  10 8 22 25 65 
iPSC derived mixed culture (neurons+glia) 2 
  
6 8 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 2 
  
5 7 
Neuroinflammation 
   
1 1 
iPSC derived neurons 5 8 22 14 49 
Axonopathies 1 
  
1 2 
Cytoskeletal Alterations 
   
2 2 
Inhibition of Cholinergic Neurotransmission 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 4 
  
5 9 
negative 
 
8 22 
 
30 
Other 
   
1 1 
Redox Cycling 
   
3 3 
NPCs 
   
1 1 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
1 1 
undifferentiated neurospheres 3 
  
5 8 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 3 
  
5 8 
total 12 8 22 88 130 
Table I4: Total number of citations for endpoint categories grouped according to mouse test 
systems. Predictivity analyses were performed for each endpoint category, species and test sys-
tem giving the true as well as false positives and negatives. 
 
 
f. n. t. n. t. p. total 
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cell free 
  
3 3 
recombinant  AChE 
  
3 3 
Stimulation of Cholinergic Neurotransmission 
  
3 3 
Immortalized cells 2 
 
25 27 
2.3D (neuroepithelial cells differentiated into 
astrocytes and neurons) 
  
1 1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
1 1 
BV-2 2 
 
13 15 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
10 10 
Redox Cycling 2 
 
3 5 
CRL-2534, astrocyte type III 
  
2 2 
Stimulation of Glutamatergic Neurotransmission 
  
2 2 
GT1-7 cells (hypothalamic cell line) 
  
2 2 
Axonopathies 
  
1 1 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
1 1 
HT-22 
  
5 5 
Redox Cycling 
  
5 5 
N9 microglia 
  
1 1 
Redox Cycling 
  
1 1 
SN4741 
  
1 1 
Redox Cycling 
  
1 1 
primary cells 7 2 108 117 
brain slices 
  
1 1 
Stimulation of Glutamatergic Neurotransmission 
  
1 1 
cerebellar granule cell 
  
3 3 
Inhibition of GABAergic Neurotransmission 
  
3 3 
cerebellar granule neurons 
  
3 3 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
2 2 
Stimulation of Cholinergic Neurotransmission 
  
1 1 
dorsal root ganglia/spinal cord cultures 
  
2 2 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
2 2 
isolated mouse hemidiaphragm muscles  
  
1 1 
Inhibition of Cholinergic Neurotransmission 
  
1 1 
mixed culture (dopaminergic neu-
rons+astrocytes) 5 
 
17 22 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 5 
 
17 22 
mixed culture (neurons+microglia) 
  
1 1 
   
  
 
 
www.efsa.europa.eu/publications 118 EFSA Supporting publication 2018:EN-1410 
 
The present document has been produced and adopted by the bodies identified above as authors. This task has been carried out exclusively by the authors in the 
context of a contract between the European Food Safety Authority and the authors, awarded following a tender procedure. The present document is published 
complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food 
Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to 
the rights of the authors. 
 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
1 1 
mixed culture (spinal cord - skeletal muscle) 
  
1 1 
Inhibition of Cholinergic Neurotransmission 
  
1 1 
mixed neuron and glia cultures 1 
 
14 15 
Inhibition of Cholinergic Neurotransmission 
  
1 1 
Inhibition of Sodium Channels 
  
2 2 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 1 
 
2 3 
Neuroinflammation 
  
1 1 
Stimulation of Cholinergic Neurotransmission 
  
6 6 
Stimulation of dopaminergic Neurotransmission 
  
1 1 
Stimulation of GABAergic Neurotransmission 
  
1 1 
murine brain microvascular endothelial cells 
  
1 1 
Enzyme Inhibition 
  
1 1 
neuron/astrocyte contact co-culture 
  
1 1 
Neuroinflammation 
  
1 1 
primary glia 
  
3 3 
Neuroinflammation 
  
3 3 
primary neurons 1 2 59 62 
Activation of Sodium Channels 
  
9 9 
Altered Calcium Signaling 
  
1 1 
Axonopathies 
  
1 1 
Inhibition of Chloride Channels 
  
1 1 
Inhibition of GABAergic Neurotransmission 
  
4 4 
Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
34 34 
Redox Cycling   1 1 
negative 
 
2 
 
2 
Neuroinflammation 
  
1 1 
Neurotransmission in General 
  
1 1 
Other 
  
2 2 
Stimulation of Cholinergic Neurotransmission 1 
 
1 2 
Stimulation of Glutamatergic Neurotransmission 
  
3 3 
dorsal root ganglia 
  
1 1 
Inhibition of Cholinergic Neurotransmission 
  
1 1 
primary tissue 
  
8 8 
brain homogenate 
  
2 2 
Stimulation of Cholinergic Neurotransmission 
  
2 2 
cell membrane 
  
2 2 
Effects on Other Neuronal Receptors 
  
2 2 
mitochondria 
  
3 3 
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Mitochondrial Dysfunction/Oxidative 
Stress/Apoptosis 
  
3 3 
synaptosomes 
  
1 1 
Inhibition of dopaminergic Neurotransmission 
  
1 1 
stem/progenitor cells  
  
19 19 
ESC 
  
3 3 
Altered Calcium Signaling 
  
1 1 
Other 
  
2 2 
ESC derived glutamatergic neurons 
  
9 9 
Inhibition of Cholinergic Neurotransmission 
  
8 8 
Stimulation of Cholinergic Neurotransmission 
  
1 1 
ESC derived neurons 
  
7 7 
Inhibition of Cholinergic Neurotransmission 
  
4 4 
Inhibition of Glycinergic Neurotransmission 
  
3 3 
total 9 2 163 174 
 
 
 
 
Table I5: Total number of citations for endpoint categories grouped according to rat test sys-
tems. Predictivity analyses were performed for each endpoint category, species and test system 
giving the true as well as false positives and negatives. 
 
f. 
n. f. p. t. n. t. p. total 
Immortalized cells 4 
  
38 42 
E18 neuroblast 
   
2 2 
Redox Cycling 
   
2 2 
HAPI 
   
8 8 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
6 6 
Neuroinflammation 
   
2 2 
N27 4 
  
23 27 
Altered Calcium Signaling 
   
1 1 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
11 11 
Redox Cycling 4 
  
11 15 
RBE4 
   
5 5 
Redox Cycling 
   
5 5 
primary cells 65 8 22 384 479 
astrocyte rich culture 1 
  
10 11 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 1 
  
8 9 
Other 
   
2 2 
brain slices 3 
 
1 29 33 
Activation of Sodium Channels 
   
2 2 
Cytoskeletal Alterations 
   
1 1 
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Inhibition of Adrenergic Neurotransmission 
   
1 1 
Inhibition of Cholinergic Neurotransmission 3 
   
3 
Inhibition of GABAergic Neurotransmission 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
  
1 4 5 
Redox Cycling 
   
5 5 
Stimulation of Cholinergic Neurotransmission 
   
4 4 
Stimulation of dopaminergic Neurotransmission 
   
8 8 
Stimulation of Glutamatergic Neurotransmission 
   
2 2 
cell membrane 
   
4 4 
Inhibition of GABAergic Neurotransmission 
   
4 4 
cerebellar granule cell 2 
  
11 13 
Inhibition of GABAergic Neurotransmission 
   
4 4 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 2 
  
4 6 
Redox Cycling 
   
3 3 
cerebellar granule neurons 
   
9 9 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
7 7 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic Neurotransmission 
   
1 1 
dopaminergic neurons 
   
1 1 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
1 1 
hippocampal CA1 pyramidal neurons  
   
1 1 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
oligodendrocyte progenitors 
   
1 1 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
1 1 
primary glia 16 
  
39 55 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 4 
  
18 22 
Neuroinflammation 11 
  
9 20 
Redox Cycling 1 
  
12 13 
primary microglia 2 
  
5 7 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 2 
  
3 5 
Neuroinflammation 
   
2 2 
primary neurons 22 
 
9 163 194 
Activation of Sodium Channels 
   
13 13 
Axonopathies 
   
5 5 
Cytoskeletal Alterations 4 
   
4 
Inhibition of Adrenergic Neurotransmission 
   
1 1 
Inhibition of Cholinergic Neurotransmission 
   
3 3 
Inhibition of dopaminergic Neurotransmission 
   
1 1 
Inhibition of GABAergic Neurotransmission 
   
15 15 
Inhibition of Glycinergic Neurotransmission 
   
2 2 
Inhibition of Sodium Channels 
   
1 1 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 9 
  
88 97 
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negative 
  
9 
 
9 
Neuroinflammation 
   
6 6 
Neurotransmission in General 
   
2 2 
Other 
   
1 1 
Redox Cycling 2 
  
11 13 
Stimulation of Cholinergic Neurotransmission 5 
  
9 14 
Stimulation of Glutamatergic Neurotransmission 2 
  
5 7 
primary oligodendrocytes 
   
1 1 
Myelin Toxicity 
   
1 1 
purkinje neurons 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
2 2 
re-aggregating brain cell cultures 6 7 4 42 59 
Axonopathies 
   
2 2 
Inhibition of Cholinergic Neurotransmission 
 
2 
 
1 3 
Inhibition of GABAergic Neurotransmission 
   
2 2 
Inhibition of Glycinergic Neurotransmission 
   
2 2 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 3 
  
8 11 
Myelin Toxicity 
   
1 1 
Neuroinflammation 
   
2 2 
Neurotransmission in General 1 
  
3 4 
Other 
   
1 1 
Redox Cycling 
   
1 1 
Stimulation of Cholinergic Neurotransmission 2 3 4 18 27 
Stimulation of Glutamatergic Neurotransmission 
   
1 1 
Stimulation of Adrenergic Neurotransmission 
 
1 
  
1 
Stimulation of Serotoninergic Neurotransmission 
 
1 
  
1 
trigeminal ganglion neurons 
   
1 1 
Stimulation of Cholinergic Neurotransmission 
   
1 1 
mixed neuron and glia cultures 13 1 8 62 84 
Activation of Sodium Channels 5 
  
3 8 
Altered Calcium Signaling 
   
5 5 
Inhibition of dopaminergic Neurotransmission 
   
1 1 
Inhibition of GABAergic Neurotransmission 5 
  
6 11 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
  
1 32 33 
negative 
 
1 6 
 
7 
Neuroinflammation 
   
1 1 
Redox Cycling 
  
1 7 8 
Stimulation of Cholinergic Neurotransmission 2 
  
4 6 
Stimulation of dopaminergic Neurotransmission 
   
1 1 
Stimulation of GABAergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic Neurotransmission 1 
  
1 2 
dorsal root ganglia 
   
3 3 
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Axonopathies 
   
3 3 
stem/progenitor cells  
   
7 7 
differentiated mesencephalic NPCs 
   
4 4 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
3 3 
Redox Cycling 
   
1 1 
differentiated striatal neural NPCs 
   
3 3 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
2 2 
Redox Cycling 
   
1 1 
primary tissue 16 
  
98 114 
brain homogenate 
   
17 17 
Enzyme Inhibition 
   
4 4 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
11 11 
Stimulation of Cholinergic Neurotransmission 
   
2 2 
cell membrane 5 
  
17 22 
Altered Calcium Signaling 2 
   
2 
Effects on Other Neuronal Receptors 3 
  
9 12 
Stimulation of Cholinergic Neurotransmission 
   
8 8 
microsome 
   
8 8 
Altered Calcium Signaling 
   
8 8 
mitochondria 6 
  
12 18 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 6 
  
10 16 
Redox Cycling 
   
2 2 
mitochondrial suspension from liver 3 
   
3 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 3 
   
3 
synaptosomal mitochondria 
   
5 5 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 
   
5 5 
synaptosomes 2 
  
39 41 
Activation of Sodium Channels 
   
6 6 
Altered Calcium Signaling 
   
4 4 
Axonopathies 
   
5 5 
Inhibition of dopaminergic Neurotransmission 
   
6 6 
Mitochondrial Dysfunction/Oxidative Stress/Apoptosis 2 
  
9 11 
Neurotransmission in General 
   
2 2 
Stimulation of Cholinergic Neurotransmission 
   
2 2 
Stimulation of dopaminergic Neurotransmission 
   
2 2 
Stimulation of GABAergic Neurotransmission 
   
1 1 
Stimulation of Glutamatergic Neurotransmission 
   
2 2 
total 85 8 22 527 642 
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Appendix J:  Performance criteria to define the readiness of test methods for 
hazard evaluation. 
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Appendix K:  Readiness check (detailed scoring) 
 
Appendix K can be found in the online version of this output (‘Supporting information’ section): 
http://dx.doi.org/10.2903/j.efsa.2018.1410  
 
